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Prevalence of tobacco smoking amongst those in treatment for opiate 
dependence is almost five times greater than that of the general 
population. Despite this, very few of those undergoing treatment for 
opiate addiction receive help to stop smoking. Contingency management 
(CM) is a behavioural intervention, based on the principles of operant 
conditioning, where desired behaviours are positively reinforced with 
some form of reward. CM may represent a potentially useful addition to 
standard stop smoking treatments for those in opiate addiction treatment, 
but has never been tested in this context in the UK. This thesis describes 
the development and piloting of an intervention, investigating the addition 
of a contingency management intervention for tobacco smoking, to 
standard stop smoking services treatment, in individuals undergoing 
treatment for opiate addiction.  
A meta-analysis was first conducted, investigating the use of CM as an 
intervention for the use of non-prescribed drug use during opiate 
addiction treatment. CM was found to be to be more effective than control 
in engendering abstinence from a wide range of drugs. Moderator analysis 
showed CM to be more effective than control in preventing use of cocaine, 
cocaine and opiates, tobacco, and poly-substance use, but not of opiates.  
Whilst carrying out the meta-analysis, it was discovered that no tool 
currently existed for assessing the quality of CM studies. This was 
addressed by the design and testing of a new tool, the CMQAT 
(Contingency Management Quality Assessment Tool). The tool underwent 
three stages of reliability and validity testing. Inter-rater reliability 
increased from slight at stage one, to fair at stage two, and was better than 
that of an established quality assessment tool (EPHPP) that achieved only 
slight agreement. Predictive validity could not be established at any stage. 
The results of the meta-analysis and CMQAT development were used to 
design a feasibility and pilot study, testing the addition of a CM 
intervention, to standard stop smoking services treatment. Forty opiate 
addiction patients were recruited into the study, and 37 were randomised 
to either an experimental (CM for smoking abstinence) or control (CM for 
attendance at the clinic) condition. The rate of recruitment was greater 
than that of other similar studies, yet only ten participants completed the 
intervention, two from the experimental condition and eight from the 
control, with none of the participants attending follow-up. The most 
widely reported reason for dropping out of the study was that the smoking 
clinic was not run at convenient times. 
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Overall, I believe this thesis constitutes a significant contribution to the 
CM literature. The findings of the meta-analysis offer further support for 
the efficacy of CM as an intervention for non-prescribed drug use during 
opiate addiction treatment. The CMQAT forms the foundation for future 
work to improve both the accuracy of quality assessments of CM trials, and 
the reporting of methods and data in published reports of CM trials. The 
feasibility/pilot study represented the first time in the UK that CM had 
been used as an intervention for tobacco smoking during opiate addiction 
treatment. The primary observation from this study was that with the CM 
protocol used, retention in treatment was poor, with only 25% of 
participants completing the five-week intervention. Taken together, the 
findings have a number of implications for research, practice and policy. 
Perhaps the most important of these though, is that implementing CM in a 
clinical setting alongside standard stop smoking services treatment, 
introduces a number of new challenges not encountered in a laboratory 
setting. Further feasibility and pilot work is required before a full scale 
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1.1 Tobacco Smoking 
1.1.1 Tobacco and Health 
Prevalence of tobacco smoking varies dramatically between countries, with 
rates in 2015 ranging from as little as 6.6%  of a country’s population 
(Nigeria) to 97.5% of the population (Kiribati) [1]. Globally, approximately 
820 million men and 176 million women are smokers [2]. Prevalence of 
smoking has been steadily decreasing globally, with age-standardised 
prevalence of daily tobacco smoking in men declining from 41.2% to 31.1%, 
an average annual rate of decline of 0.9% and for women declining from 
10.6% to 6.2% between 1980 and 2012 [3]. Recently, smoking prevalence in 
the UK dropped below 17% nationally for the first time ever [4]. Despite 
this, however, the increasing global population means that the number of 
daily smokers has actually increased, from 721 million in 1980, to 967 
million in 2012 [3].  
 Tobacco smoking is the leading cause of premature death in the 
western world [5], currently killing 6 million people per year across the 
globe and predicted to kill 8 million people annually by 2030 [6]. Smokers 
have between a two and fourfold greater risk of premature death than 
those who do not smoke [7,8] and in England alone smoking killed 74 
thousand  people in 2014 [9]. The main cause of smoking-related 
premature death occurs through cancer [10]; smoking tobacco causes over 
a quarter of all cancer deaths in the UK [11], with 270,000 new cases of 
cancer per year in Europe directly attributable to it [12]. Tobacco smoke 
contains 5000 chemicals, of which 98 are harmful to humans when inhaled 
and 60 are carcinogenic [13]. Twenty of the chemicals in cigarettes have 
been found to cause lung cancer tumours in lab studies, with polycyclic 
aromatic hydrocarbons of particular concern [14], and causal links have 
now been made between tobacco smoking and at least 14 different types 
of cancer [15]. Smoking also increases mortality through a number of other 
negative health outcomes, and in the UK smoking is responsible for 23% of 
all hospital admissions for respiratory disease and over 10% of admissions 
for circulatory diseases [9]. These deleterious health effects translate to 
profound economic costs, costing the NHS £2 billion a year to treat, and 
costing the UK economy £13.9 billion per year in total [16].  
1.1.2 Tobacco Dependence Mechanisms 
It is now widely accepted that the primary substance responsible for the 
addictive nature of tobacco smoking (but not its negative health effects 
[17,18]) is nicotine [19,20]. However, this was not always the case, and it 
was not until the surgeon general’s report in the late 1980s [21] that 
nicotine was placed on a parity with other drugs of abuse [19]. Nicotine’s 
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primary target in the brain is nicotinic acetylcholine receptors (nAChRs) 
[22]. These are found throughout both the central and peripheral nervous 
systems. Two main cholinergic projection subsystems exist, one of which 
projects to the dopaminergic neurons of the substantia nigra and ventral 
tegmental area (VTA) [23]. Nicotine has been shown to produce dopamine 
release in this region of the brain that is qualitatively similar to that of 
other drugs of abuse [24]. Dopamine release in these brain regions has 
been identified as playing a critical role in drug addiction [23,25]. This is 
therefore the proposed mechanism by which tobacco smoking becomes 
addictive, with the rapid rate of nicotine absorption in the brain and high 
amounts of nicotine attained in the brain from smoking thought to be 
crucial factors that promote and sustain nicotine addiction [26].  
1.1.3 Tobacco Smoking and Opiate Addiction 
Despite smoking prevalence in the UK  falling below 17% nationally for the 
first time [4], smoking prevalence amongst those in treatment for opiate 
addiction remains far higher, between 84-98% [27–31]. Worryingly, despite 
a large proportion of this group expressing interest in smoking cessation 
[27,28], very few are ever offered smoking cessation treatment during 
treatment. In the South London and Maudsley NHS trust for example, only 
15% of those in treatment for drug abuse were offered smoking cessation 
help during treatment in 2014 [32].  
Currently, the mechanisms underlying this high co-morbidity of 
tobacco smoking and opiate use are not well understood, with several 
potential explanations identified. One potential explanation is that of the 
common pathway of addiction, where addiction to multiple substances is 
thought to be mediated through the dopamine reward pathway [23–25]. 
Another possible explanation is that some aspects of tobacco dependence  
may be mediated through the effects of endogenous opiates [33]. For 
example, smoking is associated with lower availability of opioid receptors 
in the thalamus and basal ganglia, an effect related to craving and severity 
of addiction [34]. There is still debate about the effects of this on tobacco 
smoking, however, as opiate antagonists have thus far not proven to be 
effective in smoking cessation [35]. This said, the opiate receptor agonist 
methadone has been shown to increase tobacco smoking [36], and nicotine 
dependence to increase discomfort from opiate withdrawal during 
detoxification [37].  
Another potential joint pathway for this co-morbidity is that of cue-
reactivity, the term given to a broad range of physiological arousals and 
psychological desires that occur when drug users are presented with drug 
related cues [38]. It is thought that these responses to cues are learnt 
associations, and have been shown to occur in both tobacco smokers and 
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opiate users [39]. Research has shown how neutral stimuli (coloured cards) 
can quickly become conditioned as cues for smoking [40], and how this 
can elicit a greater urge to smoke [41]. Related to this is the phenomenon 
of state dependent memory, where the internal state of an individual 
impacts memory storage and retrieval [42]. This has been successfully 
shown to occur for tobacco smoking in humans [43] and opiates in mice 
[44,45]. Taken together with the high co-morbidity of tobacco smoking and 
opiate use, it seems logical to suggest that tobacco and opiates may act in 
some individuals as cues for each other, and that the use of one may 
induce a desire for the other. This is as yet to be substantiated with 
research but offers another potential explanation for the high co-morbidity 
of tobacco smoking and opiate use.  
1.1.4 Smoking Cessation 
Smoking cessation precipitates several different adverse withdrawal 
symptoms [46,47]. These can include irritability, anxiety, difficulty 
concentrating, increased appetite, restlessness, depressed mood, 
insomnia [48], mood swings and cigarette cravings. Anticipation of 
withdrawal symptoms has been identified as a barrier to the initiation of a 
quit attempt [40], and severity of withdrawal symptoms is associated with 
relapse to smoking during cessation [49]. Resultantly, quit rates from 
tobacco smoking are relatively low, with NHS services achieving quit rates 
of 53% at 4 weeks, falling to only 15% at one year [50]. Despite this, those 
receiving behavioural support combined with pharmacological support for 
their smoking addiction are still four times more likely to quit than those 
not receiving help [51].  
When smoking cessation treatment first began in the late 1960s, the 
approach to treatment was somewhat sporadic. One of the earliest large 
scale trials into smoking cessation, “The Smoking Control Research 
Project”, trialled a combination of counselling and tranquilising drugs to 
aid cessation [50,52,53]. Cessation rates were good, with an average 
success rate of 20% at one year follow up [53]. However, the different 
counsellors employed wildly different treatment strategies, ranging from  
an “aggressive crusading approach” to “rational persuasion” [54], 
somewhat obscuring the findings. In the early 1980s, however, the model 
for current smoking cessation interventions began to take form, now 
known as the “Maudsley Model” [50]. This approach to smoking cessation 
was one of the first to concentrate on  nicotine withdrawal, with a primary 
focus on therapy being able to tackle the initial difficult period of acute 
nicotine withdrawal [55]. This early treatment implemented five evening 
visits organised over 4 weeks, with clients expected to quit immediately 
after the first meeting [55]. Nicotine gum was also provided as part of the 
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treatment, with appropriate training as to how to use it, along with 
measurements of breath carbon monoxide (CO) levels to chart progress 
[55].  
Over the intervening years, this approach has been adapted and 
changed in line with new evidence, to what is now used across the NHS and 
in many other countries, the “Standard Treatment Program” of the NCSCT 
(National Centre for Smoking Cessation Training) [56]. These programs are 
now run by local authorities rather than the NHS, but still focus on dealing 
with initial nicotine withdrawal, and still require clients to set a quit date 
within the first week. However, the standard treatment now runs over 6 
weeks, with one session per week. As well as providing behavioural 
support, the treatment also encourages the use of evidence-based 
pharmacotherapies, namely nicotine replacement therapy (NRT). It is also 
emphasised how best to use these, and clients are encouraged to try a 
variety of different types in order to determine which best suits their 
individual needs [57]. Each of the six treatment sessions has a clearly-
defined purpose and focus. The manualised nature of the program has 
allowed its widespread use in various health care settings throughout the 
UK, and its easy adaption to specialist client groups such as those in 
addiction treatment and mental health care settings. The pharmacotherapy 
options now available to smokers are far broader than they were in the 
initial days of the Maudsley model and are not limited to NRT. NRT options 
now include patches, strips, nasal spray, gum, lozenges, inhalator, 
microtabs and mouth spray, whilst non NRT pharmacotherapy options 
include varenicline and bupropion [56]. A large body of evidence now 
exists showing that both NRT and non-nicotine-based pharmacotherapies 
are effective and efficacious in encouraging cessation [58–60], with the 
partial nicotine receptor agonist varenicline showing the greatest efficacy 
and effectiveness [61,62]. Other treatments, for example, contingency 
management (see below) have also been utilised in smoking cessation, with 
results suggesting that incentives increase cessation rates over 40% 
compared to control (60). 
1.1.5. Smoking Cessation in Opiate Use 
Smoking cessation during treatment for opiate addiction remains a 
relatively under-researched area compared to smoking cessation in the 
general public. This is somewhat surprising given the high rates of 
smoking prevalence amongst this group [27–30]. Even more so when it is 
considered that smoking tobacco during opiate detoxification results in 
significantly greater opiate craving and significantly lower rates of 
detoxification completion [37], and is associated with higher levels of illicit 
drug use [63]. To compound this issue, not only does smoking tobacco 
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have a negative effect on drug treatment, but illicit drug use can negatively 
impact on smoking cessation attempts, reducing efficacy of normal NHS 
smoking cessation treatment by nearly half [64].  
Moreover, until very recently, smoking cessation has been viewed by 
drug treatment staff as of significantly lower importance than treating 
clients’ main drug of abuse, with less than of a third of staff across seven 
community and residential addictions services in one UK trust thinking it 
should be treated early in a client’s primary addiction treatment [32]. In an 
assessment of 408 methadone clinics in the USA, only 18% offered 
individual or group smoking cessation counselling, and only 12% 
prescribed NRT [65]. Contrary to this, however, a number of studies have 
now shown that stopping smoking has no negative impact on drug 
addiction treatment outcomes, with some studies suggesting a positive 
effect [66].  
Several different treatments for smoking cessation have been trialled 
in the US in those in treatment for opiate addiction, with varying degrees 
of success. In one study, varenicline significantly increased quit rates and 
smoking reduction compared to placebo, however, this effect ceased once 
treatment was removed [67]. Similar results in cessation and smoking 
reduction have been observed with combined bupropion and nicotine 
replacement therapy [68]. Electronic cigarettes have also been shown to 
significantly reduce the number of cigarettes smoked per day in opiate 
addiction treatment [69]. A more widely researched intervention for 
smoking cessation during treatment for opiate addiction treatment is 
contingency management (see below). Four studies have shown significant 
increases in smoking abstinence and reduction in cigarette smoking in 
those in opiate addiction treatment [70–73] using contingency 
management. However, these small studies were again all carried out in 
the USA, tested a total of only 132 participants in contingency management 
conditions using a mixture or reward schedules, and had experimental 
phases lasting between two and 12 weeks. At current, no studies have been 
conducted in the UK investigating the use of contingency management as 
an intervention for tobacco smoking during treatment for opiate addiction.  
1.2 Contingency Management 
1.2.1 Underlying Theory 
Contingency management (CM) is founded on the principles of operant 
conditioning, developed by B.F. Skinner during the first half of the 20
th
 
century, from the earlier work of Konorski, and later Thorndike [74]. 
According to operant conditioning theory, changes in behaviour are 
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brought about by either positive or negative reinforcement, with positive 
reinforcers encouraging behaviours with desirable outcomes, and negative 
reinforcers discouraging behaviours that have aversive outcomes [74]. 
These basic behavioural principles (positive and negative reinforcement) 
have been used to explain a variety of human behaviours, including 
addiction. In terms of addiction, it is posited that the positive effects of 
drugs operate as positive reinforcers for further consumption with the  
desire to avoid the negative effects experienced during withdrawal acting 
as negative reinforcement [75]. The proposed neurological underpinnings 
of positive reinforcement identify the mesocorticolimbic dopamine 
system as being the primary brain circuit responsible for the rewarding 
nature of drugs [76]. It is argued that the positive reinforcing effects of 
drugs are driven by the increased dopamine release observed after their 
administration [77,78], as well as the extinction of the reinforcing effects 
of drugs after selective destruction of the system [20,79,80]. The negative 
reinforcing effects of drugs are thought to be mediated by the same 
dopamine system, and be linked to a reduction in reward function [76]. 
Namely, a decrease in dopamine and serotonin neurotransmission after 
prolonged exposure to drugs of abuse [81] causing the anhedonic effects 
associated with acute drug withdrawal [76]. CM utilises these same reward 
mechanisms to encourage healthier behaviours, in this case the reduction 
or cessation of drug use [82]. Importantly, CM focuses on the use of 
positive reinforcement rather than negative. Not only is this more pleasant 
for both clients and staff [82], but curtails the high attrition rates seen with 
negative reinforcement [83], and is generally more effective in substance 
misuse than negative reinforcement [84].  
1.2.2 Development of CM Over Time and Use in Addiction 
Treatment 
CM was first developed by F.S. Keller in the early 1960s as a means of 
teaching psychology to university students [85]. It was quickly adopted as 
a means of altering a number of behaviours, from obesity [86] to household 
energy use [87]. One of the first investigations of CM in the addictions field 
was carried out on tobacco smokers in the late 1960s. Participants handed 
over their own money at the beginning of the experiment and were paid it 
back in increments for every time they recorded being abstinent at each 
check-up [88]. Of the 25 participants, 21 remained abstinent for the course 
of the experiment, and at 12-month follow up, 38% were still abstinent.   
Contemporary CM interventions operate on a similar premise; 
however, in line with the modern focus on positive reinforcement over 
negative participants receive rewards without staking anything of their 
own. Cash is also no longer used and participants now normally receive 
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monetary vouchers that can be used against the purchase of particular 
goods (sometimes referred to as voucher-based reinforcement therapy) 
(Higgins & Silverman in [89]). Other rewards for desired behaviour can 
include clinical privileges, or on-site prize distribution [90]. Although this 
is the general format for CM interventions, there are a number of different 
variations that have been developed and tested. A body of evidence now 
exists showing CM to be effective in treating  a wide range of substance 
use (illicit drugs, alcohol and tobacco) disorders, often performing better 
than other behavioural interventions  [91–95]. CM has been observed to be 
particularly efficacious in engendering abstinence from opiates [93]. 
CM for the treatment of addiction usually takes the form of voucher-
based reinforcement therapy, where patients are rewarded with vouchers 
for displaying the desired behaviour (for example returning negative drug 
samples, or clinic attendance). Commonly, the value of the vouchers 
received escalates with each successive display of the desired behaviour 
up to a set maximum (escalating schedule). If patients do not exhibit the 
desired behaviour (i.e. relapse), then the reward value will reset to the 
minimum level and begin to increase at the same rate as before. More 
recently, a new CM protocol has been developed aimed at reducing the 
overall costs of implementing CM interventions, known as the fishbowl 
method [96]. This operates on the same basic principle as conventional CM 
but rather than participants receiving vouchers, they instead receive the 
chance to draw tickets. These tickets give them the chance to earn high, 
medium or low value gifts, or win nothing at all (25% of tickets in the 
original study) [96]. This form of CM was highly effective in encouraging 
abstinence amongst alcohol dependent patients [96].  
 The most recent development in the way that CM interventions are 
conducted, is percentile shaping [97–99]. Percentile shaping (or simply 
shaping) aims to increase patient contact with rewards, thereby increasing 
the likeliness of them achieving the desired treatment outcome. This is 
achieved by making rewards contingent, not on absolute abstinence, but 
on providing biochemically verified levels of a drug in progressively lower 
percentiles. An investigation of this in tobacco smoking cessation tested 
the effects of providing contingent rewards based on producing breath CO 
samples in the either the 10th, 30th, 50th or 70th percentile group. The 
percentile group in this case is linked to a participant’s last 10 breath 
samples. In the 70th percentile group, for example, receiving the reward is 
contingent on producing a breath sample with CO levels lower than the 7th 
lowest sample of the last nine samples delivered. In the 10th percentile 
group, on the other hand, a breath sample needs to be lower than the 
lowest of the previous 9. All percentage schedules resulted in reduced 
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breath CO levels, but those in the 70th percentile group delivered the 
lowest CO samples. Similarly, the number of participants delivering breath 
samples indicating complete abstinence was far lower in the 10th 
percentile group than any of the others [98].  
 It has been noted, however, that shaping schedules can result in 
participants receiving rewards of far greater magnitude for their first 
abstinent sample than those in non-shaping trials. This means that it may 
not be the increased contact with rewards that makes shaping successful, 
but instead simply the magnitude of reward. When this was tested, it was 
observed that standardising the rate at which rewards escalate in a shaping 
schedule (i.e. increasing only for samples showing abstinence, not for 
being lower than the previous), then non-shaping CM performs far better 
than shaping. Participants not only achieved cessation earlier, but also 
maintained it longer than those in a shaping condition [100]. 
1.2.3 CM for Smoking Cessation 
CM for the treatment of tobacco smoking is relatively under-researched 
when compared to its use as an intervention for illicit drug use. However, 
a small number of studies finding CM to be an effective intervention for 
tobacco smoking have been conducted in a range of treatment settings. For 
example, CM has been used successfully to treat smoking in pregnancy 
[101], adolescence [102,103], schizophrenia [104], and post-traumatic 
stress disorder  [105]. Although all of these studies observed significantly 
greater cessation rates or reductions in breath CO in CM conditions 
compared to control, only one [101] of these studies was carried out in the 
context of standard stop smoking treatment. This study offered pregnant 
smokers up to £400 in vouchers, over a 12-week period, for CO verified 
smoking cessation. At the primary outcome assessment, significantly more 
participants receiving rewards than not receiving rewards had stopped 
smoking (22.5% vs 8.6%). Moreover, a Cochrane review of 21 studies using 
incentives to encourage smoking cessation found that the odds ratio for 
quitting with incentives compared to without was 1.42 [106]. This suggests 
that overall, CM can act as a successful intervention for smoking cessation, 
across a number of different treatment populations.  
1.2.4 Efficacy of CM on Discontinuation of Rewards 
Although CM is often highly effective during treatment, the primary issue 
encountered with CM interventions is the high remission rates observed at 
follow-up once contingent rewards are stopped. For example, in the 
Cochrane review mentioned above, only three of the 21 studies showed 
any advantage of CM over control after 6-month follow-up. For example, 
when CM was compared to cognitive behavioural therapy (CBT) in 
23 
 
secondary-school smokers [107], CM engendered significantly greater 7-
day abstinence (36% of participants) than CBT (0%). At one month follow 
up though, only 7% of CM participants were still abstinent, compared to 4% 
in the CBT. The same has been observed in substance abuse settings, with 
a meta-analysis showing a decrease in effect size from d = 0.52 to d = 0.37 
in the three months following treatment completion [93].   
Different CM schedules do appear, however, to have differential 
effects on the longevity of treatment effects.  Escalating with reset CM, for 
example, has been found to show significantly lower tobacco smoking 
relapse in follow-up than fixed-schedule CM [108]. Similarly, in tests of 
escalating schedules with and without reset, as well as fixed reward 
schedules, escalating with reset schedules performed significantly better 
at engendering an initial period of abstinence that remained unbroken for 
the rest of the study [109]. Little research has been carried out directly 
addressing the high remission rates observed in CM, however, Kellogg and 
colleagues have identified seven key factors affecting the efficacy of CM 
interventions (target behaviour, choice of target population, choice of 
reinforcer, incentive magnitude, frequency of incentive distribution, 
timing of incentive, and duration of intervention) [82].  
1.2.5 CM for Smoking During Treatment for Opiate Addiction 
The use of CM as an intervention for smoking cessation during opiate 
addiction treatment is markedly under researched. To our knowledge, 
there are currently only four studies published that have researched CM in 
this context [70–73], all of which were carried out in the US, two by the 
same research group [70,73]. All took place in drug treatment centres (but 
not standard smoking cessation treatment, see below), with one taking 
place in a centre specifically for the treatment of drug use in pregnant 
women [71]. The total value of rewards available ranged between $362.50 
to $857.50, and two [70,72] of the four studies offered pharmacotherapy 
alongside the CM intervention, namely bupropion [70] and NRT [72]. All 
studies employed an escalating with reset CM schedules, with one of the 
studies also using a percentile shaping schedule [71]. However, there is a 
significant divide between studies in the length of intervention used and 
the number of times per week that participants were required to 
biochemically verify abstinence from tobacco smoking and receive 
rewards. The two studies run by the same research groups [70,73] lasted 
only 14 days, but recorded smoking and administered rewards on every 
day. The two remaining studies, conversely, were conducted over a much 
longer period of time (12 weeks), but biochemically measured smoking and 
administered rewards only three times a week. Notably, despite these 
studies representing the only instances of CM being used for treating 
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tobacco smoking during opiate addiction treatment, only two of the 
studies [71,73] are classified as a pilot or feasibility studies, with the other 
two [70,72] reported as full trials. These two pilot studies only reported 
efficacy data, however, not pilot or feasibility findings.  
Overall, all studies reported significantly greater smoking 
abstinence in CM conditions than in control conditions at the end of 
treatment. However, the outcomes used to measure this differ from those 
used to measure clinical efficacy in the UK. The Russell Standard [110] 
suggests that the minimum standard required of an effective treatment is 
for 40% of participants to be abstinent four weeks after the quit date. The 
two, two-week long interventions measured abstinence rates of only 30% 
[73] and 10% [70] at the 30-day follow-ups. Of the two reaming studies, one 
[71] reported a cessation rate of 31% after 12 weeks of the intervention, 
whilst the final study reported cessation rates of 25-30% at week four [72]. 
This mirrors the findings regarding the long-term effects of CM outlined 
above. It is worth noting that the Russell standard is used for smoking 
cessation in the general population, and the lower rates of cessation in 
those undergoing opiate addiction treatment may still represent a 
clinically significant reduction.  
There are also a number of other limitations in the findings of these 
studies. Firstly, none of the studies was carried out in what could be 
considered a ‘normal’ treatment environment. None of the CM 
interventions ran as an adjunct to normal stop smoking treatment, or even 
attempted to emulate the one appointment per week normally seen in 
smoking cessation treatment, instead assessing participants multiple 
times per week. Secondly, all of these studies were carried out in the US, 
making it hard to generalise their findings outside of a US opiate addiction 
treatment setting. Therefore, although CM appeared to show promise as an 
intervention for tobacco during opiate addiction treatment, it remained 
unclear not only how these results transferred to normal medical practice, 
but whether CM could even be implemented in this context at all. 
1.3 Conclusion and Aims 
1.3.1 Conclusion 
In conclusion, tobacco smoking during treatment for drug addiction, 
specifically in opiate addiction, poses a major barrier to treatment success. 
Moreover, very little has been done thus far to encourage this group to 
stop smoking, despite the steady downward trend in smoking prevalence 
observed in the general public. The result of this is not only undue 
financial stress on the already over-stretched resources of the NHS, but the 
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needless premature death of a huge number of already disadvantaged 
people. Not only is there now a great deal of evidence supporting this 
premise, but research has begun to highlight potentially effective means 
by which this can be stopped. CM has been used widely in the drug 
addictions field for a number of years, and has developed a strong 
supporting evidence base [91–95]. Moreover, it has been used not only to 
treat opiate addiction itself, but also the use of various other drugs during 
opiate addiction treatment. The use of CM for treating tobacco smoking 
during opiate addiction still remains under researched, however, and has 
never been tested in the UK. The purpose of this thesis is to address this 
issue, and aims to do so using the MRC guidelines for developing and 
evaluating complex interventions [111].  
1.3.2 Intervention Development 
Due to the specific nature of the target population and behaviour, a CM 
intervention of this type falls under that of a “complex” intervention. The 
intervention will therefore be designed under the Medical Research 
Council (MRC) guidelines for the development of complex interventions 
[111]. These guidelines constitute the important steps and processes to be 
followed when developing a complex intervention. Initially, the guidelines 
described the design process as progressing linearly through clearly 
defined phases in an iterative process. This constituted four phases; Phase 
I: Modelling, Phase II: “Exploratory Trial”, Phase III: Definitive “Randomised 
Controlled Trial”, and Phase IV: Long Term Implementation. These were 
preceded by a pre-clinical theory stage and follow a continuum of 




Figure 1 Stages of intervention development as adapted from the 2008 MRC guidelines 
for the development of complex interventions 
The most recent version of these guidelines, however, note that the 
development of interventions may not necessarily progress in a linear or 
even cyclical manner [111]. The updated guidelines instead recommend 
that the development of complex interventions should be performed 
systematically, incorporating the best quality evidence and theory 
available, and tested using a phased approach. It is these updated 
guidelines that will be implemented in this thesis (see Figure 11, chapter 
4). 
1.3.3 Aims 
There are three primary aims for this thesis: 
1. To update the literature on the efficacy of CM for treating drug use 
in the context of opiate addiction, by performing a systematic review 
and meta-analysis. At the time of commencing my PhD, the most 
recent review assessing this was published in 2000. The reason for 
the broad focus of this is due to the lack of research focussing on 
CM for tobacco smoking during opiate addiction treatment.  
2. To use the information gathered during this process to identify key 
effective components of CM interventions in this field in order to 




3. To test the feasibility of implementing this intervention in a UK 
outpatient drug treatment clinic, making recommendations for the 
potential testing of such an intervention in a full scale randomised 
control trial.  
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Chapter 2:  
 
Contingency Management for the Treatment 
of Drug Use in Opiate Addiction Treatment: 






The MRC guidelines for the development and evaluation of complex 
interventions [113] suggest that most interventions will initially go 
through a development phase. The purpose of the development stage is to 
identify the evidence base, to identify and develop theory, and in some 
cases, to model processes and outcomes. For this initial development 
stage, it is therefore commonplace to undertake some sort of formal review 
of the literature. Such a review was undertaken for this thesis to inform 
the design of the intervention and is detailed below. As mentioned in the 
previous chapter, a review on incentives for smoking cessation has already 
been carried out by the Cochrane Collaboration [106]. However, this review 
was not focussed on the treatment of tobacco smoking during opiate 
addiction treatment, necessitating the conduct of a review addressing this 
question directly. The protocol for this review is published on the 
PROSPERO website (registrations number 42016015621, available from: 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016
015621). See appendix 1 for a copy of the published article.  
2.2 Background and Aims 
Amongst those in treatment for opiate addiction, use of non-prescribed 
drugs is very common. Hair samples from 99 recently deceased opiate 
addiction treatment patients identified a range of 21 different drugs being 
used during treatment, including cocaine, amphetamine, morphine and 
diazepam [114]. Other studies have observed that over a third of patients 
entering opiate addiction treatment were also DSM-IV dependent on a drug 
other than heroin (not including nicotine) [115], and poly drug use has 
been reported to be as high as 68% [116].  These high levels of drug use 
are not limited to illicit substances. Tobacco smoking is highly prevalent 
in drug treatment in general [32], with prevalence rates of over 90% 
observed in individuals undergoing methadone treatment for opiate 
addiction [28,117]. Methadone itself has been linked to increased tobacco 
cigarette consumption, smoke intake and self-reported satisfaction of 
cigarette smoking [118] and to increased alcohol consumption compared 
with heroin use [119].  
Use of non-prescribed drugs during methadone treatment for opiate 
addiction has been associated with a range of adverse effects such as poor 
treatment retention and outcomes [120]. Use of a single drug during opiate 
addiction treatment is associated with a threefold greater risk of dropping 
out of treatment, with use of multiple drugs quadrupling the risk [121]. 
For example, cocaine use during methadone treatment has been linked to 
persistence of heroin use [122]. Similarly, as mentioned earlier, tobacco 
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smoking during opiate detoxification results in significantly greater opiate 
craving and significantly lower rates of detoxification completion [37] and 
is associated with higher levels of illicit drug use [63]. 
High prevalence rates and the links to adverse treatment outcomes 
indicate a need for effective interventions for non-prescribed drug use 
during opiate addiction treatment. One of the most widely used 
behavioural interventions is contingency management (CM). CM uses 
rewards (for example vouchers, clinical privileges or desirable items to be 
won as prizes) to positively reinforce abstinence from or reduce use of 
drugs during treatment for opiate addiction. CM differs from other 
common psychological interventions in that the focus of treatment is not 
on introspective analysis of discrepancies between goals and behaviour (as 
in motivational interviewing) or modification of flawed cognitive 
processing (as in CBT), but instead on directly influencing the 
reinforcement mechanisms involved in addiction [123]. Despite a number 
of recent reviews assessing the efficacy of CM for substance use in general 
[91,92,95,124], very little is known about the use of CM for treating use of 
non-prescribed drugs in the context of opiate addiction treatment, where 
treatment outcomes may differ.  
Whilst some of these reviews included studies assessing the use of 
CM in this context, none directly addressed the efficacy of CM for 
substance use during opiate addiction treatment.  The most recent review 
of this specific use of CM is a meta-analysis published over 16 years ago 
[125]. CM was observed to perform better overall than control, and the 
effects of CM for drug use during opiate addiction treatment were 
observed to be moderated by five factors (type of reinforcer, time to 
reinforcement delivery, targeted CM drug(s), number of urine specimens 
collected per week and type of subject assignment). However, this review 
did not search the literature systematically, increasing the risk of bias in 
the selection of study data. Similarly, it did not assess the effects of 
different drugs targeted with CM, instead only assessing the moderating 
effects of targeting single or poly drug use. The aim of the present review 
was to assess the efficacy of CM for treating the use of different non-
prescribed drugs during treatment for opiate addiction, by systematically 






2.3.1 Search Strategy  
The review was carried out in accordance with PRISMA (Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses) guidelines [126]. Studies 
were identified using a keyword search of the online databases Embase, 
PsychInfo, PsychArticles using the Ovid SP interface and Medline using 
PubMed, with the following search terms: “Contingency Management” or 
“Reward” or “Payment” or “Incentive” or Prize” and “Substance” or 
“Misuse” or “Drug” or “Narcotic*” or “Tobacco” or “Smok*” or “Stimulan*” 
or “Cocaine” or “Alcohol” and “Opiate” or “Opioid” or “Heroin” or 
“Methadone”. The search was limited to studies published between each 
database’s inception and March 2015, published in the English language 
and including only humans. See appendix 2 for full search strategy.  
2.3.2 Inclusion and Exclusion Criteria 
Studies were eligible for inclusion if they: i) Tested one or more CM 
intervention(s) aimed at substance use reduction or abstinence in patients 
receiving treatment for opiate addiction; ii) used a controlled trial design–
either a no/delayed treatment control group or an alternative therapy 
control group, or controlled by repeated participation in two or more 
treatment arms; iii) randomised participants to conditions; iv) provided 
reinforcement or punishment contingent on biological verification of 
substance use/abstinence; v) used consistent measures of substance use 
at baseline and follow-up; vi) published in a peer reviewed journal. Studies 
were excluded if: i) Participation was non-voluntary – e.g. court orders, 
prison inmates etc.; ii) means and standard deviations for treatment 
effects were not available from the published data or the authors.  
2.3.3 Study Selection 
Studies were reviewed for inclusion by three independent reviewers, with 
all studies being reviewed for inclusion twice. One reviewer (myself) 
processed all titles and abstracts as first reviewer, and two other reviewers 
(RC and LB) jointly processed half each as second reviewers. An agreement 
rate of 96% was reached between reviewers; disagreements were discussed 
and resolved by a separate reviewer.  
2.3.4 Quality Assessment  
We were unable to identify a quality assessment tool specifically for CM 
studies. Therefore, the EPHPP’s (Effective Public Health Practice Project) 
‘Quality Assessment Tool for Quantitative Studies’ [127] (referred to 
hereon as the EPHPP tool), was used to assess the internal and external 
validity of all studies, as well as any biases and confounds. This assesses 
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the quality of studies as strong, moderate or weak on six domains 
(selection bias, study design, confounds, blinding, data collection and 
withdrawals/dropouts) providing an overall score for the quality of the 
evidence in the study. A study is rated as providing strong evidence only 
when all domains are rated as moderate or strong, and a moderate rating 
when strong or moderate ratings are achieved for all bar one of the 
domains. Inter-rater reliability for the EPHPP tool  has been shown to be 
‘fair’ across the six domains and ‘excellent’ overall, often performing 
better than the Cochrane Collaboration Risk of Bias Tool [128] which is why 
it was selected for use here. All quality assessments were performed by a 
single assessor (myself). 
2.3.5 Data Extraction and Synthesis 
All data extraction was completed by a single reviewer (myself) using an 
extraction table designed specifically for the current review and agreed by 
all reviewers (see supplementary materials). Where studies did not contain 
means and standard deviations for treatment effects, authors were 
contacted up to two times to obtain the data. Requests for data were sent 
to authors of 35 studies, with data for six studies being received [129–134]. 
Where means and standard deviations were not obtained, alternative data 
including F tests, t tests and chi square were used to calculate an effect 
size where feasible [70,72,135,136]. 
2.3.6 Outcome Measures 
Standardised mean differences (Cohen’s d [137]) were calculated for each 
individual study using either 1) longest duration of abstinence (LDA) data 
or 2) percentage of biochemically verified negative samples (PNS). LDA 
refers to the longest continuous period of abstinence from a drug, often 
measured in days or weeks. PNS is a measure of the number of drug-
negative samples submitted as a percentage of the total number of samples 
submitted over the course of a trial [138]. As follow-up data were available 
for only four [70,133,139,140] of the 10 studies that included a follow-up 
period, all data used in analyses are those recorded during treatment. 
2.3.7 Moderators 
A number of possible moderators were assessed, based on those shown in 
previous reviews to impact on the efficacy of CM [93,125]. These included 
the drug targeted for intervention, the decade in which the study was 
carried out, the quality of the study, duration of the intervention, the type 
of reinforcer used, and the form of opiate treatment participants were 
undergoing.  Some moderators previously suggested to affect the efficacy 
of CM [93,125] could not be investigated due to a lack of suitable data in 
the included studies or because all studies used the same approach. For 
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example, the number of times abstinence was verified per week could not 
be investigated as 16 studies recorded this three times a week compared 
to only five recording it twice a week and one study recording it every day. 
Similarly, type of incentive (positive, negative, mixed) was not tested as all 
except two studies in both analyses used a mixed incentive. Time to 
reinforcement could not be tested as all included studies delivered 
immediate reinforcements.  
2.3.8 Data Analysis 
Meta-analyses were carried out using RevMan v5.3 [141] software. Data 
were entered into a generic inverse variance analysis in RevMan that 
analysed the efficacy of CM compared with control across all drug use 
during treatment for opiate addiction, using both LDA and PNS. All meta-
analyses were carried out as random effects analyses due to the wide 
variety of CM interventions included [142]. To allow comparison of CM to 
control, some multi-arm trials were collapsed into a two arm design by 
averaging the effects across the treatment conditions [143]. This was only 
done, however, when each arm used CM in isolation (other than normal 
pharmacological treatment for opiate addiction); if a study arm included 
CM in combination with another behavioural or pharmacological treatment 
not part of standard treatment, then this arm was not included in the meta-
analysis. This was done in order to match the design of the included 
studies with only single experimental and control arms. Control arms were 
not collapsed unless each was a standard treatment control. For example, 
one study [144] had four conditions (CM with either methadone or 
buprenorphine and performance feedback with either methadone or 
buprenorphine), so the two CM conditions were collapsed together, as were 
the two performance feedback conditions. Another study [145] also had 
four conditions (CM, methadone increase, CM + methadone increase and a 
usual care control), but no conditions were collapsed and only the CM and 
usual care control conditions were used in the analysis. The I
2
 statistic was 
used to assess the percentage of variability in treatment effect estimates 
attributable to between-study heterogeneity.  
Moderator analysis was performed using Comprehensive Meta-
analysis software V.3 [146]. Results were computed using random effects 
statistics and indicate the extent to which each moderator accounts for 
variability in effect sizes with respect to drug use outcomes. A significant 
value of Q-between indicates significant differences among effect sizes 
between the categories of the moderator variable. This method also 
calculates the mean pooled effect size for each category within the 
moderator variable being tested and whether this is significant. For the 
drug targeted for intervention, studies fell into five categories: opiates, 
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cocaine, opiates and cocaine combined, tobacco, and polysubstance use. 
For study decade, studies were grouped as being published from 1990-
1999, 2000-2009 and 2010 onwards (study publication dates ranged from 
1993 to 2015). Study quality followed the strong, moderate and weak 
ratings of the ‘Quality Assessment Tool for Quantitative Studies’ [127]. 
Intervention durations were grouped as <12 weeks, 12 weeks, and >12 
weeks. Reinforcer type was categorised as monetary vouchers and ‘other’. 
Opiate treatment similarly contained two categories, methadone treatment 
and ‘other’.   
Publication bias was assessed using the ‘failsafe N’ technique [147], 
calculated using Comprehensive Meta-analysis software V.3 [146]. This 
calculates the number of studies averaging a Z-value of zero that would be 
required to make the overall pooled effect size non-significant [147].  
2.4 Results 
2.4.1 Included Studies  
A total of 3144 studies were identified in the search, yielding a total of 22 
studies meeting inclusion criteria that could be included in the meta-
analysis (see PRISMA flow diagram, Figure 2). The included studies 
randomised a total of 2333 patients to 39 CM conditions and 33 non-CM 
control conditions. This included three studies with two CM conditions 
each collapsed into a single CM condition, four studies with three CM 
conditions each collapsed into a single CM condition, and two studies with 
two CM and two control conditions each collapsed into single CM and 




Figure 2 PRISMA flow diagram 
2.4.2 Study Description and Quality Assessment 
Eight of the 22 studies tested the effects of CM for cocaine use, two for 
opiate use, one for tobacco smoking, six for the combined use of opiates 
and cocaine, and five for polysubstance use. Twenty-one studies included 
some form of opiate substitution therapy (18 methadone, one 
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buprenorphine, one a mixed buprenorphine and naloxone tablet, and one 
suboxone), with only a single study not utilising any form of opiate 
substitution therapy. The duration of CM interventions used ranged 
between 11 days and 31 weeks, with the number of participants in each 
study ranging between 12 and 388. Seventeen studies reported retention 
rates, resulting in an average retention rate of 76.4% (range 51.2% - 97.7%). 
All studies were carried out in the US, with 13 being carried out in the same 
state (Maryland). See Table 4 at the end of this chapter for a full description 
of included studies and interventions. Methodological quality assessment 
using the EPHPP rated two studies as overall providing strong evidence, 10 
studies moderate evidence and 10 studies weak evidence (Table 1). 










Cocaine        
Epstein et al. 2003 2 1 1 2 1 2 Strong 
Katz et al. 2002 2 1 3 2 1 1 Moderate 
Kidorf et al.  1993 3 1 1 2 1 1 Moderate 
Petry et al. 2007 3 1 1 3 1 2 Weak 
Silverman et al. 1996 3 1 1 2 1 1 Moderate 
Silverman et al. 1998 2 1 1 2 1 3 Moderate 
Umbricht et al. 2014 3 1 1 1 1 2 Moderate 
Vandrey et al. 
2007 
3 1 3 2 1 3 Weak 
Opiates 
       
Ling et al. 2013 2 1 3 2 1 2 Moderate 
Preston et al. 2000 3 1 3 1 1 1 Weak 
Opiates and Cocaine 
       
Chutuape et al. 2000 3 1 1 2 1 3 Weak 
Epstein et al. 2009 3 1 1 2 1 2 Moderate 
Groß et al. 2006 3 1 1 2 1 2 Moderate 
Katz et al. 2002 2 1 1 2 1 3 Moderate 
Petry et al. 2002 2 1 1 2 1 1 Strong 
Schottenfeld et al. 2005 3 1 1 1 1 3 Weak 
Tobacco 
       
Dunn et al. 2010 2 1 1 3 1 2 Moderate 
Poly-substance 
       
Chutuape et al. 1999 3 1 3 2 1 3 Weak 
Downey et al. 2000 3 3 3 2 1 3 Weak 
Kidorf et al. 1996 3 1 3 2 1 3 Weak 
Peirce et al. 2006 3 1 1 3 1 2 Weak 
Petry et al. 2015 3 1 1 2 1 3 Weak 




The meta-analysis for LDA (longest duration of abstinence) from all 
substances combined contained 18 studies randomising 2059 patients to 
31 CM conditions and 25 non-CM control conditions. The random effects 
meta-analysis produced a pooled effect size of d=0.57 (95% CI: 0.42 - 0.72), 
with CM performing significantly better than control (Figure 3). A moderate 
[143] level of the variability of effects between studies was due to between-
study heterogeneity (I
2
 = 51%).   
 
Figure 3 Forest plot for LDA during treatment of all substances combined. (1) = Cocaine, 
(2) = opiates, (3) = opiates and cocaine, (4) = Tobacco, (5) = Poly-substance 
 
For PNS (percentage of negative samples), 12 studies randomising 
1387 patients to 24 CM conditions and 21 non-CM control conditions were 
included and the pooled effect size was d=0.41 (95% CI: 0.28 - 0.54), again 
with CM performing significantly better than control (Figure 4). Variability 
of effects was not due to between-study heterogeneity (I
2
 = 0%).   
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Figure 4 Forest plot for PNS during treatment of all substances combined. (1) = Cocaine, 
(2) = opiates, (3) = opiates and cocaine, (4) = Tobacco, (5) = Poly-substance 
2.4.4 Moderator Analysis  
The only moderator found to have a significant effect on the efficacy of 
CM was intervention drug target, but only for LDA (Tables 2 and 3). Within 
each of the categories of the six moderators, CM performed significantly 
better than control in all but three instances. Within drug targeted for 
intervention, CM performed no better than control for treating non-
prescribed opiate use for both LDA and PNS. Within intervention duration, 
CM failed to encourage significantly better LDA than control in studies with 
intervention duration of less than 12 weeks. Within opiate treatment type, 
CM did not result in significantly greater PNS than control for studies 




Table 2 Random effects moderator analysis results for LDA 
Moderator k1 
Effect Size 
(d)2 95% CI 
Z 
Value P value Q between (df)3 
P of Q 
between 
        
Drug targeted  
for intervention 18     
10.75 (4) 0.03 
Cocaine 6 0.75 0.45-1.04 4.91 <0.001   
Opiates 1 -0.10 -0.61-0.41 -0.40 0.70   
Opiates and cocaine 6 0.48 0.32-0.64 5.85 <0.001   
Tobacco  1 1.02 0.37-1.67 3.10 <0.01   
Poly substance 4 0.62 0.27-0.98 3.45 <0.01   
        
Study decade      1.31 (2) 0.52 
1990-1999 4 1.08 0.14-2.02 2.23 0.02   
2000-2009 10 0.53 0.41-0.65 8.67 <0.001   
2010 onwards 4 0.53 0.32-0.74 4.92 <0.001   
        
Study Quality       2.66 (2) 0.23 
Strong 2 0.87 0.48-1.27 4.37 <0.001   
Moderate 8 0.57 0.32-.82 4.47 <0.01   
Weak 8 0.51 0.30-0.72 4.75 <0.001   
        
Intervention 
Duration      1.30 (2) 0.52 
< 12 Weeks 2 0.26 -0.41-0.93 0.77 0.44   
12 Weeks  12 0.63 0.44-0.82 6.42 <.001   
> 12 Weeks 4 0.53 0.27-0.79 4.04 <.001   
        
Reinforcer type      0.022 0.88 
Monetary Vouchers 16 0.57 0.41-0.74 6.86 <.001   
Other' 2 0.54 0.13-0.95 2.55 0.01   
        
Opiate treatment      0.65 0.42 
Methadone 13 0.61 0.42-0.80 6.45 <0.001   
Other 5 0.47 0.20-0.74 3.46 <0.01     
1Number of studies, 2Weighted random effects, 3 A significant value of Q-between indicates significant differences 





Table 3 Random effects moderator analysis results for PNS 
Moderator k1 
Effect Size 
(d)2 95% CI Z Value P value Q between (df)3 
P of Q 
between 
        
Drug targeted  
for intervention      6.43 (4) 0.17 
Cocaine 4 0.4 0.13-0.67 2.89 <0.01   
Opiates 3 0.18 -0.11-0.46 1.23 0.22   
Opiates and cocaine 2 0.43 0.18-0.67 3.42 <0.01   
Tobacco  2 1.02 0.37-1.67 3.09 <0.01   
Poly substance 1 0.49 0.23-0.74 3.74 <0.001   
        
Study decade      1.10 (2) 0.58 
1990-1999 2 0.51 0.25-0.77 3.83 <0.001   
2000-2009 3 0.30 0.01-0.59 2.01 0.05   
2010 onwards 7 0.40 0.20-0.60 3.93 <0.001   
        
Study Quality       0.36 (2) 0.84 
Strong 1 0.48 0.21-0.75 3.43 <.01   
Moderate 5 0.36 0.06-0.66 2.32 0.02   
Weak 6 0.44 0.30-0.58 0 <0.001   
        
Intervention 
Duration      0.32 (2) 0.85 
< 12 Weeks 5 0.47 0.28-0.67 4.73 <.001   
12 Weeks  2 0.42 0.18-0.67 3.35 0.04   
> 12 Weeks 5 0.37 0.02-0.71 2.06 <0.01   
        
Reinforcer type      0.41 (1) 0.52 
Monetary Vouchers 9 0.39 0.23-0.54 4.82 <0.001   
Other' 3 0.51 0.17-0.85 2.94 <0.01   
        
Opiate treatment      0.35 (1) 0.55 
Methadone 8 0.45 0.30-0.60 6.00 <0.001   
Other 4 0.32 -0.08-0.72 1.58 0.12     
1Number of studies, 2Weighted random effects, 3 A significant value of Q-between indicates significant differences among 
effect sizes between the categories of the moderator variable 
 
2.4.5 Publication Bias 
There is widespread acceptance of the fact that studies reporting positive 
results are far more likely to be published than studies reporting null 
findings, resulting in an over representation of positive results within the 
literature [148–150]. The ‘failsafe N’ [147] calculates the number  of studies 
reporting null results that would be required to overturn the statistically 
significant difference between CM and control observed above. For LDA, 




Overall, the random effects analyses showed CM performed significantly 
better than control in encouraging abstinence from a range of different 
drugs in patients undergoing treatment for opiate addiction. This was the 
case when measuring both LDA and PNS, producing medium and small 
[137] pooled effect sizes respectively. Moderator analysis performed on 
drug targeted for intervention, decade in which the study was carried out, 
quality of the study, duration of the intervention, type of reinforcer used, 
and form of opiate treatment, showed drug target for LDA data to be the 
only characteristic significantly moderating the efficacy of CM, driven 
primarily by the ineffectiveness of CM in treating opiate use. Despite only 
a single significant moderator effect, within each of the six moderator 
categories CM was found to perform significantly better than control in all 
but three cases. CM performed no better than control in encouraging 
abstinence from non-prescribed opiates during treatment for opiate 
addiction, measuring both LDA and PNS. CM also performed no better than 
control for LDA in studies with interventions less than 12 weeks long, and 
PNS in studies where usual opiate treatment was anything but methadone 
treatment. CM for other non-prescribed drug use in treatment for opiate 
addiction had no negative impact on usual treatment retention compared 
to three-month follow-up retention rates observed in usual opiate 
treatment [151–153].  
This review has a number of limitations. One aim of the moderator 
analysis was to analyse the effects of CM by target drug type. To improve 
on the work of Griffith et al., (2000), five categories of drugs were used 
rather than two. However, one of them, polysubstance use, combined 
studies with four differing definitions of this, making results hard to 
integrate. CM still performed better in this category though, suggesting a 
robustness of effects across a variety of different drug combinations. 
Another limitation is that the review does not contain any grey literature. 
This means that any CM studies that have been conducted yet never 
published are not included in the analysis. 
The current review does have a number of strengths however. It is 
the first review in over 16 years to address directly the efficacy of CM for 
encouraging abstinence from non-prescribed drug use during treatment 
for opiate addiction. This is important as CM has gained considerable 
support in this time, having been recommended since 2007 as a treatment 
for drug misuse by the National Institute for Health and Care Excellence 
[154]. The findings of the current review support those of the previous 
reviews carried out in the field; finding an overall positive small to medium 
[137] effect size for CM in treating drug use in opiate addiction treatment 
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[125]. This is in contrast to the usual small effect size of psychological 
interventions in the field [94].  Findings of the present review are also 
similar to those of previous reviews assessing the use of CM for drug use 
overall, regardless of treatment setting, which found similar small to 
medium effect sizes for drug use in general [91–93,95,124]. The 
robustness of the effects of CM across different client groups suggests 
potential utility in treating a diverse range of individuals and needs within 
the addictions field. 
We found no evidence of CM working better than control in 
encouraging abstinence from non-prescribed opiates during treatment, 
which is in contrast to Prendergast et al., (2006) who identified CM as one 
of the most effective treatments for opiate use. The current review 
included only two studies of this type, compared to four (different) studies 
included in the previous review because of differing review aims. 
Moreover, three of the four opiate studies in the previous review 
systematically reduced methadone doses to zero over the course of the 
intervention, thereby increasing the likelihood of relapse to opiates and 
perhaps handing those receiving CM a competitive advantage over those 
not. Studies in the current review, however, maintained medication doses 
throughout the duration of the intervention, possibly eliminating this 
advantage and leading to the observed non-significant finding. With more 
data, however, results for opiates may more closely follow the trends 
observed with other drugs.  
The moderator analysis performed in the current review has also 
produced contradictory results to previous reviews. Previous reviews 
[93,125] found four of the six moderators analysed here to have a 
significant effect on the efficacy of CM (drug targeted for intervention, the 
decade in which the study was carried out, the quality of the study 
evidence, the length of the intervention period). The current study only 
found a significant effect for drug targeted for intervention. A possible 
explanation for this is differences in analysis, with the previous reviews 
adopting a fixed effects analysis, and the current the more conservative 
and more widely recommended [143] random effects analysis. Support for 
this comes from more recent reviews that have adopted this same random 
effects analysis. Lussier et al., (2006) for example analysed the effects of 
three (drug targeted for intervention, the decade in which the study was 
carried out, the quality of the study evidence) moderators also analysed in 
the current and previous reviews, finding none of them to have a 
significant effect. 
More general limitations within the field have also been identified, 
for example a lack of data available for meta-analysis. In the current 
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review, a total of 21 studies that met all other inclusion criteria could not 
be included in the quantitative data synthesis. This lack of available data 
is even more pronounced for follow-up, with only 10 of the 22 included 
studies utilising some sort of follow-up element in their study design, with 
data available for only four. These four studies [70,133,139,140] had 
follow-up periods ranging between 30 days and nine months, with none of 
the studies observing a significant difference between CM and control 
conditions at follow-up. CM is often criticised for poor follow-up results, 
but given the paucity of data reported in the included studies, we were not 
able to explore this here. Another concern is the quality of the studies 
included, with only two studies being rated by the EPHPP as providing 
strong evidence, and 20 papers providing weak evidence. Notably, every 
study in the current review was performed in the US, with at least 13 
performed in the same state and 17 having at least one co-author from the 
same institution. This significantly limits the generalisability of the 
currently available evidence on CM for non-prescribed drug use in opiate 
addiction treatment.  
This lack of evidence particularly highlights the need for more 
research on the effectiveness of CM as an intervention for tobacco 
dependence during opiate addiction treatment. The systematic search 
returned only four studies testing interventions for tobacco smoking in 
this treatment context, only one of which [70] could be included in the 
meta-analysis due to missing data in the other three. This small study 
(n=40) tested a 14-day escalating with reset CM intervention, against a 
yoked control group (voucher earnings were yoked to those of a participant 
in the experimental condition). CM participants achieved over double the 
number of PNS than controls (55% vs 17%), and a LDA nearly triple that of 
controls (7.7 vs 2.4 days). These promising findings further reinforce the 
need for more studies investigating the effectiveness of CM as an 
intervention for tobacco smoking during treatment for opiate addiction. It 
is similarly important that future research studies are carried out in a 
wider range of countries, include follow-ups to investigate relapse after 
the removal of rewards, and focus on improving the overall quality of the 
data that are published. 
In conclusion, CM appears to be an efficacious treatment of the use 
of cocaine, non-prescribed opiates and cocaine, tobacco, and 
polysubstance use during opiate addiction treatment, but not for use of 
non-prescribed opiates. Evidence of longer-term efficacy in this treatment 
context remains lacking, as is research into the effects of CM on tobacco, 
providing the rationale for the intervention for the intervention developed 
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Chapter 3:  
 





3.1 Introduction and Aims 
 
3.1.1 Introduction 
During the process of conducting the meta-analysis, it became clear that 
there was no quality assessment tool set up specifically for use with CM 
papers. Due to the complex nature of CM interventions, there are a number 
of specific elements of the interventions that can impact their efficacy as 
previously discussed [82]. It can therefore be argued that the currently 
available means of assessing study quality assess only the generic 
methodological qualities of CM studies. This is because the most widely 
used quality assessment tools (for example the Cochrane Collaboration’s 
tool for assessing risk of bias [143]) are designed to assess the quality of 
any randomised controlled trial regardless of the nature of the 
intervention used. What this effectively means, is that any current quality 
assessment made of a CM study disregards the quality of the CM 
intervention itself. Moreover, it can result in unfair appraisals of study 
quality, due to the incompatibility of some common trial practices with CM 
interventions, for example, allocation concealment. Due to the importance 
of accurately assessing study quality in systematic reviews and meta-
analyses, the decision was made to attempt to create, for the first time, a 
quality assessment tool that could be used specifically for CM studies. This 
chapter details the design and preliminary reliability and validity testing 
of such a tool. Development took place in two stages: stage one included 
the initial development of the tool and reliability and validity testing; stage 
two included refining the tool in light of the stage one findings and the re-
testing of reliability and validity.  
3.1.1 Existing Quality Assessment Tools 
The first step in development of the new quality assessment tool was 
identifying an extant quality assessment tool that could act as a template. 
A recent meta-analysis of quality assessment tools identified a total of 21 
different tools [155]. Quality assessment tools for RCTs were most 
prevalent, with six different tools being identified. Quality assessment 
tools were also found for assessing studies of various other 
methodologies. These included: two tools for assessing non-randomised 
intervention studies; three for case-control, cohort, cross-sectional and 
case series studies; three for diagnostic accuracy studies; three for animal 
studies; three for systematic reviews and meta-analyses, and one for 
assessing clinical practice guidelines. 
Due to the majority of CM studies being tested using an RCT design 
[91,93–95,125,156], RCT quality assessment tools were most pertinent to 
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the design of the new tool for assessing quality in CM studies. The six 
studies identified in the meta-analysis included: the Cochrane 
Collaboration’s tool for assessing risk of bias [143]; the PEDro scale 
(Physiotherapy Evidence Database scale) [157]; the JADAD scale [158]; the 
Delphi list [159]; CASP (Critical Appraisal Skills Programme) checklist RCTs 
[160]; and the NICE (National Institute For Health and Clinical Excellence) 
Methodology Checklist for RCTs [161]. I additionally identified a further 
two tools used to assess the quality of RCTs:  the EPHPP Quality 
Assessment tool for Quantitative Studies, identified whilst carrying out my 
meta-analysis, [127] and the National Institute of Health’s Quality 
Assessment of Controlled Intervention Studies [162].  
In 2008 the JADAD scale was the most widely used as well as the 
most reliable and valid [163], however, the Cochrane Collaboration’s tool 
has also become equally widely used and accepted [155]. More recently, 
however, the EPHPP Quality Assessment tool for Quantitative Studies [127] 
has grown in prominence, not only being recommended by the Cochrane 
Collaboration [143] but also being shown experimentally to outperform the 
Cochrane Collaboration’s tool for assessing risk of bias as previously 
discussed[128].  
 Despite the relatively large number of different quality assessment 
tools available, the majority of tools, including the three most widely used, 
all follow a very similar format. Each of the tools includes a series of 
different criteria used to assess studies on a two or three-point scale. The 
EPHPP tool, for example, assesses studies on six criteria (selection bias, 
study design, confounds, blinding, data collection and withdrawals and 
dropouts) each of which is rated as either strong, moderate or weak. The 
Cochrane Collaboration’s tool assesses papers along seven criteria 
(random sequence generation, allocation concealment, blinding of 
participants and personnel, blinding of outcome assessment, incomplete 
outcome data, selective reporting and other sources of bias) rating them 
as either low, high, or unknown risk of bias [164]. The modified JADAD 
uses a series of nine yes or no questions (Is this an RCT study?; Reported 
as randomised?; Randomisation is appropriate?; Double blinding is 
reported?; Double blinding is appropriate?; Withdrawals are reported by 
number and reasons her arm?; Method used to assess adverse events is 
described?; Method of statistical analysis is described?; Inclusion and/or 
exclusion of the requirements is described?) to rate the quality of papers. 
However, as important as these generic methodological aspects are for the 
overall quality of a study, their generic nature necessarily means that 
intervention specific aspects are overlooked. Consequently, when these 
tools are applied to complex behavioural interventions such as CM, an 
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objective rating of quality cannot be achieved. Another important element 
of study quality is the implementation of an intervention, namely, the 
degree to which the implementation of an intervention follows 
recommended practice. This issue of implementation in the appraisal of 
study quality is something that all current quality assessment tools fail to 
address [155], again compromising the ability of these tools to assess 
study quality objectively when used in practice.  
A number of different process evaluation frameworks aimed at 
addressing this dual issue of including both intervention specific aspects 
and treatment implementation in quality appraisal have been suggested 
[165–167]. One area where this is beginning to be addressed is in 
behavioural interventions for smoking cessation, where a taxonomy of the 
behaviour change techniques used has been developed [168,169]. The 
application of this for the improvement of treatment was assessed in a 
recent study. Thirty different group support manuals used by English stop 
smoking services were assessed using the taxonomy. An average of seven 
behaviour change techniques were identified in each manual, with two 
positively associated with short term quit rates [170]. This not only 
highlights the importance and utility of assessing the active elements of 
behavioural interventions, but also draws into question why more detail 
on behaviour change techniques are not included in quality assessment 
tools. The issue of poor reporting of implementation in behavioural 
interventions is still widespread, with only 5-30% of experimental studies 
reporting their interventions in detail [166]. Resultantly, treatment 
implementation also remains largely unreported despite its documented 
importance for the quality of both the design and implementation of 
interventions [171]. With complex behavioural interventions such as CM, 
the efficacy of the intervention is so closely linked to its design and 
implementation that any quality rating that neglects these issues is 
severely limited. Any new quality assessment tool for a complex 
intervention should therefore attempt to include this in its design.  
3.1.2 Aims of Developing the CMQAT (Contingency 
Management Quality Assessment Tool) 
The rationale for designing the current quality assessment tool was to 
create a tool that allowed a fairer appraisal of quality than allowed by 
current quality assessment tools, that includes not only methodological 
quality but also assesses how factors shown to impact efficacy are 
implemented. The aims of this study therefore were to: 




2. Test the reliability and validity of the newly developed tool, and 
compare this against an established quality assessment tool.  
3.2 Stage One: Development and Testing of the 
Quality Assessment Tool 
3.2.3 Developing Assessment Criteria 
In order to achieve these aims, it was imperative to identify key 
intervention elements that have been shown to impinge on the overall 
quality of CM interventions; the rationale behind this being that these 
could then be used as criteria against which to rate the quality of CM 
studies. In 2007 the NIDA (National Institute on Drug Abuse) and SAMHSA 
(Substance Abuse and Mental Health Services Administration) engaged the 
leading researchers in the CM field to create a document outlining the 
foundations and principles of CM, including the key elements impacting 
efficacy of CM [82]. The seven core elements of CM interventions were 
identified in the introductory chapter (chapter 1) and are discussed in 
detail below: 
1. Target behaviour: All CM interventions, regardless of the target 
behaviour, should incentivise behaviour using a “reinforcement” rather 
than “reward” schedule [90]. A “reward” schedule entails the completion 
of a large, often long-term goal (for example 4 weeks abstinence), whereas 
a “reinforcement” schedule breaks behaviours down into smaller steps 
that are each rewarded. This is important as it is the inability to achieve 
these longer-term goals that CM is designed to remedy. The desired target 
behaviour and exactly what is expected from those receiving the 
intervention should be clearly and formally laid out at the beginning of 
treatment [82], and the target behaviour should be readily measurable and 
objectively verifiable [172].  
The target behaviour that rewards are made contingent upon is very 
important, especially in terms of differentiating between the goal of the 
intervention and target behaviour. In interventions for substance use 
disorders, for example, the ultimate goal and hence the most obvious 
target behaviour, is long-term abstinence. However, a number of different 
behaviours can be targeted either individually or in combination, for 
example, treatment adherence [173,174]. Similarly, percentile shaping, 
where the goal of the intervention is abstinence but the target behaviour 
is gradual reduction of use, may work better than making rewards 
contingent on abstinence from the outset [97,98,100,175].  
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2. Choice of target population: As resources are often limited, it is 
important to identify a target population most in need of treatment, even 
though it would be ideal to treat an entire population. Using the fishbowl 
method of CM (where tickets representing different value rewards are 
picked from a container) can often be useful in this context as it reduces 
the overall cost of delivering the intervention, allowing a wider population 
to be treated than a standard CM intervention of the same cost. Also, 
different formulations of reward schedule may work better for different 
populations. Percentile shaping for example has been found to be 
particularly successful in the treatment of “hard to treat” smokers [97,98]. 
Target populations can also differ by treatment centre location. For 
example, when testing CM to encourage methadone clinic attendance in 
China, prize-based CM was significantly better at retaining patients in 
methadone maintenance therapy than usual treatment. However, the 
difference in the two conditions was only significant in the treatment 
centre based in a rural part of China and not for the centre in the urban 
area [176].  
3. Choice of reinforcer: The most widely used CM reinforcer in addictions 
research is monetary vouchers, however, they are not necessarily the most 
effective. When asked, individuals in treatment for opiate addiction report 
they would rather receive take-home methadone doses than cash 
incentives [177,178]. This is borne out in meta-analysis findings, where 
take-home doses of methadone have been observed to be most effective in 
treating substance use disorder (SUD) amongst those in treatment for 
opiate addiction [125]. This means that a key factor in choosing the right 
reinforcer may well involve polling the treatment population or 
participants to ascertain the most popular incentives. However, this must 
also be balanced with what the treatment centres, where these 
interventions are carried out, feel is most suitable for their clients. For 
example, a common concern amongst clinicians and to some degree 
researchers is that providing cash vouchers may result in relapsed drug 
use. This fear is not supported by research, however, where cash has been 
shown to be of no greater risk than monetary vouchers [129,179]. Some 
research has shown cash rewards to be more effective than both goods 
based and voucher based rewards in drug treatment [129,180]. Other 
research, though, has shown there to be no difference in efficacy between 
using cash or voucher incentives [129,179]   
4. Incentive Magnitude: According to theories of operant conditioning 
(the behavioural principle on which CM is built) the larger the magnitude 
of the reward the more appealing it is and the more effective it will be at 
encouraging the desired behaviour [181]. Incentive magnitude has also 
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been observed in a meta-analysis to moderate the efficacy of CM, with large 
incentives performing significantly better than smaller ones in 
encouraging abstinence [91]. 
5. Frequency of incentive distribution: This is closely related to the 
behaviour being encouraged, and the ease with which it can be verified. In 
substance use disorders, CM interventions normally follow an “FR1” (fixed 
ratio 1) pattern, meaning that every time the desired behaviour is 
observed, the incentive is given. The necessity for this schedule of 
incentive distribution in CM for substance use disorders can make the 
treatment prohibitively expensive, especially when it is taken into account 
that higher magnitudes of reward will result in greater efficacy of the 
intervention. The “fishbowl” method of CM was created in order to combat 
this issue, where rather than being given rewards outright, participants are 
instead allowed to draw tickets from a container for each display of the 
desired behaviour. The proportion of “winning” tickets and the monetary 
values of these are assigned dependent on the study being conducted. This 
allows an FR1 schedule to be maintained, even with large magnitude 
rewards, with the actual attainment of tangible goods controlled at 
whatever fixed ratio rate is deemed necessary, simply by altering the 
proportion of “winning tickets”.  
6. Timing of the incentive: The time delay between the verification of a 
desired behaviour taking place, and receiving the reward for doing so, can 
be instrumental in the efficacy of a CM intervention. This is especially the 
case in individuals with SUDs, who show increased bias toward immediate 
reinforcement than delayed reinforcement [182]. A meta-analysis has 
shown that timing of incentive operates as a moderator to the efficacy of 
CM, with immediate rewards performing significantly better than delayed 
rewards in encouraging abstinence [91]. It is recommended that rewards 
should be received within 48 hours of displaying the behaviour to be most 
effective [82]. This is especially important in the treatment of SUDs due to 
the exaggerated delay discounting observed in those with addictions [182]. 
This is a result of the temporal order of reinforcement in addiction.  The 
positive reinforcing effects of a drug’s use happen very quickly after its 
use, whereas any negative effects usually happen a lot later, meaning that 
the negative effects of drugs do not act as negative reinforcers [89].  
7. Duration of the intervention: As noted above, one of the primary 
shortfalls of CM is that once rewards for behaviour are removed, 
participants will often return to using drugs. It would therefore seem to be 
imperative that interventions are run for long enough to allow patients to 
change their behaviour for a sustained period of time so that the risk of 
relapse is low. There is very little research that addresses duration of 
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intervention as a moderator of treatment efficacy. One meta-analysis 
suggested that there may be no effect on treatment outcomes [125] at all, 
however, significant methodological heterogeneity between the included 
studies was likely to explain this observation. Conversely, the results of 
my own meta-analysis show that, at least for the LDA outcome, CM 
performed no better than control in interventions under 12 weeks long. 
Until experimental research is carried out directly investigating this, there 
is no “ideal” length of CM intervention, and cues should instead be taken 
from the standard treatment techniques used for each individual drug.    
3.2.4 Creating Rating Criteria and Calculating Study Quality 
The EPHPP quality assessment tool was chosen as the template from which 
to create the new tool as it is recommended for use with RCTs by the 
Cochrane Collaboration [143], and has also been shown to have excellent 
inter-rater reliability [128]. Resultantly, I translated the seven core 
principles of CM outlined above to fit this template, creating the new 
quality assessment scale, to which I gave the acronym CMQAT 
(Contingency Management Quality Assessment Tool).  
As discussed in the previous chapter, the EPHPP tool rates studies as 
either strong (one), moderate (two) or weak (three) across six criteria 
(selection bias, study design, confounders, blinding, data collection 
method, and withdrawals and dropouts). The overall quality rating given 
to a study is then based on the number of weak ratings that the study 
receives over these six criteria. Studies receiving no weak ratings are rated 
as providing strong evidence overall, studies receiving one weak rating as 
providing moderate evidence and all other studies as providing weak 
evidence. For the CMQAT, we wanted to implement a similar system of 
scoring, however felt that it was more logical to assign higher scores for 
higher quality (i.e. reversing the scoring system of the EPHPP). Therefore, 
the assessments for each criterion in the new quality assessment tool 
would be three for strong, two for moderate and one for weak. The initial 
descriptions of strong, medium and weak ratings on each of the seven 
criteria are outlined below in section 3.5, alongside the changes made to 
criteria in light of stage one testing, and the resulting new criteria used 
during stage two testing.  
Four different methods for calculating the overall quality of the 
studies were assessed during reliability and validity testing because of 
concerns that the strict method of rating studies implemented by the 
EPHPP tool had the potential of being overly stringent, resulting in studies 
being rated as providing poorer quality evidence than they actually do.  
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Scoring method 1 “Strict”: This was a replication of the scoring used in the 
EPHPP tool but with scores reversed (i.e. 3 for strong and 1 for weak).  
Scoring method 2 “Lenient”: The second was a less stringent version of the 
EPHPP method, allowing studies with a single weak rating and at least three 
strong ratings to be classified as providing strong evidence, and studies 
receiving two weak ratings to be classified as providing moderate strength 
evidence. This again used the reverse scoring system to the EPHPP method 
(3 for strong and 1 for weak) 
Scoring method 3 “Sum”: Global rating based on the sum of quality rating 
scores across the six rating criteria 
Scoring method 4 “Average”: Global rating based on the average of quality 
rating scores across the six rating criteria.  
3.3 Stage One: Reliability and Validity Testing 
Methods 
 
3.3.1 Study Selection 
In order for validation testing to be performed, a selection of CM studies 
that could be tested using the CMQAT was required. Having previously 
performed a systematic search for CM studies whilst carrying out the meta-
analysis, it was decided that the 22 studies returned by this search would 
be used for testing the new tool. All of the included studies assessed the 
efficacy of CM in encouraging abstinence from non-prescribed drug use 
during opiate addiction treatment. Full details of the systematic search and 
included studies can be found in Chapter 2, and also in appendix 2. 
 
3.3.2 Reliability and Validity Measures 
Current evidence suggests that very few of the tools commonly used to 
assess the quality of studies have actually gone through validation testing 
[163]. This posed some problems for the development of the current tool 
as there is very little precedent in the literature as to how to go about 
validity and reliability testing in this specific context. It was therefore 
decided that two common measures of validity and reliability would be 
measured, namely inter-rater reliability and predictive validity.  
3.3.3 Inter-Rater Reliability Testing 
Inter-rater reliability is a quantitative measure of the degree of agreement 
between different coders on the same scale [183]. I and two other 
researchers (Assessors 1, 2 and 3) rated each of the studies, and then I 
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calculated the level of agreement between the three. This was calculated 
as Fleiss’s Kappa, a statistical measure that allows for comparisons of rater 
agreement between two or more raters [184]. This produces a score 
between zero and one, with scores of 0.01-0.2 representing slight 
agreement, 0.21-0.40 fair agreement, 0.41-0.60 moderate agreement, 0.61-
0.80 substantial agreement and 0.81-1.00 almost perfect agreement [184].  
3.3.4 Predictive Validity Testing 
Predictive validity tests the degree to which the scores of one scale are 
predictive of those of another [185]. In the current case, this was tested by 
calculating the correlation between the overall quality scores of studies 
using the CMQAT by each of the three assessors and the effect size of each 
study. The effect sizes of 22 studies across two different treatment 
outcomes were used to conduct this testing: twelve studies with effect 
sizes calculated based on percentage of negative samples, and 18 with 
effect sizes based on longest duration of abstinence. In performing the 
predictive validity testing, the quality scores of the relevant studies for 
each treatment outcome and the effect sizes of studies for each of these 
treatment outcomes were correlated. This predictive validity testing was 
also performed using the EPHPP quality assessment tool, in order to 
investigate whether this established quality assessment tool was 
predictive of the strength of study outcome. Correlations between effect 
size and EPHPP score were calculated using the ratings assigned to studies 
by Assessor 3 (myself) only. Ratings assigned using the EPHPP tool were 
performed following the instructions supplied with the tool. Due to the 
small sample size of studies being rated, and the large number of similar 
scores resulting from the strong, moderate or weak rating scale, 
correlations were calculated as Kendall’s tau with pairwise deletion. 
3.4 Stage One: Results 
3.4.1 Missing Data 
Whilst carrying out the quality assessments, it was discovered that a 
number of the published articles were missing data pertaining to the 
“frequency of incentive distribution” and “timing of the incentive” criteria. 
In total, 19 of the 22 studies were missing information required to 
complete the quality assessment. For the studies with missing data, each 
was provisionally marked as weak for the criteria for which data were 
missing. The authors of these studies were then contacted to clarify these 
details. Twelve of the authors contacted replied, all of which clarified the 
missing details on the papers.  
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3.4.2 CMQAT Quality Ratings and Inter-Rater Reliability 
Criterion and global quality ratings for all papers, along with percentage 
agreement between the three assessors, are shown in Figures 5 and 6 
below. The number of studies rated overall as providing strong, moderate 
or weak evidence by each of the three reviewers is shown in Table 5.
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Criterion Ratings     
   
 
   
 
       
 
   
 
   
 Target 







 Frequency of  
distribution  
Timing of  
incentive  
Duration of  
intervention 
Study A1 A2 A3  A1 A2 A3  A1 A2 A3  A1 A2 A3  A1 A2 A3  A1 A2 A3  A1 A2 A3 
Katz 2002 2 3 3  2 3 3  2 3 2  3 3 3  2 3 2  1 1 1  1 2 2 
Silverman 1998 3 3 3  3 3 3  2 3 2  3 3 3  3 3 2  1 3 1  2 2 2 
Epstein 2003 3 3 3  3 1 2  2 3 2  2 2 2  3 3 1  1 3 2  2 2 2 
Groß et al. 2006 3 3 3  2 2 3  2 3 2  1 1 1  3 3 1  3 3 3  1 3 1 
Ling 2013 3 3 3  2 2 3  2 1 2  2 2 2  2 3 2  1 3 2  1 3 1 
Vandrey 2007 3 3 3  2 3 2  2 3 3  1 1 1  2 3 2  2 1 2  2 2 1 
Dunn 2010 3 3 3  2 2 3  2 3 2  3 3 3  3 3 3  3 1 1  2 2 1 
Kidorf et al. 1993 2 3 1  1 2 3  1 1 1  1 1 1  3 1 1  1 1 3  1 1 1 
Chutuape et al. 1999 3 3 3  3 3 1  3 3 3  2 2 2  3 3 1  2 3 1  1 3 3 
Kidorf et al. 1996 3 3 3  2 3 1  2 1 3  3 3 3  2 3 1  1 3 1  1 2 1 
Peirce et al. 2006 3 3 3  2 3 3  2 3 2  1 1 1  2 3 2  3 3 2  1 3 2 
Chutuape et al. 2000 3 3 3  2 3 3  2 3 3  3 3 3  3 1 1  1 1 1  1 3 1 
Petry et al. 2002 3 3 3  2 3 3  2 3 2  2 2 2  3 3 2  2 3 3  1 3 2 
Preston 2000 3 3 3  2 3 2  2 3 2  2 2 2  3 3 2  2 1 2  1 3 1 
Schottenfeld et al. 2005 3 3 3  3 3 2  2 3 2  2 2 2  3 3 1  3 3 3  1 3 1 
Epstein et al. 2009 3 3 3  3 2 3  2 3 2  2 2 2  3 3 2  3 3 2  1 3 2 
Petry 2007 3 3 3  3 3 3  2 3 2  2 2 2  2 3 2  2 3 1  1 3 2 
Petry et al. 2015 3 3 3  2 3 3  2 3 2  1 1 1  2 3 2  2 3 3  2 3 2 
Silverman 1996 3 3 3  1 3 3  2 3 2  2 2 2  2 2 2  2 3 1  1 3 2 
Umbricht 2014 3 3 3  3 3 2  2 3 2  2 2 2  2 3 2  1 3 1  1 3 1 
Downey et al. 2000 3 3 3  3 2 1  2 3 2  2 2 2  3 3 2  1 1 1  1 3 1 
Katz et al. 2002 3 3 3  2 2 2  2 3 2  2 2 2  3 3 2  3 3 3  1 3 1 
                            
Percentage Agreement1  
Target 







 Frequency of  
distribution  
Timing of  
incentive  
Duration of  
intervention 
 A1 A2 91%  A1 A2 41%  A1 A2 9%  A1 A2 N/A 
 A1 A2 55%  A1 A2 41%  A1 A2 23% 
 A3 A1 91%  A3 A1 27%  A3 A1 86%  A3 A1 N/A 
 A3 A1 41%  A3 A1 50%  A3 A1 59% 
 A3 A2 95%  A3 A2 41%  A3 A2 18%  A3 A2 N/A 
 A3 A2 18%  A3 A2 41%  A3 A2 23% 
 
Figure 5 Stage one criterion ratings for CMQAT. A1= Assessor 1, A2= Assessor 2, A3= Assessor 3, 
1 
Percentage agreement calculated as the number of the 
same rating given to studies for each criterion, expressed as a percentage. 
2
 Percentage agreement was not calculated for Incentive Magnitude as this is 





 Strict  Lenient  Sum Score 
  Average Score  
 
A1 A2 A3  A1 A2 A3  A1 A2 A3  
 
A1 A2 A3 
 
Katz 2002 1 2 2  2 3 3  13 18 16 
  1.86 2.57 2.29  
Silverman 1998 2 3 2  3 3 3  17 20 16 
  2.43 2.86 2.29  
Epstein 2003 2 2 2  3 3 2  16 17 18 
  2.29 2.43 2.00  
Groß et al. 2006 1 2 1  2 3 1  15 18 14 
  2.14 2.57 2.00  
Ling 2013 1 2 2  2 3 2  14 18 19 
  2.00 2.57 2.11  
Vandrey 2007 2 1 1  2 1 2  14 16 14 
  2.00 2.29 2.00  
Dunn 2010 3 2 1  3 3 3  17 16 16 
  2.43 2.29 2.29  
Kidorf et al. 1993 1 1 1  1 1 1  11 11 11 
  1.57 1.57 1.57  
Chutuape et al. 1999 1 2 1  1 3 1  16 19 14 
  2.29 2.71 2.00  
Kidorf et al. 1996 1 2 1  2 3 1  13 17 13 
  1.86 2.43 1.86  
Peirce et al. 2006 2 3 2  2 3 2  15 20 19 
  2.14 2.86 2.11  
Chutuape et al. 2000 1 1 1  2 2 1  15 17 15 
  2.14 2.43 2.14  
Petry et al. 2002 2 3 3  2 3 3  15 20 17 
  2.14 2.86 2.43  
Preston 2000 2 2 2  2 3 2  15 18 14 
  2.14 2.57 2.00  
Schottenfeld et al. 2005 2 3 1  3 3 2  17 20 14 
  2.43 2.86 2.00  
Epstein et al. 2009 2 3 3  3 3 3  17 19 16 
  2.43 2.71 2.29  
Petry 2007 1 2 2  2 3 2  14 19 19 
  2.00 2.71 2.11  
Petry et al. 2015 3 3 2  3 3 3  15 20 16 
  2.14 2.86 2.29  
Silverman 1996 1 3 2  2 3 2  14 20 19 
  2.00 2.86 2.11  
Umbricht 2014 1 2 1  1 3 2  13 19 13 
  1.86 2.71 1.86  
Downey et al. 2000 1 2 1  2 3 1  15 17 14 
  2.14 2.43 1.56  
Katz et al. 2002 2 3 2  3 3 2  16 19 15 
  2.29 2.71 2.14  
 
        
         
Percentage Agreement1  Strict  Lenient  Sum Score
2  Average Score2  
 A1 A2 23%  A1 A2 75%  A1 A2 r= 0.508 p= 0.016 
 A1 A2 r= 0.510 p= 0.015 
 A3 A1 55%  A3 A1 55%  A3 A1 r= 0.255 p= 0.252 
 A3 A1 r= 0.481 p= 0.024 
 A3 A2 45%  A3 A2 32%  A3 A2 r= 0.523 p= 0.012 
 A3 A2 r= 0.588 p= 0.004 
 
Figure 6 Stage one overall ratings for the CMQAT. A1= Assessor 1, A2= Assessor 2, A3= Assessor 3, 
1 
Percentage agreement calculated as the number of 
the same rating given to studies for each criterion, expressed as a percentage. 
2
 Pearson’s correlation and associated p value.
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Table 5 Number of studies rated by each assessor as providing strong, moderate and weak 
evidence on CMQAT 
  Overall Quality Ratings (N, %) 
Assessor  
and rating method Strong Moderate Weak 
    
Assessor 1, Strict 2 (9.09%) 9 (40.91%) 11 (50.00%)  
Assessor 2, Strict 8 (36.36%) 11 (50.00%)  8 (36.36%) 
Assessor 3, Strict 2 (9.09%) 10 (45.45%) 10 (45.45%) 
    
Assessor 1, Lenient 7 (31.82%) 12 (54.55%) 3 (13.64%) 
Assessor 2, Lenient 19 (86.36%) 1 (4.45%) 2 (9.09%) 
Assessor 3, Lenient 6 (27.27%) 10 (45.45%) 6 (27.27%) 
 
Inter-rater reliability testing yielded an overall kappa value of k= .095 (p= 
.293) for the strict scoring system and k= .065 (p= .479) for the lenient 
scoring system, both signifying only slight agreement. Significant positive 
correlations were observed between assessors one and two, and assessors 
two and three for the sum scoring method, and between all assessors for 
the average scoring method.  
3.4.3 CMQAT and EPHPP Predictive Validity 
Correlations between the four different overall scoring methods for the 
CMQAT (strict, lenient, sum score and average score) and the effect sizes 
of the studies rated are shown in Table 6. No significant correlations were 
observed between any of the CMQAT scoring methods for the three 
assessors, and effect sizes of the studies rated. 
Table 6 Correlations between CMQAT quality scores and study effect sizes for each of the 
three assessors 
  Marking Criteria 
Effect Size Type Strict Lenient Sum Score Average Score 
Assessor 1 
    
Longest Duration of Abstinence (N= 18) 
τ = 0.380  
(p= 0.855) 
τ = 0.075  
(p= 0.714) 
τ = 0.174  
(p= 0.368) 
τ = 0.174  
(p= 0.368) 
Percentage of Negative Samples (N= 12) 
τ = 0.250  
(p= 0.315) 
τ = 0.000  
(p= 1.000) 
τ = -0.065  
(p= 0.779) 
τ = -0.065  
(p= 0.779) 
Assessor 2 
    
Longest Duration of Abstinence (N= 18) 
τ = 0.137  
(p= 0.510) 
τ = 0.131  
(p= 0.539) 
τ = 0.191  
(p= 0.325) 
τ = 0.191  
(p= 0.325) 
Percentage of Negative Samples (N= 12) 
τ = -0.297  
(p= 0.226) 
τ = -0.385  
(p= 0.133) 
τ = -0.408  
(p= 0.078) 
τ = -0.408  
(p= 0.078) 
Assessor 3 
    
Longest Duration of Abstinence (N= 18) 
τ = 0.113  
(p= 0.582) 
τ = 0.206  
(p= 0.306) 
τ = 0.249 
(p= 0.198) 
τ = 0.249 
(p= 0.198) 
Percentage of Negative Samples (N= 12) 
τ = -0.250  
(p= 0.315) 
τ = 0.000  
(p= 1.000) 
τ = 0.050  
(p= 0.831) 





Correlations between the EPHPP quality scores and the effect sizes of the 
studies rated are shown below in Table 7. No significant correlations were 
observed between EPHPP scores of the three assessors, and effect sizes of 
the studies rated. 
Table 7 Correlations between EPHPP quality scores and study effect sizes  
Effect Size Type EPHPP Score 
Longest Duration of Abstinence (N=18) τ = 0.212 (p= 0.268) 
Percentage of Negative Samples (N= 12) τ = 0.032 (p= 0.888) 
 
3.5 Assessment Criteria Revisions 
 
3.5.1 Alteration Process 
Between stage one and two testing, the three reviewers discussed their 
experiences of using the rating criteria for the CMQAT. Particular attention 
was given to those criteria on which agreement during stage one was 
especially low. This process led to a number of changes being made to the 
stage one criteria before stage two testing. The stage one criteria, along 
with the changes made and the resulting new criteria are outlined below in 
section 3.5.2. As well as these changes to criteria, a number of other 
changes were made including the addition of a set of instructions for the 
application of the tool. The formatted versions of the stage two rating 
criteria and instructions are shown in appendix 3. 
3.5.2 Changes Made to Criteria 
General instructions (introduced after stage one): 
• Each of the quality rating criteria is marked on a three-point scale 
that rates the paper as strong (3), medium (2) or weak (1) for that 
criterion.  
• Where the information required for a rating to be made is missing in 
the published paper, the study should be rated as weak for that 
criterion. Authors should then be contacted to clarify this 
information and the assessment altered accordingly.   
• All contingency management schedules should fall under that of 
“reinforcement” rather than “reward” [90]. The “reward” model 
entails the completion of a large, often long-term goal (for example 
two weeks of abstinence), whereas the “reinforcement” model breaks 
behaviours down into smaller steps (for example 2 days of 
abstinence) that are each rewarded. Any study implementing a 
“reward” schedule of reinforcement should not be rated, and should 




1. Target behaviour: 
Stage one rating criteria and instructions: 
The type of target behaviour that is incentivised should fall under that 
of “reinforcement” rather than “reward” [90]. Any schedule falling 
under the “reward” definition should be given a weak rating. The 
“reward” model entails the completion of a large, often long-term 
goal, whereas the “reinforcement” model breaks behaviours down into 
smaller steps that are each rewarded. 
Strong – Both observable and measurable with biochemical 
verification or treatment staff / experimenter verification 
Moderate – Both observable and measurable with participant self-
report data only 
Weak – Neither observable nor measurable, ill-defined target 
behaviour or not related to condition being treated  
Changes made: 
• Any schedule falling under the “reward” definition should be 
excluded rather than given a weak rating 
• Use of self-report data for contingent rewards now to result in a weak 
rating. 
• Behaviour must be both measurable AND observable in order for a 
strong rating to be awarded. 
• If behaviour measurable but not observable then a moderate rating 
should be given. 
• Added stipulation that the CM schedule needs to be maintained 
throughout duration of the study. 
 
Stage two instructions: 
• “Measurable” refers to a behaviour that can be measured using an 
objective recording method, for example, urine, blood or breath 
levels of a drug [186].  
• “Observable” refers to the behaviour being directly observable and 
validated by a member of the treatment team. For example observed 
or pH or heat tested urine samples [186]. 
• The same contingency management schedule should be maintained 
for the duration of the intervention, unless there is an a priori 
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investigative motive for not doing so. Any study that alters the 
contingency management schedule without this being part of the 
initial study design should be marked as weak for this criterion.     
 
Stage two rating criteria: 
Strong (3) – Both observable AND measurable, with biochemical 
verification or treatment staff / experimenter verification 
Moderate (2) – Measurable but not observable  
Weak (1) – Neither observable nor measurable, ill-defined target 
behaviour or not related to condition being treated OR self-report 
2. Target population: 
Stage one rating criteria and instructions: 
Strong – Highly specific and very well-defined target population / 
condition, with few potentially confounding between-participant 
differences, and with good justification for the use of CM.  
Moderate – Less specific and less well-defined target population / 
condition OR some potentially confounding between-participant 
differences, with some justification for the use of CM. 
Weak – Non-specific and ill-defined target population / condition with 
a great deal of potentially confounding between-participant 
differences; little or no justification for the use of CM OR differences 
between participants not reported. 
Changes made: 
• Instructions added to make it clearer where the data for this criterion 
come from – i.e. from the testing of between-participant variables.  
• Removed the need for a justification of the use of CM as this was too 
subjective. 
Stage two instructions: 
• “Between-participant differences” – Demographic variables/ 
participant characteristics statistically tested for differences 
between groups (e.g. experimental vs control) 
Stage two rating criteria: 
73 
 
Strong (3) – Specific and well-defined target population / condition 
AND no significant between-participant differences 
Moderate (2) – Specific and well-defined target population / condition 
AND any significant between participant differences have been 
controlled for in analysis. 
Weak (1) – Non-specific and ill-defined target population / condition 
AND/OR significant between-participant differences, that have NOT 
been controlled for in analysis OR between-participant differences not 
reported (contact authors to request data) 
3. Choice of reinforcer: 
Stage one rating criteria and instructions: 
Strong – The choice of reinforcer has been influenced by the 
participants taking part in the study or has been shown empirically to 
be of maximum utility in the particular treatment population. 
Moderate – The choice of reinforcer has been shown in previous 
research to be of some efficacy, but may not be of optimum efficacy. 
Weak – The choice of reinforcer is not based on consultation with 
participants and has either no or limited empirical support. 
Changes made: 
• Altered to make it clearer that participant input into the choice of 
rewards needs to be made prior to the initiation of the study. 
Stage two instructions: 
• The choice of reinforcers used should only be considered to have 
been influenced by participants if this was done prior to the 
initiation of the study. For example, the exchange of earned vouchers 
for goods of participants’ choice would not fall under this definition, 
unless participants had input as to whether they wanted rewards to 
take this form or not. 
Stage two rating criteria: 
Strong (3) – The choice of reinforcer has been influenced by the 
participants taking part in the study AND shown empirically to be of 
utility in the particular treatment population. 
74 
 
Moderate (2) – The choice of reinforcer has been shown in previous 
research to be of some efficacy, but participants have not been 
consulted. 
Weak (1) – The choice of reinforcer is neither based on consultation 
with participants nor has empirical support. 
4. Incentive magnitude 
Stage one rating criteria and instructions: 
Monetary vouchers should be adjusted for inflation and the average 
weekly value calculated based on receiving all rewards. Clinical 
privileges should be ranked based on their intrinsic value to patients.  
Strong – Studies with reward values in the top quartile of ranked 
studies. 
Moderate – Studies with reward values in the middle two quartiles of 
ranked studies. 
Weak – Studies with reward values in the bottom quartile of ranked 
studies. 
Changes made: 
• Made clearer as to how this should be calculated and also added 
more information to the instructions to allow the ranking of non-
monetary vouchers. 
 
Stage two instructions: 
• For monetary vouchers/cash rewards, the total available reward 
value for each study should be adjusted for inflation from the year 
the study was conducted to the current year. This value should then 
be divided by the number of weeks that the study ran for, and the 
studies ranked based on these average weekly reward values.   
• Studies using other reward types, for example, clinical privileges 
should be ranked as moderate, unless there is evidence in the 
literature that these are of greater intrinsic value than monetary 
vouchers/cash rewards ranked in the middle quartile.  
• If quality assessments are being conducted on only a small number 
of studies, or outside of the context of a systematic review/meta-
analysis, the reward values of similar studies in the relevant field 
should instead be used a reference point for rating incentive 
magnitude. Incentives of a greater magnitude than those commonly 
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used in the field should be rated as strong, those on a par with those 
commonly used in the field as moderate, and those of lower 
magnitude than those commonly used in the field as weak. 
 
Stage two rating criteria: 
Strong (3) – Studies with reward values in the top quartile of all 
studies being rated 
Moderate (2) – Studies with reward values in the middle two quartiles 
of all studies being rated 
Weak (1) – Studies with reward values in the bottom quartile of all 
studies being rated 
5. Frequency of incentive distribution 
Stage one rating criteria and instructions: 
Strong – Explicit evidence of this being set to establish total 
compliance with agreed behavioural goals (e.g. drug abstinence)  
Moderate – Evidence of some consideration of this being set to 
establish total compliance with agreed behavioural goals (e.g. drug 
abstinence)  
Weak – No evidence of this being set to establish total compliance 
with agreed behavioural goals (e.g. drug abstinence) 
Changes made: 
• This was altered so that the moderate rating now applies to any 
study that uses a frequency of incentive distribution capable of 
capturing total compliance with behavioural goals, but does not 
explicitly report this as the motivation for implementing the 
frequency of incentive distribution used.  
Stage two instructions: 
• If data are missing for frequency of incentive distribution, score the 
study as moderate if the frequency would capture total compliance 
with agreed behavioural goals (for example testing for cocaine every 
two days [187]). Consistent with the general instructions, authors 
should still be contacted for explicit verification of this and the 
quality assessment adjusted accordingly. 
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Stage two rating criteria: 
Strong (3) – Explicit evidence of this being set to establish total 
compliance with agreed behavioural goals (e.g. drug abstinence)  
Moderate (2) – Evidence of this having the ability to establish total 
compliance with agreed behavioural goals (e.g. drug abstinence) OR 
no evidence of the frequency to establish total compliance provided 
but the frequency would catch all drug use 
Weak (1) – No evidence of this being set to establish total compliance 
with agreed behavioural goals (e.g. drug abstinence) 
6. Timing of the incentive 
Stage one rating criteria and instructions: 
Based on the meta-analysis of (Griffith et al., 2000): 
Strong – Immediate reward on display of desired behaviour 
Moderate – Reward administered within 24 hours of display of 
desired behaviour 
Weak – Reward administered after 24 hours of display of desired 
behaviour OR timing of incentive administration unclear  
Changes made: 
• Clarified so that a strong rating constitutes rewards administered the 
same calendar day as evidence of desired behaviour, moderate the 
next calendar day and weak any time after this. 
Stage two instructions: 
• It should be noted that for “fishbowl” type interventions (where for 
each verified display of the desired behaviour, participants earn the 
right to draw tickets from a bowl that can represent money or 
prizes), it is the earning of draws from the “fishbowl” that 
constitutes the reward, not the later exchange of these earned 
rewards for physical goods.  
Stage two rating criteria: 
Based on the meta-analysis of (Griffith et al., 2000) 
Strong (3) – Reward administered on the same calendar day as display 
of desired behaviour 
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Moderate (2) – Reward administered one calendar day after the 
display of desired behaviour 
Weak (1) – Reward administered more than one calendar day after 
display of desired behaviour OR timing of incentive administration 
not reported (contact authors to request data) 
7. Duration of the intervention 
Stage one rating criteria and instructions: 
Strong – Explicit justification of the intervention duration based on 
previous research or the length of other treatments being 
administered to patients (e.g. methadone treatment, drug detox etc.)  
Moderate – No explicit justification of the intervention duration but 
it is evident that it follows either a precedent in the literature or other 
treatments being administered to patients (e.g. methadone treatment, 
drug detox etc.) 
Weak – No explicit justification of the intervention duration and no 
evidence of following either a precedent in the literature or other 
treatments being administered to patients (e.g. methadone treatment, 
drug detox etc.) 
Changes made: 
• Clarified criteria so that strong rating is only available to studies that 
explicitly justify length of intervention. 
Stage two instructions: 
• Aligning with other treatment: This refers to the length of the 
contingency management treatment following the length of another 
treatment being administered to participants. For example, 
treatment for illicit drug use often takes place over 12 weeks [188] 
or for smoking cessation (in the UK) over six weeks [56]. Therefore, 
a contingency management that followed the duration of another 
treatment given to participants, but did not explicitly state this as 
the motivation for the treatment duration used, would be rated as 
providing moderate strength evidence. Authors should still be 
contacted for explicit verification of intervention duration and the 
quality assessment adjusted accordingly.  
Stage two rating criteria: 
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Strong (3) – Explicit justification of the intervention duration being 
based on empirical support of efficacy  
Moderate (2) – No explicit justification of the intervention duration 
but it follows clinical precedent or aligns with other treatments being 
administered to patients (e.g. methadone treatment, drug detox etc.) 
Weak (1) – No explicit justification of the intervention duration and 
no evidence of following either a precedent in the literature or other 
treatments being administered to patients (e.g. methadone treatment, 
drug detox etc.) 
3.6 Stage Two: Validation Testing Methods 
 
3.6.1 General Methods 
After the changes outlined above had been made to the rating criteria, 
inter-rater reliability testing was re-conducted. One of the stage one 
assessors (A1) was no longer available, so an alternative reviewer (A4) 
performed the stage two ratings alongside myself and the other reviewer 
who rated studies during stage one. Inter-rater reliability was calculated in 
the same way as during stage one, and the same method of calculating the 
four overall quality scores for the CMQAT was also implemented. 
3.6.2 Study Selection  
The 20 studies used for stage two assessments were identified in the same 
systematic search as those in stage one. However, these studies were not 
included in the meta-analysis due to it not being possible to calculate 
effect sizes for any of these studies. 
3.6.3 Predictive Validity 
As effect sizes could not be calculated for the studies being assessed 
during stage two, it was not possible to perform predictive validity testing 
during this stage of testing.  
3.6.4 EPHPP Quality Assessments 
As predictive validity testing was not possible during stage two, the inter-
rater reliability of the EPHPP was additionally tested. All three assessors 
therefore rated stage two studies using the EPHPP tool as well as the 
CMQAT. The aim of this was to assess whether the CMQAT could achieve 
similar levels of inter-rater reliability as an established quality assessment 
tool, i.e. the EPHPP. Ratings assigned using the EPHPP tool were carried out 
in accordance with the instructions supplied with the tool. 
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3.7 Stage Two: Results  
 
3.7.1 CMQAT Quality Ratings and Inter-Rater Reliability 
Criterion and global quality ratings for all papers, along with percentage 
agreement between the three assessors, are shown in Figures 7 and 8 
below. The number of studies rated overall as providing strong, moderate 




Ratings                            
 Target 







 Frequency of  
distribution  
Timing of  
incentive  
Duration of  
intervention 
Study A1 A4 A3  A1 A4 A3  A1 A4 A3  A1 A4 A3  A1 A4 A3  A1 A4 A3  A1 A4 A3 
Katz et al. 2004 2 2 2  2 2 2  2 2 2  2 2 2  3 1 3  2 1 3  2 2 2 
Sigmon 2004 3 3 3  1 3 1  2 2 2  1 1 1  2 2 3  1 1 1  3 1 1 
Rawson 2002 2 3 2  3 3 3  2 2 2  2 2 2  3 2 2  3 3 2  2 2 3 
Correia 2005 3 3 3  2 3 3  2 2 2  2 2 2  3 2 3  1 1 1  3 1 1 
Hall 1979 3 3 3  1 1 1  2 1 2  2 2 2  2 2 2  1 1 1  2 2 2 
McCaul 1984 3 3 3  1 1 3  2 1 2  1 1 1  1 1 1  3 1 1  3 2 2 
Tuten 2012 2 3 3  3 3 3  2 2 2  2 2 2  2 2 1  1 1 1  1 1 2 
Iguchi 1996 3 3 3  3 3 3  2 2 2  3 3 3  2 1 3  3 1 3  3 1 1 
Stitzer 1992 3 3 3  3 1 1  2 2 2  3 3 3  3 1 2  1 1 3  2 1 1 
Kosten 2003 2 3 3  3 3 3  2 2 2  2 2 2  3 2 2  1 3 1  2 2 2 
Carpenedo 2010 3 3 3  3 1 1  2 3 2  2 2 2  2 3 2  1 3 1  3 2 3 
Winstanley 2011 3 3 3  2 2 3  2 2 2  2 2 2  2 2 2  1 1 1  3 2 2 
Iguchi 1997 3 3 3  3 3 3  2 1 2  1 1 1  2 2 2  1 3 1  2 2 2 
Preston 2001 2 3 3  2 2 2  2 2 2  2 2 2  2 2 2  2 3 1  1 2 2 
Correira 2003 2 2 2  3 1 1  2 2 2  1 1 1  2 1 2  1 1 1  3 1 3 
Shoptaw 2002 3 3 2  3 3 2  2 2 2  1 1 1  1 1 2  1 3 1  2 2 2 
Cutuape 1999 3 3 3  3 1 3  2 2 2  3 3 3  2 2 2  1 3 3  2 1 2 
Dunn 2008 3 3 3  3 3 3  2 2 2  3 3 3  3 3 3  3 3 3  3 1 1 
Silverman 1999 3 3 3  3 3 1  2 2 2  3 3 3  2 2 2  3 3 3  2 1 1 
Robles 2002 3 3 3  1 3 3  2 2 2  2 2 2  2 3 2  1 3 1  3 2 1 
                            











 Frequency of  
distribution  
Timing of  
incentive  
Duration of  
intervention 
 A1 A4 80%  A1 A4 65%  A1 A4 80%  A1 A4 N/A 
 A1 A4 55%  A1 A4 50%  A1 A4 35% 
 A3 A1 80%  A3 A1 55%  A3 A1 100%  A3 A1 N/A 
 A3 A1 60%  A3 A1 70%  A3 A1 40% 
 A3 A4 90%  A3 A4 70%  A3 A4 80%  A3 A4 N/A 
 A3 A4 45%  A3 A4 50%  A3 A4 70% 
 
Figure 7 Stage two criterion ratings for CMQAT. A1= Assessor 1, A2= Assessor 2, A3= Assessor 3, 
1 
Percentage agreement calculated as the number of the 
same rating given to studies for each criterion, expressed as a percentage. 
2
 Percentage agreement was not calculated for Incentive Magnitude as this is 















Study A1 A4 A3  A1 A4 A3  A1 A4 A3   A1 A4 A3  
Katz et al. 2004 3 1 3  3 2 3  15 12 16   2.14 1.71 2.29  
Sigmon 2004 1 1 1  1 1 1  13 13 12   1.86 1.86 1.71  
Rawson 2002 3 3 3  2 3 3  17 17 16   2.43 2.43 2.29  
Correia 2005 2 1 1  3 2 2  16 14 15   2.29 2.00 2.14  
Hall 1979 1 1 1  2 1 2  13 12 13   1.86 1.71 1.86  
McCaul 1984 1 1 1  1 1 1  14 10 13   2.00 1.43 1.86  
Tuten 2012 1 1 1  2 2 2  13 14 14   1.86 2.00 2.00  
Iguchi 1996 3 1 2  3 1 3  19 14 18   2.71 2.00 2.57  
Stitzer 1992 2 1 1  3 1 2  17 12 15   2.43 1.71 2.14  
Kosten 2003 2 3 2  2 3 2  15 17 15   2.14 2.43 2.14  
Carpenedo 2010 2 2 1  3 3 2  16 17 14   2.29 2.43 2.00  
Winstanley 2011 2 2 2  2 2 2  15 14 15   2.14 2.00 2.14  
Iguchi 1997 1 1 1  2 2 2  14 15 14   2.00 2.14 2.00  
Preston 2001 2 3 2  2 3 2  13 16 14   1.86 2.29 2.00  
Correira 2003 1 1 1  2 3 1  14 9 12   2.00 1.29 1.71  
Shoptaw 2002 1 1 1  1 2 2  13 15 12   1.86 2.14 1.71  
Cutuape 1999 2 1 2  3 2 3  16 15 17   2.29 2.14 2.43  
Dunn 2008 3 2 2  3 3 3  20 18 18   2.86 2.57 2.57  
Silverman 1999 3 2 1  3 3 2  18 17 15   2.57 2.43 2.14  
Robles 2002 1 3 1  2 3 2  14 18 14   2.00 2.57 2.00  
          
 
       
      
 
   
 
       
Percentage Agreement  Strict  Lenient   Sum Score 
2  Average Score 
2 
 A1 A4 50%  A1 A4 40%  A1 A4 r= 0.359, p= 0.120  A1 A4 r= 0.360, p= 0.119 
 A3 A1 70%  A3 A1 65%  A3 A1 r= 0.827, p=<0.001  A3 A1 r= 0.823, p=<0.001 
 A3 A4 60%  A3 A4 45%  A3 A4 r= 0.408, p= 0.074  A3 A4 r= 0.405, p= 0.076 
Figure 8 Stage two overall ratings for the CMQAT. A1= Assessor 1, A2= Assessor 2, A3= Assessor 3, 
1 
Percentage agreement calculated as the number of 
the same rating given to studies for each criterion, expressed as a percentage.  
2
 Pearson’s correlation and associated p value.
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Table 8 Number of studies rated by each assessor as providing strong, moderate and weak 
evidence on CMQAT stage two 
  Overall Quality Ratings (N, %) 
Assessor  
and rating method Strong Moderate Weak 
    
Assessor 1, Strict 5 (25.00%) 7 (35.00%) 8 (40.00%) 
Assessor 2, Strict 4 (20.00%) 4 (20.00%) 12 (60.00%) 
Assessor 3, Strict 2 (10.00%) 6 (30.00%) 12 (60.00%) 
    
Assessor 1, Lenient 8 (40.00%) 9 (45.00%) 3 (15.00%) 
Assessor 2, Lenient 8 (40.00%) 7 (35.00%) 5 (25.00%) 
Assessor 3, Lenient 5 (25.00%) 12 (60.00%) 3 (15.00%) 
 
In stage two testing, there was a general improvement in percentage 
agreement between assessors across all rating criteria, and also overall for 
the strict, but not the lenient scoring method. However, agreement for 
criterion one decreased between stage one and two. Inter-rater reliability 
testing yielded an overall kappa value of k= .335 (p=>.001) for the strict 
rating system and k= .201 (p= .034) for the lenient scoring system, both 
signifying “fair” agreement. A significant positive correlation was 
observed between A1 and A3 (the two assessors testing at stages one and 
two) for both the sum and average scoring methods. No significant 
correlations were observed between A4 and either of the other two 
assessors.  
3.7.2 EPHPP Quality Assessment Tool Quality Ratings and Inter-
Rater Reliability 
Criterion and global quality ratings for all papers assessed with the EPHPP 
quality assessment tool, along with percentage agreement between the 
three assessors, are shown in Figure 9 below. The number of studies rated 
overall as providing strong, moderate or weak evidence by each of the 
three assessors is shown in Table 9.
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EPHPP Ratings                            
















Study A1 A4 A3  A1 A4 A3  A1 A4 A3  A1 A4 A3  A1 A4 A3  A1 A4 A3  A1 A4 A3 
Katz et al. 2004 2 3 3  1 1 1  1 1 1  2 3 2  1 1 1  1 1 3  1 3 3 
Sigmon 2004 3 3 2  1 1 1  3 1 3  2 3 2  1 1 1  2 1 1  3 3 2 
Rawson 2002 3 3 3  1 1 1  1 1 1  2 3 2  2 1 1  3 3 3  3 3 3 
Correia 2005 3 3 2  3 2 1  3 NA 3  2 3 2  1 1 1  3 3 3  3 3 3 
Hall 1979 1 1 3  1 1 1  3 3 3  2 3 2  1 1 1  3 3 3  3 3 3 
McCaul 1984 3 3 3  1 1 1  1 1 1  2 2 2  1 1 2  2 3 3  2 3 3 
Tuten 2012 2 1 3  1 1 1  1 1 1  2 3 2  2 1 1  3 3 3  2 3 3 
Iguchi 1996 2 2 3  1 1 1  1 1 1  2 3 2  1 1 1  2 2 2  1 2 2 
Stitzer 1992 2 3 3  1 3 1  1 1 3  2 3 2  1 1 1  1 2 2  1 3 3 
Kosten 2003 2 2 3  1 1 1  1 1 1  1 3 1  1 1 1  3 3 3  2 3 3 
Carpenedo 2010 2 2 2  1 1 1  1 3 1  2 3 2  1 1 1  3 3 3  2 3 2 
Winstanley 2011 2 2 3  1 1 1  1 1 1  2 3 2  1 1 1  3 2 2  2 2 2 
Iguchi 1997 2 1 2  1 1 1  1 1 1  2 3 3  1 2 1  2 2 2  1 2 2 
Preston 2001 2 3 3  1 1 1  2 1 1  2 3 2  1 1 1  1 1 1  1 3 2 
Correira 2003 2 3 3  3 2 1  3 NA 1  2 3 3  1 1 1  2 3 3  3 3 3 
Shoptaw 2002 2 2 3  1 1 1  1 1 1  2 3 2  2 2 1  2 3 1  1 3 2 
Cutuape 1999 2 3 3  1 1 1  1 1 3  2 3 2  1 1 1  1 3 3  1 3 3 
Dunn 2008 2 3 3  1 1 1  1 1 1  2 3 2  2 1 1  2 3 2  1 3 2 
Silverman 1999 2 2 3  3 2 1  1 NA 3  2 3 2  1 1 1  2 2 3  2 2 3 
Robles 2002 3 3 3  1 1 1  1 1 1  2 3 2  1 1 1  3 3 1  3 3 2 
                            















 A1 A4 60%  A1 A4 80%  A1 A4 70%  A1 A4 5% 
 A1 A4 80%  A1 A4 60%  A1 A4 40% 
 A3 A1 25%  A3 A1 85%  A3 A1 75%  A3 A1 90% 
 A3 A1 75%  A3 A1 50%  A3 A1 30% 
 A3 A4 50%  A3 A4 80%  A3 A4 65%  A3 A4 15% 
 A3 A4 85%  A3 A4 75%  A3 A4 40% 
 
Figure 9 EPHPP criterion and overall ratings of all three assessors for stage two studies, with overall quality ratings calculated as according to the EPHPP 
instructions (the same system as the strict rating method of the CMQAT). A1= Assessor 1, A2= Assessor 2, A3= Assessor 3. 
1
 Percentage agreement 
calculated as the number of the same rating given to studies for each criterion, expressed as a percentage.  
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Table 9 Number of studies rated by each assessor using the EPHPP quality assessment 
tool as providing strong, moderate and weak evidence 
  Overall Quality Ratings (N, %) 
Assessor  
and rating method Strong Moderate Weak 
    
Assessor 1 8 (40.00%) 6 (30.00%) 6 (30.00%) 
Assessor 2 0 4 (20.00%) 16 (80.00%) 
Assessor 3 0 9 (45.00%) 11 (55.00%) 
 
Inter-rater reliability testing of the EPHPP quality assessment tool yielded 
an overall kappa value of k= .051 (p= .607), signifying only slight 
agreement.  
3.8 Stage Three Methods 
For stage three testing, the assessor from stage two (A4) that did not assess 
the studies from stage one, used the updated rating criteria to assess the 
stage one studies. This was conducted in order to ascertain whether the 
updated rating criteria had increased the predictive validity of the tool. As 
in stage one, correlations were calculated between the quality ratings of 
the studies and the effect sizes for both longest duration of abstinence and 
percentage of negative samples. 
3.9 Stage Three Results 
3.9.1 CMQAT Quality Ratings 
Criterion and overall quality ratings and shown below in Figure 10. The 
number of studies rated overall as providing strong, moderate or weak 














Timing of the 
incentive 
Duration of the 
intervention 
Strict Lenient Sum Average 
Katz 2002 3 3 2 3 2 1 3 2 3 17 2.43 
Silverman 1998 3 2 2 3 2 1 2 2 2 15 2.14 
Epstein 2003 2 2 2 2 2 1 2 2 2 13 1.86 
Groß et al. 2006 3 3 1 1 2 1 2 1 1 13 1.86 
Ling 2013 2 2 2 2 1 3 3 2 2 15 2.14 
Vandrey 2007 3 1 2 1 2 2 2 1 2 13 1.86 
Dunn 2010 2 3 2 3 3 1 1 1 2 15 2.14 
Kidorf et al. 1993 2 3 1 1 1 3 1 1 1 12 1.71 
Chutuape et al. 1999 3 1 2 2 2 3 2 2 2 15 2.14 
Kidorf et al. 1996 3 1 2 3 1 3 1 1 1 14 2.00 
Peirce et al. 2006 3 3 2 1 1 3 3 1 2 16 2.29 
Chutuape et al. 2000 3 3 2 3 3 2 2 3 3 18 2.57 
Petry et al. 2002 3 3 2 2 2 3 2 3 3 17 2.43 
Preston 2000 3 3 2 2 3 1 1 1 2 15 2.14 
Schottenfeld et al. 2005 3 3 2 2 2 1 2 2 2 15 2.14 
Epstein et al. 2009 3 3 2 2 2 3 3 3 3 18 2.57 
Petry 2007 2 3 2 2 1 3 3 2 3 16 2.29 
Petry et al. 2015 3 3 2 1 2 1 2 1 2 14 2.00 
Silverman 1996 3 2 2 2 2 1 2 2 2 14 2.00 
Umbricht 2014 3 3 2 2 2 1 2 2 2 15 2.14 
Downey et al. 2000 2 3 2 2 2 2 3 3 3 16 2.29 
Katz et al. 2002 2 1 2 2 2 1 2 1 2 12 1.71 
Figure 10 Stage three criterion and overall quality ratings 
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Table 10  Number of studies rated by the assessor using the CMQAT as providing strong, 
moderate and weak evidence in stage three 
  Overall Quality Ratings (N, %) 
Rating 
Method  
Strong Moderate Weak 
Assessor 
4, Strict 
4 (18%) 9 (41%) 9 (41%) 
Assessor 
4, Lenient 
6 (27%) 13 (59%) 3 (14%) 
3.9.2 Predictive Validity 
Correlations between the four different overall scoring methods for the 
CMQAT (strict, lenient, sum score and average score) and the effect sizes 
of the studies rated are shown in Table 11. No significant correlations were 
observed between any of the CMQAT scoring methods and effect sizes of 
the studies rated.  
Table 11 Correlations between CMQAT quality scores and study effect sizes for each of 
the three assessors 
  Marking Criteria 
Effect Size Type Strict Lenient Sum Score Average Score 
Longest Duration of 
Abstinence (N= 18) 
τ = 0.154 τ = 0.040 τ = 0.160 τ = 0.161 
(p= 0.455) (p= 0.848) (p= 0.932) (p= 0.932) 
Percentage of Negative 
Samples (N= 12) 
τ = -0.453 τ = -0.164 τ = -0.066 τ = -0.067 




The seven core principles of CM, as laid out by the leading researchers in 
the field [82], were translated into quality rating criteria using the EPHPP 
quality assessment tool as template. Preliminary reliability and validity 
assessments of the resulting quality assessment tool, the CMQAT, were 
then assessed involving four assessors in three stages. During stage one 
testing, inter-rater reliability between the three assessors was only “slight” 
[184]. In predictive validity testing, all correlations between CMQAT scores 
and the effect sizes for the rated studies were non-significant. Correlations 
between the EPHPP quality scores and effect sizes of rated studies were 
also non-significant. Rating criteria were improved in light of stage one 
results, and in stage two testing, the inter-rater reliability between the 
three assessors increased to “fair” [184]. The inter-rater reliability for the 
same assessors, assessing the same studies, using the EPHPP quality 
assessment tool, was only “slight” [45].  Predictive validity testing was not 
possible during stage two as effect sizes could not be calculated for the 
studies used during this stage of testing. Stage three testing re-rated stage 
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one studies with the updated criteria, allowing assessment of predictive 
validity. No significant correlations were observed between the CMQAT 
quality ratings and study effect sizes.  
There are a number of limitations to this research. The main 
limitation is the restricted amount of reliability and validity testing that 
the CMQAT has undergone. Although both inter-rater reliability and 
predictive validity testing have been performed twice, a number of other 
types of reliability and validity testing should also be undergone in order 
to examine the potential of using the tool for assessing the quality of 
studies. Similarly, the tool has only been tested by a very limited number 
of assessors, with a small number of studies taken from a narrow spectrum 
of the CM literature (pertaining to SUD CM interventions). Related to this, 
there is the potential that as I both created the initial outline for the CMQAT 
and acted as an assessor during stages one and two, a certain amount of 
bias may exist in the ratings assigned in both these stages. Another 
limiting factor of the current work is that although predictive validity 
testing has been conducted twice, no significant correlations were 
observed either time, with no discernible improvement in predictive 
validity. This draws into question the methods being used to test 
predictive validity. It was the assumption here, that studies rated as being 
of higher quality should produce larger effect sizes. However, a study 
assessing the relationship between study quality and effect size, using a 
random selection of RCTs investigating interventions used for circulatory 
and digestive diseases, mental health, and pregnancy and childbirth, 
observed that lower quality studies overestimated the effectiveness of an 
intervention, artificially inflating effect sizes [189]. This may explain why 
more of the correlations observed in stage three are negative than those 
from stage one, with those that are not negative in stage three still being 
closer to zero than those in stage one. This has quite serious implications 
for future testing of the validity of the CMQAT. Whether this over-
estimation of effect size by lower quality studies also occurs in CM studies, 
and the implications of this for ascertaining the predictive validity of the 
CMQAT, merits further investigation. The potential implications of this are 
discussed in more detail in the discussion chapter (chapter six).  
Despite these limitations, there are strengths to the current work. 
This is the first time that a quality assessment tool has been created and 
tested for use specifically with CM studies, and therefore represents a 
significant contribution to the contingency management field. At the 
current time, any quality assessment of CM studies does not reflect an 
objective appraisal of study quality. The CMQAT therefore, even in its early 
stage of development, begins to address this issue, offering a more 
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objective assessment of the quality of CM studies than is currently 
available. Despite the limited scope of the results presented here, and the 
limitations outlined above, the current work provides a foundation for the 
further development of the tool. 
There are a number of directions for future research and the further 
development of the tool, with a number of important issues that require 
addressing before the use of the tool can progress. Firstly, it should be 
considered what forms of further reliability and validity testing should be 
performed on the tool. It would seem that measuring the test-retest 
reliability of the tool, for example, may represent a potentially useful 
means of further ascertaining the reliability of the CMQAT. Similarly, 
testing split-half reliability [190] may be a useful means for ascertaining 
the internal consistency of the tool. Testing with methods developed under 
item response theory [191] may help uncover whether any latent quality 
constructs exist within the tool. Other types of validity testing however, 
for example convergent validity, may be of only limited utility given the 
relative uniqueness of the CMQAT and the difficulties involved in finding 
another tool against which to compare the CMQAT in this context. It may 
also be necessary to better define what should be expected from the 
validity and reliability testing already implemented. For example, the 
inter-rater reliability achieved in the second stage of testing is low, 
representing only “fair” agreement. Despite this, inter-rater reliability was 
greater than “slight” agreement achieved with the EPHPP quality 
assessment tool, raising the question of exactly what level of agreement is 
enough to recommend the tool for use in research. Furthermore, as 
mentioned in the previous chapter, a prior study [128] showed the EPHPP 
to have “excellent” inter-rater reliability, which contrasts starkly with our 
observation of only slight agreement. It may be that there is some sort of 
practice effect [192] taking place, or alternatively it may be that the EPHPP 
is more difficult to apply to CM studies as opposed to more conventional 
RCTs. Whatever the underlying cause of this discrepancy in inter-rater 
reliability may be, it merits further investigation. Another focus of future 
research should be to determine which of the different scoring methods 
trialled here is best. The percentage agreement between assessors 
increased for the strict rating system from stage one to two, but decreased 
for the lenient. This improvement in agreement may implicate the strict 
method as potentially the more useful of the two. It may be, however, that 
the sum or average scoring systems are of greater utility for weighting 
analyses during meta-analysis, as implementing these continuous scale 
scoring methods offers a finer grain appraisal of quality than grouping 
studies under the three categories of strong moderate or weak. 
Interestingly, significant positive correlations between ratings were found 
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amongst more of the assessors in stage one than in stage two, but the 
correlations observed in stage two were stronger and more significant. As 
the improvement in the strength of correlation between stage one and two 
was in the two assessors that took part in both stages, this may suggest 
that some sort of practice effect is taking place. More research, and 
consultation with a wide range or researchers is required before the most 
appropriate scoring method can be agreed. 
Perhaps the most important element in the further development of 
the tool however, is its application by a broader range of assessors in a 
wider range of research fields. Validity and reliability testing of the CMQAT 
by experts implementing CM interventions for a wide range of behaviours, 
not just addictions, is imperative for ensuring that the CMQAT is suitable 
for use with all varieties of CM study. Given that the principles of CM that 
the CMQAT criteria are based on were constructed from the perspective of 
addictions interventions, it may be useful to perform some sort of Delphi 
experiment with researchers in other fields, similar to that used in the 
development of the Cochrane Collaborations risk of bias tool [193]. This 
would allow the development of the rating criteria to reflect more 
accurately the breadth of behaviours that CM interventions can be used to 
treat. Further to this, there is the potential that the formulation of the 
CMQAT paves the way for the development of reporting guidelines for CM 
studies, similar to the CONSORT statement [194] designed to improve the 
reporting of randomised controlled trials. This may even feed into the 
design of future CM studies, improving the quality of evidence concerning 
its efficacy, and improving outcomes for service users. An associated issue 
is that of treatment implementation. As mentioned earlier, implementation 
plays a pivotal role in the quality of any intervention, but is often poorly 
reported and at current, not included in the assessment of study quality. 
The CMQAT contains some elements related to the implementation of CM, 
but does not currently include a direct appraisal of this in its assessment. 
The initial intent of the CMQAT was to assess study quality based on the 
seven identified core components of CM, and only once this has been 
successfully completed can assessment of implementation be further built 
into the tool. 
Overall, the work reported here signifies the first steps towards the 
objective reporting of quality in CM studies. This has implications not only 
for the synthesis of systematic reviews and meta-analysis of CM studies, 
but also for the design and conduct of trials. There is a great deal of further 
testing and refinement required before the tool can be implemented in 
practice, namely in testing the CMQAT across a broader range of CM 
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From the results of the meta-analysis, it was clear that there was a 
significant gap in the literature concerning the use of contingency 
management (CM) as an intervention for tobacco smoking during opiate 
addiction treatment. As previously mentioned, only four studies [70–73] 
testing CM for tobacco dependence during opiate addiction treatment were 
identified in the systematic search, only one [70] of which could be meta-
analysed. CM has also never been tested in this context in the UK before, 
forming the basis for the decision to develop an intervention to test this. 
Due to the specific nature of the target population and behaviour, an 
intervention of this type falls under that of a “complex” intervention, and 
was therefore designed under the Medical Research Council (MRC) 
guidelines for the development of complex interventions [111] (see Figure 
11).  
 
Figure 11 Key elements of the development and evaluation process, as adapted from the 
2016 MRC guidelines. *The element represented by the work carried out in the Meta-
analysis and CMQAT (Chapters 2 and 3). ∆The element represented by the pilot/feasibility 
study (chapters 4 and 5) 
 These guidelines constitute the key elements required in the 
development of a complex intervention, starting at the development stage 
with research progressing systematically from this point [111]. The 
systematic review and meta-analysis, and the development of the quality 
assessment tool (CMQAT), constituted the first two elements of the 
development element of intervention design. These two projects 
highlighted the necessary evidence and theory regarding the use of CM in 
this treatment population that was required to develop the current 
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intervention. We then further decided that, given a small number of 
studies had already explored the use of CM for tobacco smoking during 
opiate addiction treatment [70–73], and that CM is so widely used across 
many types of drug addiction treatment, that modelling processes would 
be unnecessary. The next key element in the development of the current 
intervention therefore, is that of feasibility and piloting. The purpose of 
this is to test the procedures involved with the intervention in order to 
ascertain their acceptability, whilst allowing the estimation of likely 
recruitment and retention rates [111]. It also allows for the preliminary 
testing of any potential intervention effects as secondary outcomes, as was 
done here.  
As mentioned previously, not only is there a large body of evidence 
outlining the use of CM in drug addiction, but there are a few studies 
published  investigating its use for tobacco smoking in opiate addiction 
treatment [70–73]. Additionally, the study centre (an outpatient drug 
addiction treatment centre) where I had chosen to conduct the current 
intervention had previously implemented CM interventions in its opiate 
addiction treatment clients, including a large, cluster randomised trial 
investigating the efficacy of CM for hepatitis B vaccination completion 
[195]. The decision was therefore made that a pilot/feasibility study would 
be the most appropriate design. The methods for this pilot study are 
outlined below and have also been published in the journal BMJ Open 
(appendix 4).  
4.2 Methods and Design 
4.2.1 Objectives 
Primary objective: To investigate whether a CM intervention can be 
successfully added to standard stop smoking services treatment, in 
patients undergoing outpatient treatment for opiate addiction, in order to 
identify any elements that need changing before carrying out a full scale 
randomised controlled trial (RCT). 
Secondary objectives: To gather preliminary findings regarding the 
effects of the CM intervention on smoking behaviours in this group, and 
any possible effects the intervention may have on opiate addiction 
treatment outcomes. 
4.2.2 Study Site 
A pivotal element of the pilot study was that CM was integrated into 
standard stop smoking services treatment in the UK. This required the 
identification of an addiction treatment centre that also ran a stop smoking 
clinic. A number of potential study sites were considered, however, only 
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one of these had an extant stop smoking clinic and was therefore chosen 
as the study site. This centre was also locally accessible, and had a close 
working relationship with my department, making it an ideal location for 
the study. 
Between August 2014 and July 2015, smoking cessation treatment 
was run by the team at the treatment centre. Prior to this, it had been run 
by a specialised local authority stop smoking team. In the period between 
July 2015 and the initiation of the current study, there was no stop 
smoking service run at the treatment site, necessitating the re-training of 
staff at the treatment staff before the study could commence. During the 
period of time that the service was being run by the treatment centre, a 
total of 34 drug addiction clients were admitted into the service. These 
clients attended an average of 2.65 (SD=2.42) sessions, with seven of these 
achieving CO validated abstinence at week 4 (19).  
4.2.3 Participants, Recruitment, Inclusion Criteria and 
Randomisation 
As this was a pilot study, the primary outcome was not the efficacy of the 
study intervention. Consequently, the sample size was not calculated to 
ascertain efficacy. Instead, the method outlined by Viechtbauer et al [196] 
for calculating the sample size based on the probability of any issues that 
may arise was been used. A sample size of 40 using the above rationale is 
powerful enough to provide over 90% certainty of detecting any issues that 
occur with a probability of over 5%. The study therefore aimed to recruit 
40 patients, all undergoing current treatment for opiate addiction.  
Participants were recruited from the study site either through self-
referrals in response to advertisements shown in the treatment centre, 
directly recruited by myself in the treatment centre, or through referrals 
from treatment centre staff.  
Participants were eligible for inclusion if they wanted to quit 
smoking (complete abstinence), were between 18 and 65 years old, 
undergoing pharmacological treatment for opiate addiction, smoked a 
minimum of ten cigarettes per day (in order to capture anything from ‘light 
smoking’ and over [197,198]), and provided informed consent. Participants 
were ineligible for inclusion in the study if they exhibited insufficient 
English skills to understand study protocols, were currently undergoing 
treatment for other drugs of abuse or were taking part in other research. 
Pregnant women were not excluded. 
Participants interested in taking part in the study were given an 
information sheet and then asked to return to the treatment centre no 
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sooner than 24 hours later to sign their consent to take part in the study. 
If participants had already been given an information sheet by a member 
of staff, and had had at least 24 hours to consider whether they wanted to 
take part in the study, they were consented immediately. Once consent 
was obtained, participants were then immediately randomised into either 
experimental (CM for abstinence) or control (CM for attendance) 
conditions. Randomisations were performed by myself using the service 
provided by the company ‘sealed envelope ltd.’ [199], utilising random 
permuted blocks within strata. Randomisation was stratified based on 
participants’ current smoking frequency (between 10 and 20 per day, and 
more than 20 per day [32]). 
 
4.2.4 Study Design 
A two-arm, randomised controlled design was utilised for the pilot study. 
A CM intervention was provided as an adjunct to the standard stop 
smoking services treatment provided at the treatment centre, with CM 
rewards available during weeks 2 to 5 of the stop smoking treatment. In 
light of our meta-analysis findings that little is known regarding the 
longer-term effects of CM, a six-month follow-up was included in the 
design of the pilot study. The study was conducted in compliance with the 
principles of the Declaration of Helsinki [200], the principles of Good 
Clinical Practice, and all applicable regulatory requirements. The rationale 
for the chosen design is described in the following sections and the main 





Figure 12 Flow diagram of the main elements of the study 
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4.2.5 Standard Treatment 
The standard smoking cessation treatment provided at the treatment 
centre follows the treatment program set out by the National Centre for 
Smoking Cessation and Training (NCSCT) [56] and The National Institute 
for Health and Care Excellence (NICE) guidelines for smoking cessation 
[201]. This treatment combines manualised behavioural support to stop 
smoking with nicotine replacement therapy (NRT) and takes place over six 
weeks with one session per week. In the first meeting, the service user’s 
readiness and ability to quit is assessed, information for the remainder of 
the treatment program is given and a quit date for the next week is set. For 
the remaining five weeks, clients attend the clinic to receive behavioural 
support and have their abstinence biochemically verified. In the study 
clinic, NRT is available free of charge to all individuals engaged with 
smoking cessation treatment, in the form of nicotine patches, gum, 
inhalators, mouth or oral spray, and oral strips. At the time of the study, 
the clinic also additionally offered e-cigarettes (on a trial basis), which had 
a nicotine content of 18mg/ml. These e-cigarettes were disposable and 
securely sealed, initially designed for use in high-security environments 
such as prisons [202]. The smoking cessation treatment provided at the 
treatment centre does not include treatment with bupropion or 
varenicline.  
During the six weeks of treatment, service users are given a week’s 
supply of NRT or e-cigarettes at a time. At the end of the six weeks, service 
users are given a two-week supply of NRT or e-cigarettes before exiting the 
treatment. The type of NRT received is decided by clients with guidance 
from the cessation worker and can constitute a single form of NRT or a 
combination of different types. Clients’ breath carbon monoxide (CO) 
levels are measured using a Bedfont piCO+ Smokerlyzer breath CO 
monitor. Measurements are taken at the initial visit and at each subsequent 
visit over the next five weeks, to biochemically verify self-reported 
abstinence from smoking (CO<10ppm [110]). NRT and e-cigarette use is 
recorded throughout treatment. 
4.2.6 Contingency Management Intervention 
Target Behaviour 
The target behaviour chosen for the current intervention was smoking 
abstinence, which was chosen over other similar target behaviours for a 
variety of reasons. The primary reason for this being chosen over, for 
example, a gradual reduction in smoking, is that the intervention is 
designed to run as an adjunct to the NCSCT tobacco cessation treatment 
used at the treatment centre [203]. One of the key requirements of this 
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treatment is that service users set a quit date for the week following their 
initial visit, to which they are then expected to adhere. Meta-analysis of 
behavioural and pharmacological smoking cessation treatments has shown 
there to be no difference in cessation rates when smoking is reduced 
gradually compared to quitting abruptly [204]. It was initially thought that 
CM encouraging a gradual reduction in smoking (known as percentile 
shaping) was more effective than CM encouraging abstinence [97,98,175]. 
It was later shown however, that this increased efficacy over CM schedules 
rewarding abstinence was driven simply by higher reward values for initial 
abstinence; when this was controlled for, no difference between the 
schedules was observed [100].  The decision not to implement gradual 
reduction was also a pragmatic one, as this would have been far harder to 
implement than abstinence due to the stop smoking clinic running only 
once per week.  
Use of an Active Control Group 
Central to the concept of all controlled trials, is that the experimental and 
control conditions differ only in the treatment that they receive, allowing 
conclusions to be drawn from any differences observed in results obtained 
[205]. Normally, this would involve assigning participants to one of two 
conditions: an experimental group receiving a treatment or a control group 
receiving either no treatment, or treatment as usual. The design of CM 
treatments, however, complicates the use of this simple experimental 
design. Due to the nature of CM, in order to receive rewards participants 
must not only display the desired behaviour(s) being encouraged, but also 
display a variety of other associated behaviours, for example attending the 
treatment centre, attending on a specific day at a specific time, submitting 
to biochemical testing of abstinence etc. This effectively means that 
participants in the experimental condition of a CM study are effectively 
being reinforced for performing a number of separate actions. Therefore, 
without an appropriate control, it is impossible to disentangle the effects 
of these two separate reinforced actions on observed changes in 
behaviour.  
One method of circumventing this issue, employed in six of the 21 studies 
included in the meta-analysis presented earlier (and three of the four 
previous studies using CM as an intervention for tobacco smoking during 
opiate addiction treatment [70,71,73]), is the use of a yoked control 
condition. This is an active control condition where participants in the 
control condition also receive rewards. Each participant in the control 
condition is yoked to a participant in the experimental condition, receiving 
the same rewards as them but unaware of this yoking. This method was 
considered for the current study but given the limited resources available 
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and the complex nature of its implementation, an alternative method was 
required. A simpler and more easily implemented version of this method 
was therefore used, namely, rewarding participants for attendance at the 
treatment centre independent of their smoking status. This allowed any 
effects of the intervention on tobacco smoking to be isolated from those 
of attendance at the study centre. It would have been preferable to have 
included a third, no treatment condition, but again, limited resources 
meant that this was not possible. 
Contingency Management Schedule 
The CM intervention followed an escalating with reset schedule, where 
reward values increase in a set increment value for each successive 
verified display of the desired behaviour. When the desired behaviour is 
not observed, no reward is given, and the reward value for the next verified 
display of the desired behaviour is reset to that of the initial reward. 
Reward values then begin to rise again in the same way as before. This CM 
schedule was chosen as not only is this one of the most common schedules 
used in the CM literature [206], but was used in all four of the previously 
conducted CM studies for smoking in opiate addiction treatment [70–73]. 
However, unlike these previous studies, the length of the CM intervention 
to be used in the current study was based on the length of the NCSCT 
smoking cessation treatment [56]. The CM intervention, therefore, ran for 
five weeks in total, starting in week two of the standard stop smoking 
services treatment and ending in week six (Table 12). Participants in the 
experimental condition were rewarded for smoking abstinence, defined as 
producing a breath CO reading of <10ppm [110]. Participants in the control 
condition were rewarded for attending the smoking cessation clinic. After 
each smoking cessation treatment session, the cessation worker completed 
a slip of paper that recorded each participant’s individual participant 
number, and their breath CO reading for that session. This was then given 
to me, as I sat in an adjacent room and administered rewards where 
appropriate. Due to the nature of the CM intervention, it was not possible 
to blind participants to treatment allocation. Cessation workers were not 
made aware of treatment allocation, but could not be considered to be 
blinded to treatment allocation as it is possible that clients may have 
discussed this with them. Similarly, as I was responsible for both 
participant randomisation and incentive distribution I was similarly un-
blinded. At the end of the CM intervention, participants were asked to 
complete a client satisfaction and well-being survey, previously used to 




Setting an appropriate reward value was particularly complex due to an 
intervention of this type having never been conducted previously in the 
UK. The initial calculation of reward value was modelled on the reward 
values of four studies previously conducted in the US, all investigating CM 
for tobacco cessation in opiate addiction treatment [70–73] . The maximum 
possible amount that could be earned over the course of the intervention 
in each study was adjusted for inflation from the year that the study was 
conducted to the year 2016, and an average reward value per day 
calculated. The average daily reward value calculated from these studies 
was £12.45 (SD £7.13). However, if this reward value had been 
implemented in the current study this would have resulted in an overall 
maximum incentive magnitude of £522.90, potentially costing £20,916 if 
delivered successfully to all 40 participants. This was not only far beyond 
the available funding for the current PhD study, but would not have been 
feasible if it was later implemented as a RCT, or integrated nationally into 
normal treatment.   
However, a recent UK study investigating the efficacy of CM in 
encouraging completion of a hepatitis B vaccination programme, found 
that a reward magnitude of only £30 administered over a four-week period 
(£0,£5, £10, £15), significantly increased completion of the vaccination 
programme compared to control [195]. Although this study was conducted 
over a four-week period, participants only attended three treatment 
sessions compared to the six sessions over a six-week period in the current 
intervention. The decision was therefore made to approximately double 
the average daily reward values of this study (£1.07), increasing them 
slightly to fit with the escalating with reset CM schedule being used. This 
resulted in a maximum possible reward value of £115, averaging £2.73 per 
day over the six-week study. 
Reward values were the same in both conditions, beginning at £5 and 
doubling each time the incentivised behaviour was recorded, up to a 
maximum of £40. All rewards were delivered as “Love2Shop” vouchers (see 
below). Over the course of the whole intervention, participants could earn 




Table 12 Reward schedule for a participant that remains abstinent and/or attends all 
smoking cessation treatment meetings (dependent on condition) for the duration of the 
intervention. Maximum total reward: £115 
Smoking Cessation 
Treatment Week Number 
1 2 3 4 5 6 
CM Week Number  1 2 3 4 5 
Reward Value £0.00 £5.00 £10.00 £20.00 £40.00 £40.00 
 
Vouchers Rather Than Other Reward Types 
Current evidence suggests that the most effective reward type for 
participants in opiate addiction treatment are increases in opiate 
substitution medication, or the ability to take this home rather than 
supervised consumption at the treatment centre [125,208]. This was not 
possible to implement in the treatment centre chosen for the current trial 
however, forcing the use of an alternative reward type (for a more detailed 
discussion of reward types, see Chapter 3, section 3.2.3). The most 
commonly used reward in CM studies is money, primarily due to it being 
an almost universally conditioned reinforcer [179], and therefore rewards 




The primary outcome was assessed by recording the number of 
participants completing the five weeks of the intervention in each 
condition. Success was defined as 60% or more of participants completing 
treatment, in-line with retention rates observed in similar studies [70,73].  
The secondary objectives of the study were to gather preliminary findings 
regarding the effects of the CM intervention on smoking behaviour in this 
group, and any possible effects the intervention may have on opiate 
addiction treatment outcomes. The smoking abstinence outcome was 
recorded as point prevalence abstinence, and biochemically verified with 
abstinence defined as a breath CO reading of under 10ppm at each session 
[110]. Data concerning the opiate addiction treatment outcome were 
assessed by accessing participant medical records to ascertain 
participants’ opiate addiction treatment, including drug types (methadone, 
buprenorphine etc.) and dosage as well as illicit drug use throughout the 




At the six-month follow up (see below for follow-up procedures), the 
following measures were recorded: 
Point prevalence smoking abstinence: Self-reported smoking abstinence 
for 7 days before follow-up and exhaled air CO <10pm [110]. 
Continuous abstinence: Self-reported smoking abstinence since end of 
treatment and exhaled air CO<10ppm. Participants smoking five or fewer 
cigarettes during the six-month follow-up will be considered self-reported 
quitters using the continuous outcome measure [110].  
Illicit drug use and treatment, collected at the end of the study from 
participants’ medical records. 
All those lost to follow-up will be treated as though smoking [110].   
Other Measures 
At the first stop smoking treatment session, a number of demographic and 
smoking behaviour variables were recorded. Demographic variables 
included gender, ethnic group, employment status, how they heard about 
the service and whether pregnant and breastfeeding. Smoking behaviour 
variables included the type of tobacco that participants smoked, how many 
cigarettes per day they smoked, how soon after waking they had their first 
cigarette, how many years they had been smoking, what ages they started 
smoking and whether they lived with a smoker. Other variables collected 
included quitting confidence, importance, confidence and readiness (all 
measured on a ten-point scale), whether they had tried to quit smoking 
before and if so how many times, the number of weeks since their last quit 
attempt, their longest duration of abstinence from smoking, whether they 
had ever tried NRT and if so the number of types and the length of time 
used for, whether they had ever tried bupropion, and if they had ever used 
any other cessation aid.  The collection form showing the information 
collected can be found in appendix 5. As many contact details as possible 
were recorded for each participant in order to increase the probability of 
participants being able to be followed up. This included the details of 
relevant friends and family members.  
 
4.2.8 Follow-Up Procedures 
Six months after their set quit date, I contacted participants up to three 
times, in order to ascertain their self-reported smoking status. In order to 
test the optimal follow-up method, participants were pseudo-randomised 
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by recruitment order to be contacted by text and phone call, or email and 
phone call. All participants were asked to return to the clinic in order to 
have their breath CO levels tested to verify abstinence. Once this was done, 
participants would have completed their participation in the study. 
Participants then received a £10 voucher for completing the follow up 
procedure.  
4.2.9 Planned Analysis 
As the primary objective of the intervention was retention rather than 
efficacy, this was reported using descriptive statistics, namely means and 
standard deviations for the number of participants retained at the end of 
treatment in each condition. Any differences between conditions were 
reported using t-tests for continuous and chi square for categorical data, 
or their non-parametric equivalents. Baseline demographics, smoking 
behaviour and opiate treatment and drug use behaviour were compared 
between conditions using t-tests for continuous and chi square for 
categorical data, or their non-parametric equivalents.  
For the secondary objectives, differences between the groups in point 
prevalence smoking abstinence were investigated using t-tests for 
continuous and chi square for categorical data, or their non-parametric 
equivalents. Data for opiate use and opiate treatment outcomes were also 
compared between conditions using t-tests and chi square tests, or their 
non-parametric equivalents, dependent on data. Any questionnaire data 
were reported using descriptive statistics. All statistics were performed as 
two tailed tests using an alpha value of 0.05. 
4.3 Ethics 
There were a number of delays experienced during the application for 
ethical approval. The application for sponsorship of the study by the 
university’s R&D service was made on the 17/03/2016, and this was 
granted on the 22/04/2016. After this was granted, the IRAS (Integrated 
Research Application System) form was completed, and submitted on the 
10/05/2016. The application was submitted during the time where HRA 
approval systems were being changed, causing some further delays. The 
study received final ethical approval from the London – City and East 
ethics committee on the 16
th
 of June 2016 (reference 16/LO/0990).   
4.3.1 Risks to Participants 
There is no known risk associated with the CM behavioural intervention. 
Smoking cessation can precipitate a number of uncomfortable withdrawal 
symptoms. These will be attenuated by the stop smoking services 
treatment provided at the treatment centre, an evidence-based treatment 
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that includes nicotine replacement therapy, e-cigarettes and behavioural 
support. Any information recorded from participants will be anonymised 
using a participant ID number, the master sheet for which will be stored in 
a locked cabinet at the treatment centre. This ensures that no identifiable 
information will ever leave the treatment centre. 
4.3.3 Informed Consent 
The participant information sheet and consent form can be found in 
appendix 6. Participants will receive both the study intervention and 
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5.1 Recruitment and Participants 
 
5.1.1 Recruitment 
A total of 40 participants were recruited. Recruitment took place over an 
18-week period, beginning in October 2016 and ending in February 2017. 
The recruitment rate over this 18-week period is shown in Figure 13 below. 
There was a plateau in recruitment between weeks eight and 11 due to the 
Christmas holiday period. The Christmas break also resulted in a break in 
the experimental procedures for some participants. The break fell between 
study sessions three (19/12/2016) and four (09/01/2017), for three 
participants (one in the experimental condition and two in the control), 
resulting in a three week break in treatment. Recruitment began so close 
to the Christmas period due to delays in obtaining approval for the trial 
from the Health Research Authority (HRA). An overhaul of their application 
process resulted in a significant backlog of applications, delaying the start 
date of the study. After ethical approval was granted, it then transpired 
that clinical pressures within the treatment centre had led to the smoking 
cessation clinic being temporarily closed. This necessitated the re-training 
of staff and re-launch of the smoking cessation clinic, causing further 
significant delays to the initiation of the pilot study.  
 
Figure 13 Recruitment Rate over the 18-week recruitment period 
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5.1.2 Participant Flow Through Study 
Figure 14 below shows participant flow through the study. Due to 
implementation of multiple methods of recruitment, the number of 
participants approached and assessed for eligibility is unknown. For 
example, key workers were asked to consider their caseloads for 
participants, but it was not possible to record the number of participants 
they approached.  
 
Figure 14 Participant flow through study 
At the outset of the study, participants were asked how many 
cigarettes they smoked per day, randomised to conditions, and informed 
of their allocation to condition at the time of signing consent. However, 
the first participant consented into the study immediately dropped out 
after being assigned to the experimental condition (CM for abstinence), so 
participants were subsequently informed of their allocation after their 
108 
 
baseline session. Conversely, the recording of demographic information 
was switched from the baseline session to when consent was signed. This 
was done when it was noted that a number of participants were signing 
consent but not turning up for their baseline session. Collection of 
demographics was not possible for some participants though as they 
simply left the treatment centre after signing consent and did not return 
for their baseline session.  
Of the 40 participants initially recruited, 10 were removed from the 
analysis. Three participants were removed from the analysis after not 
being randomised after not providing the information necessary for 
randomisation and not returning to participate, and five for not returning 
to provide demographic variables after signing consent. Two further 
participants were removed from the analysis after study completion, one 
for not being found on the treatment centre’s database and another when 
it transpired that they were not in treatment for opiate dependence, but 
for cocaine abuse. All analyses, unless otherwise stated, include the 
remaining 30 participants, 13 in the experimental condition (CM for 
abstinence) and 17 in the control (CM for attendance). 
5.1.3 Recruitment Method 
As described in chapter 4, a number of different methods of recruitment 
were utilised: self-referral in response to advertisements shown in the 
treatment centre, direct recruitment by the PI in the treatment centre, or 
through referrals from treatment centre staff. (Table 13).  
Table 13 Method of recruitment by treatment condition 
  
Intervention (CM for 
abstinence), n (%) 
Control (CM for 
attendance), n (%) 
Comparison 





Key worker 4 (31%) 5 (29%) 
Study advert/word of mouth 3 (23%) 7 (41%) 
Direct recruitment by 
experimenter 
6 (46%) 5 (29%) 
χ2= Chi-square test 
 
5.1.4 Participant Demographics 
Overall, participants were predominantly male (n=19, 63%) and white 
(n=19, 63%). All participants were eligible for free prescriptions and the 
majority (n=29, 97%) had been unemployed for 12 months or more. 
Participants did not differ significantly across conditions on the 
demographic variables where tests could be carried out (Table 14).  
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Table 14 Demographic variables by condition 
  Intervention (CM for abstinence),  
N (%) 






















Gender    
Female 
Male 
5 (39%)  
8 (61%) 




Eligible for free 
prescriptions?    
Yes 13 (100%) 17 (100%) N/A
2 




















χ2= Chi-square test, 1Difference not tested due to empty cells, 2Difference not tested as no difference  
 
5.1.6 Smoking Behaviour 
Overall, participants smoked an average of 19.67 cigarettes per day 
(Median= 20, SD=7.87), began smoking at an average age of 15.33 (Median= 
15.00, SD=3.82) years old, and had smoked for an average of 26.80 
(Median= 27.00, SD=9.37) years. Most participants (N=25, 83%) smoked 
hand-rolled cigarettes and consumed their first cigarette of the day less 
half an hour after waking up (N=24, 80%). The majority of participants 
(N=21, 70%) had tried to quit smoking at least once before, having tried to 
quit an average of 3.23 (Median= 1.00, SD=4.92) times prior to the study, 
with an average of 153.23 (Median= 104.00, SD=163.77) weeks since their 
last quit attempt and average longest duration of abstinence of 41.84 
(Median=12.00, SD=65.00) days. Just over half (N=17, 57%) of participants 
had tried nicotine replacement therapy (NRT), using it for an average of 
13.01 (Median=2.25, SD=22.36) weeks and tried an average of 2.64 
(Median=2.00, SD=1.27) types. The majority (N=19, 63%) of participants 
had not previously used an e-cigarette, and just under half of the 
participants (N= 14, 47%) lived with another smoker. Average scores for 
quitting importance, readiness and confidence (out of ten) were 9.10 
(Median=10.00, SD=1.86), 7.83 (Median=8.00, SD=2.06) and 6.70 (Median= 
7.00, SD=1.91) respectively. Participants randomised to the control 
(attendance) condition reported significantly greater quitting confidence 
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than those in the experimental (abstinence) conditions. Participants did 
not differ significantly across conditions on any other smoking behaviour 
measure (Table 15). 
Table 15 Smoking behaviour variables by condition 
  Intervention (CM for 
abstinence) mean (SD)/ 
Median (range)/ N (%) 
Control (CM for 
attendance) mean (SD)/ 
Median (range)/ N (%) 
Comparison 
Cigarettes smoked per day 20.00 (5.77) 19.41 (9.33) t=-0.199 (p=0.843) 





12 (71%)  
5 (29%) 
 
Age began smoking 15.00 (9.00) 15.00 (21.00) 
U=94.000  
(Z=-0.694, p=0.487) 
Number of years smoking 25.31 (11.92) 27.94 (7.93) t=0.757 (p=0.455) 
Live with another smoker    
Yes 
No 
4 (31%)  
9 (69%) 
10 (58.80%)  
7 (41.20%) 
χ2= 2.330 (p=0.127) 
Time to first cigarette    
<30 minutes 
>30 minutes 
11 (85%)  
2 (15%) 
13 (77%)  
4 (23%) 
χ2= 0.305 (p=0.580) 
Previously tried to quit smoking    
Yes 
No 
10 (77%)  
3 (23%) 
11 (65%)  
6 (35%) 
t=0.524 (p=0.469) 
Number of previous quit attempts 1.00 (20.00) 1.00 (10.00) 
U=92.000 
(Z=-0.795, p=0.457) 
Weeks since last quit attempt 104.00 (492.00) 156.00 (620.00) 
U=51.500  
(Z=-0.594, p=0.553) 
Longest period of smoking abstinence 
(days) 
16.00 (77.80) 7.25 (259.80) 
U=75.000  
(Z=-0.110, p=0.912) 
Previously tried NRT    
Yes 
No 
8 (62%)  
5 (39%) 
9 (53%)  
8 (47%) 
χ2= 0.222 (p=0.638) 
Weeks NRT used for 8.00 (77.70) 2.00 (31.50) 
U=27.500  
(Z=-0.425, p=0.671) 
Number of NRT types tried 3.00 (4.00) 2.00 (4.00) 
U=24.500  
(Z=-1.143, p=0.277) 
Ever used an e-cigarette    
Yes 
No 
4 (31%)  
9 (69%) 
7 (41%)  
10 (59%) 
χ2= 0.344 (p=0.558) 
Quitting importance 10.00 (9.00) 10.00 (2.00) 
U=93.500  
(Z=-0.810, p=0.483) 
Quitting readiness 7.46 (2.07) 8.12 (2.09) t=0.857 (p= 0.399) 
Quitting confidence 5.00 (5.00) 8.00 (6.00) 
U=54.000 
(Z=-2.424, p=0.015) 




5.2 Primary Outcome: Intervention Adherence 
5.2.1 Treatment Completion  
Overall, 10 participants completed the five-week intervention, attending 
all five study sessions, resulting in a retention rate of 33% (25% retention 
of the original 40 recruited). The number of participants in each condition 
attending at each session is shown below in Table 16.  
Table 16 Number of participants in each condition attending each treatment session 
  Overall Abstinence (intervention) Attendance (control) 
Attendance N (%)    
Baseline 19 8 (62%) 11 (65%) 
Session 1 14 5 (38%) 9 (53%) 
Session 2 12 3 (32%) 9 (53%) 
Session 3 12 4 (31%) 8 (47%) 
Session 4 11 3 (31%) 8 (47%) 
Session 5 10 2 (15%) 8 (47%) 
    
 
A total of 19 (63%) participants attended their baseline session, with a 
mean of 2.33 (SD=2.78) of the five study sessions attended. Whilst a greater 
proportion of control participants completed treatment, there was no 
significant difference between conditions for any of the primary outcome 
measures (Table 17). 
Table 17 Primary outcome data by condition 
  Abstinence (intervention)  
N (%)/ Median (range) 
Attendance (control)  
N (%)/ Median (range) 
Comparison 
Attended baseline    
Yes 
No 
8 (62%)  
5 (38%) 




   
 








2= 3.326  
(p=0.068) 
   
 
Number of study 
sessions attended 
1 (6) 2 (6) 
U= 85.500  
(Z= -1.154, p=0.248) 




5.3 Secondary Outcomes: Smoking Behaviour and 
Opiate Treatment  
5.3.1 Issues encountered measuring smoking  
Given the very high levels of attrition observed, testing the effects of the 
intervention on smoking was difficult. Moreover, part way through the 
study, a major flaw was discovered in the use of breath CO validation in 
administering the rewards. At the outset of the study, self-reported 
smoking data were not recorded by the experimenter, as CO validation was 
being used to assign rewards to participants in the experimental condition. 
However, once self-reported smoking data collection was introduced, it 
became evident that a large number of the participants that self-reported 
smoking were providing breath CO samples signifying abstinence (i.e. 
lower than 10ppm). This meant that participants in the experimental 
condition were smoking yet receiving rewards for being abstinent. 
Resultantly, the decision was made to begin recording the number of 
cigarettes that participants were smoking per week and also the number of 
days per week that they were smoking cigarettes (this is a measure 
commonly used in the illicit drugs field, but not the smoking field). Data 
collection for this began in December 2016, meaning data were recorded 
for only 11 of the 30 participants included in the main analysis. These data 
should not be considered as representing the efficacy of the intervention 
for treating tobacco smoking and, therefore, only a brief overview of these 
results is presented. A number of interesting observations were made, 
however. These are considered in detail in the discussion below.  
 
5.3.2 Smoking behaviour  
Self-reported point prevalence abstinence (CO verified) at each treatment 
session was calculated for all 30 participants, with failure to attend a study 
session treated as smoking (in either condition). Overall, point prevalence 
abstinence was low across all five sessions, with a high of only 7% at 
session one. Breath CO recordings were also analysed, with missing data 
at each session removed from calculation of averages. Overall, mean 
breath CO was 19.6ppm at baseline and 9.3 ppm at session 5, though this 
reduction was non-significant. 
As mentioned above, the number of cigarettes that participants 
smoked per week and the number of days per week smoking were recorded 
for 11 of the 30 participants in the final analysis. The number of cigarettes 
smoked in the last seven days across both conditions reduced from an 
overall average of 137.73 (SD=62.82, median=140.00, range=220.00) at 
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baseline to 14.10 (SD=30.59, median=4.00, range=100.00). A Wilcoxon 
signed-rank test showed this reduction to be significant (Z=-2.023, 
p=0.043), though given the small sample size this should be interpreted 
with caution. The number of days smoking in the last seven days reduced 
from an overall average of 7 (SD=0, median=7.00, range=0, n=11) at 
baseline to 4.33 (SD=3.28, median=7.00, range=7.00, n=9) at session 5. A 
Wilcoxon signed-rank test showed this change to be non-significant (Z=-
1.000, p=0.317).  
5.3.3 Opiate Treatment 
When designing the study, it was intended that details of participants’ 
opiate treatment data at both baseline and the final session could be 
recorded from participant medical records. The treatment centre agreed 
that this was something that we could do, and the appropriate access 
credentials were obtained prior to completion of the study. However, when 
the retrieval of these data was undertaken, it was discovered that the 
recording of these data was not adequate enough to allow this to be done. 
For all participants, there was only a single entry for their opiate treatment 
and in the majority of cases this was over 12 months old. For this reason, 
it was not possible to investigate any potential effects of the intervention 
on opiate treatment. 
5.4 End of Treatment Questionnaire 
Of the 10 participants who completed treatment, nine completed the end 
of treatment questionnaire; eight from the attendance condition and one 
from the abstinence condition. As discussed in the methods chapter 
(chapter 4), all of these participants received vouchers during the 
intervention and although not part of the intervention tested here, all 
participants had received e-cigarettes. The responses of participants to 
these questions are shown below in Tables 18, 19 and 20.  
Overall, participants reactions were positive, with the majority of 
participants reporting that they would recommend the service to others 
(N=8), would return to the service if they resumed smoking (N=7), and that 
the information dispensed regarding medications available was useful 
(N=9). Two thirds of respondents (N=6) reported that they would have 
attempted to quit smoking even if vouchers were not available. The 
majority of respondents (N=7) were either satisfied or very satisfied with 
the support that they received to stop smoking and how supportive the 
staff were. Vouchers, e-cigarettes and weekly breath CO measurements 
were all rated as either helpful or very helpful by the majority of 
respondents. Notably, e-cigarettes were rated as helpful or very helpful by 
more participants than vouchers (N=6 vs N=8). Most of the respondents 
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(N=5) received only a single form of NRT (alongside e-cigarettes), with 
nicotine gum rated as being the most useful. 
Table 18 Participant (N=9) responses to the end of treatment questionnaire questions, N 
(%) 
  Response, N (%)   
Question Yes No Unsure 
Would you recommend this service to other smokers who want to stop 
smoking? 
 8 (89%) 1 (11%) 0 
 
   
In the event that you started smoking again would you go back to the 
service for help with stopping smoking? 
 7 (78%) 1 (11%) 1 (11%) 
 
   
If you returned to the service for help with stopping smoking in the 
future do you think that you would be welcomed back? 
 7 (78%) 0 2 (22%) 
 
   
When you contacted the service were you given an appointment date or 
told how long you would have to wait? 
 7 (78%) 2 (22%) 0 
 
   
Was the length of time you had to wait for your first appointment 
acceptable to you? 
 8 (89%) 1 (11%) 0 
 
   
Are the appointment times you were given convenient for you?  9 (100%) 0 0 
 
   
Is the place where you go for your appointments convenient for you to 
get to? 
 9 (100%) 0 0 
 
   
Was the information that you were given about the choice of medication 
helpful? 
 9 (100%) 0 0 
 
   
Was it easy to get hold of your medicine once you had chosen which 
medication you were going to use for your stop smoking attempt? 
 9 (100%) 0 0 
 
   
Would you have tried to quit smoking if there were no vouchers being 
offered? 




Table 19 Participant (N=9) responses to the end of treatment questionnaire questions, N 
(%) 
  Response, N (%) 
          
Question 
Very 
Unsatisfied /  
Unhelpful 










Overall, how satisfied 
are you with the 
support you have 
received to stop 
smoking? 
1 (11%) 0 1 (11%) 2 (22%)  5 (56%) 0 
 
      
How satisfied are you 
with how supportive 
staff have been? 
1 (11%) 0 1 (11%) 2 (22%)  5 (56%) 0 
 
      
How helpful has the 
information and 
advice that staff have 
given to you during 
your appointment 
been? 
1 (11%) 0 0 3 (33%)  5 (56%) 0 
 
      
How helpful has the 
written information 
that staff have given 
to you been? 
0 0 0  5 (56%) 3 (33%) 1 (11%) 
 
      
Do you find having 
your carbon 
monoxide (CO) 
reading done at every 
visit helpful?  
1 (11%) 0 0 2 (22%) 6 (67%) 0 
       
How helpful were the 
vouchers in stopping 
smoking? 
1 (11%) 0 2 (22%) 1 (11%)  5 (56%) 0 
 
      
How helpful were e-
cigarettes for 
stopping smoking? 


























Which of the following 
types of nicotine 
replacement therapy did 
you receive? 
       
Single NRT (N=5) 2 (22%) 1 (11%) 1 (11%) 1 (11%) 0 0 0 
Dual NRT (N=3) 1 (11%) 2 (22%) 0 2 (22%) 1 (11%) 0 0 
Multiple NRT (N=1) 1 (11%) 1 (11%) 1 (11%) 1 (11%) 0 0 0 
 
Which of the following 
types of nicotine 
replacement therapy did 
you find most useful? 
2 (22%) 4 (44%) 1 (11%) 2 (22%) 0 0 0 
 
Participants were additionally asked “If you were to do the study again, 
what would be more likely to make you take part if you got: Vouchers, Free 
e-cigarettes, both, or other”. Three participants (33%) said they would be 
more likely to take part if given free e-cigarettes, and five (56%) said they 
would be more likely to take part if given both free e-cigarettes and 
vouchers. One participant did not answer this question.  
5.5 Non-Completer Questionnaire 
As such a high attrition rate was observed in the study, it seemed prudent 
to attempt to understand the reasons behind this. For this reason, a short 
questionnaire was created, and participants who had consented to take 
part in the study but not completed treatment were contacted by telephone 
to answer the four questions.  Six (21%) of the 29 participants who did not 
complete the treatment were willing to answer the questionnaire. The 




Table 21 Participant responses to the non-completer questionnaire, N (%) 
Question 1 What made you decide to take part in the study in the first place?  (Tick all that apply) 
Answer 1 Wanted to stop smoking: 6 (100%)  
Wanted to get the vouchers: 3 (50%) 






"I did like the e-cigs but didn't know about them originally" 
"Mainly to give up smoking but also the vouchers, I thought I would get the money in one go though, 
but I guess I could have saved up.  Don’t get cravings for cigarettes anymore and I use the spray that 
gets rid of the cravings if I do."  
 
Question 2 Why did you decide to stop taking part in the study? (Tick all that apply) 
Answer 2 Didn't really want to stop smoking: 0  
Life factors: 2 (33%)  
Decided I could stop smoking alone: 0  
Voucher values weren't high enough: 0  
None of the treatments were suitable for me: 0 
Not enough sessions: 0  
Session times didn't work with my schedule: 0 





"I pulled out as knew couldn't stop straight away as was in the stop smoking condition" 
"I went back home and have only just returned" 
"I couldn't smoke cannabis without using tobacco" 
"I went on holiday to Barbados" 
"I moved down to Kent so had to stop coming. They don't offer e-cigarettes here so I have started 
smoking again"  
 
Question 3 What would have made you stay in the study?  (Tick all that apply) 
Answer 3 Higher value vouchers: 0 
More regular sessions (more than once per week): 3 (50.00%) 
More sessions on different days: 3 (50.00%) 
Guaranteed access to e-cigarettes: 0 





"Maybe higher vouchers but it was the smoking not the vouchers that made me want to take part the 
most" 
"Wasn't working at the time but now I work 8-5 so don't have time" 
"Being able to smoke with the weed and not smoking cigarettes" 
"Nothing, I would have taken part if it wasn't for the fact that I was going to go on holiday" 
"If I hadn't moved away I would have stayed in the study" 
  
Question 4 If you think that more vouchers would have made you stay, how much would you need paying over the 
six weeks to make you stay?  (Tick the one that applies most) 
Answer 4  £150: 0, £170: 0, £190: 0, £200: 0 (No participants answered this question)  
 
5.5 Follow-Up  
Only a single participant could be contacted for six-month follow-up. They 
reported not having smoked since the end of treatment, but CO verification 




5.6.1 Summary of Results 
Overall, 40 participants were recruited into the study, taking a total of 18 
weeks. Of the 40 participants recruited, ten completed the five-week 
intervention. This retention rate of 25% is far lower than the 60% retention 
rate required to deem the study successful (based on retention rates in 
other similar studies [70,73]). More attendance condition participants 
completed treatment than abstinence condition participants, but this 
difference was not statistically significant. It was impossible to ascertain 
any effects of the intervention on opiate addiction treatment or drug use 
due to the paucity of data recorded on the treatment centre’s electronic 
database. Of the 10 participants that completed the intervention, nine 
completed the end of study questionnaire. Eight of these respondents 
reported that they would recommend the intervention to other people, six 
found vouchers either helpful or very helpful in giving up smoking but 
would have attempted to give up smoking had vouchers not been available. 
Six of the 29 participants that did not complete the intervention agreed to 
answer the non-completer questionnaire. All respondents reported 
wanting to take part in the study to give up smoking and would have stayed 
in the study had more sessions been available on more days. Taken 
together, these findings may suggest that the frequency and provision of 
smoking cessation are the key barriers in engendering smoking cessation 
in those undergoing treatment for opiate addiction. The provision of e-
cigarettes also seemed to be attractive. A number of smoking behaviour 
variables were collected but given the high attrition rate and consequent 
small sample size, the data produced are of only limited utility and results 
should be interpreted with caution. Neither point prevalence nor breath 
CO changed significantly over the course of the intervention. The number 
of cigarettes smoked in the last seven days did reduce significantly.  
Overall, the CM intervention did not appear to be effective. Retention 
rates were far lower than anticipated, with too few participants remaining 
in treatment across the two conditions to allow any meaningful 
comparison of secondary outcomes across conditions. 
5.6.2 Pilot and Feasibility Results 
Although the results of the primary and secondary objectives of the study 
are hampered by high attrition rates, a number of very important pilot and 
feasibility observations were made as the study progressed. These will be 
discussed in the order in which each became apparent during the running 




The first important pilot/feasibility finding became apparent before the 
study had even begun recruiting. When initially securing the study site, we 
were informed that the treatment centre had a functioning smoking 
cessation service. When the study was ready to be implemented, however, 
it transpired that this was no longer the case and that re-training of staff 
in using the NCSCT stop smoking programme [56] was required. This raises 
an important concern for interventions that run as an adjunct to standard 
care. Additionally, ensuring that all participants receive the same fidelity 
of standard care treatment is vital if the results obtained are to accurately 
reflect the effects of the intervention being implemented. It would seem 
important, then, to at least record the fidelity of all behavioural 
interventions delivered to participants, both standard care and the adjunct 
intervention. This itself raises another question over standardising normal 
care procedures and the effects that this may have on treatment. It may 
be, for example, that attempting to standardise normal treatment practices 
across participants and/or treatment centres artificially elevates the 
fidelity of the standard care intervention above what it would normally be. 
This may in turn lead to the intervention appearing to be of different 
efficacy than it would be if implemented in an environment outside of the 
study. 
Recruitment 
A number of other important pilot/feasibility findings came early on in the 
implementation of the study. For example, the three-week interruption of 
recruitment over Christmas period. A break in recruitment like this is not 
in itself particularly detrimental. What is more concerning, is that there 
were a number of participants already recruited into the study by this 
point. The efficacy of CM is based on there being constant and 
uninterrupted reinforcement for the desired behaviours [82]. As a result, 
disruptions to the reward schedule can severely curtail the efficacy of the 
intervention. Had there been time, the start date of the current study 
would have been delayed to accommodate this, but, with the study having 
already been severely delayed, this was not possible. Any future studies 
should therefore ensure that all participants have an uninterrupted period 
in which they can participate in the study, with initiation of their 
participation delayed if necessary. An additional observation linked to 
recruitment was our inability to record the number of participants that 
were approached or assessed for eligibility. This was because multiple 
methods of recruitment were employed, including the use of key workers 
at the study site. Given their busy schedules and high client load, it was 
not reasonable to expect the keyworkers to record these data. It would be 
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beneficial, however, if in the future this information could be recorded 
somehow, as it gives an impression of the level of interest in the 
intervention among potential participants. Related to this, given the 
number of keyworkers at the treatment centre and their contact with 
potential participants, it is somewhat surprising to see that slightly more 
participants were recruited directly by the investigator than by 
keyworkers. Although we held a pre-study meeting with keyworkers to 
introduce the study and allow them to ask questions, additional meetings 
and training would be advisable as a means of potentially boosting 
recruitment by keyworkers. It has, however, been reported that treatment 
staff in addictions treatment may not see quitting smoking as important, 
or even as advisable, during treatment for illicit drug use [32]. It may, 
therefore, be a difficult task engaging key workers with interventions such 
as the one in the current study, that aim to encourage smoking cessation 
in those undergoing treatment for opiate addiction. 
Treatment Allocation and Data Recording 
Another important finding is the changes that were made when 
participants were told of their randomisation and when demographic 
information was recorded. As mentioned above, the first participant 
recruited had hoped to be randomised to the attendance condition but 
dropped out when allocated to the abstinence condition. For this reason, 
we began informing participants of their allocation to at the end of the 
baseline session. There was another change early on in the study of when 
collection of demographic data took place. Initially, this was planned to be 
collected at the baseline session, however, when very few participants 
returned for their baseline session, this was instead recorded at the signing 
of consent. It is possible that these two issues could have been avoided 
had there been a single data collection and treatment assignment session 
that occurred at baseline. One of the problems inherent in the study that 
may have exacerbated the issues encountered with informing participants 
of treatment allocation and data recording, is that the smoking clinic ran 
for only two hours on Monday afternoon. Therefore, if a participant signed 
consent on a Monday afternoon after the smoking cessation clinic had 
finished, it was an entire week before their baseline session and two weeks 
before they would have a chance of receiving their initial reward of only 
£5. Therefore, as well as having a single baseline session where 
demographics are collected and treatment allocations made, having two or 
three of these sessions each week and rewarding participants for attending 
these session, may be beneficial additions to the design of future trials.  
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Biochemical Verification of Smoking Abstinence 
Another learning point from the study was the use of breath CO as the 
measure on which rewards in the experimental group were made 
contingent. As noted above, part way through the study it became clear 
that participants were providing breath CO samples indicative of not 
smoking (<10ppm), despite self-reporting smoking. As the rewards for 
abstinence group participants were based on this measure and not self-
report, participants could continue smoking whilst receiving rewards for 
quitting. This undermines the intervention’s intended means of 
effectiveness. Future studies should implement the use of both self-report 
and biochemical measures to assess abstinence, as recommend in the 
Russell Standard [110]. 
Quality of Participant Drug Treatment Records 
A final pilot/feasibility finding was observed at the end of the study, when 
an attempt was made to access the electronic treatment records of the 
participants. The aim of this was to investigate any potential effects of the 
intervention on opiate addiction treatment outcomes and illicit drug use. 
When these data were accessed, though, it was found that the recording of 
the data rendered any of these aims impossible. Not only were a number 
of the records on the system over 12 months out of date, but one 
participants did not even have an entry on the system. This participant 
were therefore removed from the analysis, further limiting sample size. It 
would be beneficial, both to research and treatment, if efforts were made 
to increase the quality of the recording of this information. Until then, it 
may be better to instead obtain this information directly from the 
treatment staff at the beginning and end of the intervention. Alternatively, 
it may instead be preferable to check at consent whether a participant is 
present on the system and the quality of the information recorded about 
them.  
5.6.3 Limitations 
The current study has a number of limitations. One of the main limitations 
of the study is the poor retention rates achieved, with only 10 participants 
completing treatment. Similar studies have observed retention rates of 60% 
or more [70,73], over double that observed in the current study. It is 
unclear why retention in the current study was so low. Although this is a 
pilot and feasibility study, designed and conducted to detect issues such 
as poor retention, this still poses a problem. The issue with so few 
participants being retained is that this severely limits any inferences that 
can be made regarding the secondary outcomes. An associated limitation 
is the inability to follow-up any participants long-term to verify smoking 
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abstinence, compromising the ability to determine any potential long-term 
effects of the intervention.  
Another limiting factor of the current study, is that it coincided with 
the redesign of the stop smoking service in the treatment centre and the 
simultaneous introduction of e-cigarettes as a novel form of NRT. E-
cigarettes have been shown in a number of studies [209–212] to aid 
smoking cessation. As all participants completing treatment were given e-
cigarettes during treatment, it is, therefore, very difficult to separate the 
effects of the intervention from those of e-cigarettes. This also severely 
limits the generalisability of the pilot study findings, as the study was 
effectively carried out in a stop smoking service unlike any other in the 
UK, as to our knowledge e-cigarettes are not currently offered as part of 
standard smoking cessation treatment in substance misuse centres in the 
UK. The introduction of e-cigarettes to the stop smoking treatment 
provided at the clinic was a snap decision made by the management at the 
treatment centre, which could not have been anticipated at the outset.  
A final limitation of the study is having only two conditions. As 
mentioned in the previous chapter, the nature of CM interventions means 
that participants are effectively rewarded for two things; in the case of this 
study, attending the treatment centre and abstinence from tobacco 
smoking. Because of this, it is important to have a control condition that 
allows the effects of rewarding for attendance and abstinence to be 
differentiated. This was the rationale behind the two conditions used in 
the current study. However, what the current trial did not include, was a 
condition where participants received standard care, without any rewards. 
This was because limited resources allowed for only two conditions. 
Without such a standard care condition, it is impossible to draw 
conclusions about the feasibility or efficacy of CM as compared to usual 
treatment. Future studies should, therefore, not only include a condition 
that differentiates between rewarding attendance and abstinence, but also 
a condition that allows comparison between rewarding attendance or 
abstinence with treatment as usual. 
5.6.4 Strengths 
Despite a number of limitations, the current study has some strengths. For 
example, despite the limited number of participants attending baseline, 
the randomisation method used created a balanced sample. Participants 
did not differ significantly across conditions on any of the demographic 
or opiate treatment and drug use variables and for all but one (quitting 
confidence) of the smoking behaviour variables. The primary strength of 
this pilot study, though, is that it is the first study of CM for smoking 
cessation during opiate addiction treatment conducted in the UK and the 
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first of its kind outside of the US. It therefore represents the first step 
towards the potential use of CM for smoking cessation in UK drug 
addictions services. Related to this, a further strength is that, to my 
knowledge, this is the first study of its type anywhere in the world to 
integrate CM techniques with stop smoking services in routine clinical 
practice. As a result, this pilot study suggests a shift in the focus of 
research is needed, from the efficacy of CM in treating smoking cessation 
during opiate addiction treatment, to its integration with standard care.  
5.6.5 Implications and Recommendations for Future Research 
Although the findings of this pilot study are somewhat limited by low 
retention rates, they still present a number of important implications for 
future research. The poor retention rates observed in this study, 
particularly amongst participants randomised to the abstinence condition, 
suggest that implementing a CM intervention for smoking cessation during 
treatment for opiate addiction may be more difficult than initially 
envisaged. However, recruitment did not seem to be an issue. The 
recruitment rate observed during this pilot study is better than that of 
Tuten et al. [71], who investigated the efficacy of contingent rewards for 
reducing cigarette smoking amongst pregnant women receiving treatment 
with methadone for opiate addiction. Moreover, the number of participants 
recruited into the stop smoking service over the four-month study 
recruitment period, is greater than the number recruited in the 12 months 
that the stop smoking services were run by the treatment centre before 
initiation of the pilot study. This suggests that CM may have the potential 
to engage a larger portion of individuals in this environment and 
population for smoking cessation treatment. This also illustrates that there 
is a demand for smoking cessation treatment among these individuals. It 
is important to note, however, that it is unclear to what extent the e-
cigarettes being offered as part of smoking cessation treatment played a 
role in this rate of recruitment. Notably, of the nine respondents to the end 
of treatment questionnaire, a third reported they would be more likely to 
take part again if given free e-cigarettes and over half of respondents 
reported that they would be more likely to take part if given both free e-
cigarettes and vouchers. None of the respondents reported that they would 
be more likely to take part if just given vouchers. These findings only 
represent a small portion of the participants that did not complete 
treatment, but, suggest that e-cigarettes may have played some role in the 
observed recruitment rates.    
It is also unclear exactly why this recruitment rate did not translate 
into higher rates of study completion. Given that in CM interventions 
allocation concealment is not possible, it may simply be that participants 
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agreed to take part in the study hoping that they would be randomised to 
the attendance condition, deciding not to take part once randomised to the 
abstinence condition. However, as later in the study, participants were not 
randomised to conditions until their baseline assessment, this does not 
account for the large number of participants that consented to take part in 
the study yet did not attend their baseline session. An alternative 
explanation for this may simply be that the lives of the participants 
recruited were not suited to the regular and repeated attendance required 
by a CM intervention. Another potential explanation may be that the stop 
smoking service runs for only two hours, one day a week, making it too 
restrictive to fit in with the lives of most participants. Some support for 
this is seen in the non-completer questionnaire, where all respondents 
reported that either more regular treatment sessions (more than once per 
week), or more sessions on different days, would have made them stay in 
treatment. Yet another potential explanation may be that the reward values 
implemented in this pilot study were simply not high enough to encourage 
study completion in the majority of participants. The four studies 
previously conducted using CM to encourage smoking cessation during 
opiate addiction treatment [70–73], all offered participants substantially 
larger monetary rewards than the current pilot study. As previously 
discussed (Chapter 4, section 4.2.6), the reason for the use of lower value 
rewards in this pilot study was in part due to the fact that these higher 
value rewards could never be implemented in usual practice, as they are 
simply too expensive. If this is the case, the implication would be that 
although CM may represent an effective intervention for tobacco smoking 
in this population, the economic burden of treatment precludes it from 
ever being implemented in practice. Without further research, however, 
any explanation as to the low rates of study completion is simply 
speculation, and this should therefore be a focus of future research.  
The main implications for future research, however, come from 
observations from the pilot/feasibility study. One implication is that the 
method of biochemical verification upon which rewards are made 
contingent, requires careful consideration for future studies. In CM 
studies, it is imperative that abstinence is biochemically verified at all 
times, with no opportunity for non-abstinence being rewarded as 
abstinence. If participants can earn rewards for abstinence whilst being 
non-abstinent, it becomes impossible to ascertain for certain whether any 
observed effect of the intervention is actually valid. The Russell Standard 
[110], which outlines the standards for the measurement of efficacy in 
smoking cessation studies, recommends that abstinence be measured 
using biochemically verified self-report. Biochemical validation usually 
takes the form of breath CO, as used in the current study. That is, if a 
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participant self-reports abstinence from smoking, they are required to 
provide a negative breath sample (this was not implemented in the current 
study as efficacy was not of primary concern). Although this methodology 
is in many ways compatible with CM interventions (using breath CO 
verified self-reported smoking status to administer rewards), this would 
only be possible if it was certain that the method of biochemical 
verification could detect any cases of non-abstinence. Making provision of 
rewards contingent on biochemical verification of self-reported abstinence 
using breath CO levels may, therefore, not be viable when participants are 
seen only once per week. This leaves two options for accurate biochemical 
verification: either participants are required to attend the clinic multiple 
times per week, or another biochemical measure of smoking abstinence is 
used, for example, urine cotinine levels. Cotinine is a metabolite of the 
nicotine in cigarettes and can remain in the body for several days after 
smoking [213]. It therefore offers for more accurate verification of 
smoking status than breath CO, that is only effective over a 12-24 hour 
period [213]. However, when using NRT products, as is standard practice 
in UK smoking cessation treatment, cotinine levels cannot be used to verify 
smoking status as NRT treatments also metabolise to cotinine [214]. 
Resultantly, metabolites of tobacco smoking that do arise with NRT use, 
such as anabasine or anatabine should instead be used to verify smoking 
abstinence [214].  The issue with using these measures, however, is that at 
the current time there are no commercially available tests that allow 
immediate testing and results. This precludes their use with CM 
interventions, as one of the core principles underlying the efficacy of CM 
is the immediacy of rewards on the display of the desired behaviour [82]. 
This leaves only the first option, testing multiple times a week, as the only 
currently viable option. The feasibility of this should be another key focus 
of future research in the field. 
Testing participants more than once a week, although more 
expensive and time consuming, may also provide an answer to a number 
of the other pilot/feasibility results observed. Offering multiple testing 
sessions per week would also reduce the potential for long periods of time 
between signing consent and baseline sessions, as seen in this study. This 
would also increase the feasibility of the idea of having participants attend 
a single session where they sign consent, demographics are collected and 
the baseline session completed. Whether or not these sessions should be 
rewarded would require further investigation and may negatively impact 
the economic viability of the interventions. 
Given that this is the first time such an intervention has been carried 
out in the UK, and the results reported here, perhaps the primary focus of 
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future research should be in the design of a study protocol more amenable 
to the needs of potential participants. For example, qualitative interviews 
with both potential participants and also treatment staff would offer vital 
insight into methods or elements of experimental design that either may 
or may not work. Limited resources meant that this was not possible in the 
current study, but doing so may have avoided some of the issues, such as 
low treatment completion and low attendance at baseline, that were 
observed.  
5.6.6 Conclusion 
Overall, the desired retention rates and results of previous CM intervention 
studies investigating tobacco smoking in opiate addiction [70–73] could 
not be replicated here. Whether this was due to the higher reward values 
used in these other studies, the availability of e-cigarettes in our study, or 
due to their interventions not being integrated with standard stop smoking 
treatment, is unclear.  What is clear, is that despite the re-launch of the 
treatment centre’s stop smoking service, the offer of free e-cigarettes and 
the potential to earn a total of £115 in vouchers, very few participants 
could be maintained in smoking cessation treatment or encouraged to 
attend their baseline appointment. This suggests that in the current 
climate in addiction treatment centres, the methods used in this pilot and 
feasibility study are not enough to have the desired impact on smoking in 
substance misusers. However, although the desired retention rates could 
not be achieved, this pilot study brings to light a number of important 
issues for the application of CM as an adjunct to normal smoking cessation 
treatment in opiate addiction treatment. These issues included difficulties 
in standardising treatment, methods of recruitment, notifying participants 
of treatment allocation, timing of recording demographic data, 
biochemical verification of abstinence, and quality of the recoding of drug 
treatment data. Future research should focus on the value of rewards 
required to achieve acceptable retention rates in this client group, the 
utility of more accurate biochemical verification of smoking status, the 
effects of combining standard care with multiple testing sessions per 
week, and on the other issues outlined above such as implementing 
multiple trial sessions per week. Finally, this is the first time that an 
intervention of this kind had been conducted in the UK. As such, it lays the 
foundation for further investigation into the use of CM for smoking 
cessation in opiate addiction treatment. It is important that similar 
interventions are conducted in an effort to combat the high prevalence of 










6.1 Summary of Findings 
Smoking rates amongst opiate dependent individuals range from 80-98% 
[27–31], nearly five times higher than that of the general population [4]. 
Moreover, smoking tobacco  during methadone treatment for opiate 
addiction increases discomfort from opiate withdrawal, posing a major 
barrier to treatment success [37]. Research has shown that a large majority 
(79%) of individuals receiving substance misuse treatment in the UK want 
to quit smoking, but that very few (15%) are offered support to do so [32]. 
Additionally, stopping smoking during treatment for drug addiction can 
actually improve treatment outcomes [215], indicating an urgent need for 
the development of effective smoking cessation treatments for those 
undergoing treatment for opiate addiction. Contingency management (CM) 
is a widely used behavioural intervention in addictions treatment, and uses 
positive reinforcement to encourage desired behaviours [82]. A meta-
analysis of CM treatments for substance dependence concluded that CM is 
one of the most effective substance abuse treatments, with those 
undergoing treatment for opiate addiction responding best [93]. 
Furthermore, in the US, CM has been used with some success as an 
intervention for tobacco smoking during treatment for opiate addiction 
[70–73]. Despite a growing body of evidence, no study has yet combined 
CM with standard UK stop smoking services treatment, in individuals 
receiving treatment for opiate addiction. Therefore, the aim of this thesis 
was to use the behavioural intervention CM to address the high prevalence 
of tobacco smoking in those undergoing treatment for opiate addiction. In 
order to achieve this aim, the thesis followed the MRC guidelines for the 
development of complex interventions [111].  
6.1.1 Meta-Analysis 
The initial stage of the MRC guidelines for the development of complex 
interventions, entails a comprehensive search for existing theory and 
evidence. CM is a widely researched intervention in the addictions field, 
with a number of recent systematic reviews and meta-analyses [91–95] 
supporting its efficacy  for this purpose. Despite this, the last review that 
specifically addressed the use of CM for treating the use of non-prescribed 
drugs during opiate addiction treatment, was performed in 1999 [125]. 
Moreover, this review was not performed systematically, raising concerns 
over potential bias in the selection of included studies.  For this reason, it 
was decided that the best course of action was to perform an updated 
meta-analysis. It was initially thought that this new meta-analysis should 
be performed solely on the use of CM for tobacco smoking during opiate 
addiction. However, it was later decided that this should be broadened to 
include use of all non-prescribed drugs during opiate addiction treatment. 
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The reasons for doing this were twofold: firstly, during initial searches, 
there were very few studies investigating CM for tobacco smoking during 
opiate addiction treatment; secondly, as a motivating factor for conducting 
the review was to inform the design of a pilot study, including a broader 
range of literature had the potential to enable a more optimal design of the 
pilot study.  
The systematic search returned a total of 43 studies meeting 
inclusion criteria, however, only 22 studies were included in the 
quantitative synthesis, primarily due to missing data. Overall, the meta-
analysis found CM to be more effective than control in engendering 
abstinence from a wide range of drugs during opiate addiction. This was 
the case for both of the outcome measures assessed, longest duration of 
abstinence and percentage of negative samples. Target substance was the 
only significant moderator of CM efficacy. Moderator analysis showed CM 
to be more effective than control in preventing use of cocaine, cocaine and 
opiates, tobacco, and poly-substance use, but not of opiates. The largest 
effect size for CM was observed in the study investigating the efficacy of 
CM for tobacco smoking.  
6.1.2 Design and Development of the CMQAT 
Whilst carrying out the quality assessment of studies included in the meta-
analysis, I discovered that there was no existing tool specifically for the 
assessment of quality in CM studies. This not only posed quite serious 
issues for the way that the quality of CM studies was currently being 
assessed, but also represented an opportunity to investigate in more 
detail, the elements of CM that impact its efficacy as an intervention. As a 
result, the decision was made to create a new quality assessment tool, the 
CMQAT (Contingency Management Quality Assessment Tool), that would 
address this issue. The first step in the development of this tool was to 
construct the rating criteria that would be used to assess quality. For this, 
I used the seven core principles of CM, as defined by leading researchers 
in the field [82]. These were then translated into rating criteria, using the 
EPHPP (Effective Public Health Practice Project) quality assessment tool as 
a template, with a three-point scoring scale both for each criterion and 
overall quality ratings. The tool was then subject to three stages of validity 
and reliability testing. Inter-rater reliability was tested using Fleiss’s 
Kappa, a statistical measure that allows for comparisons of rater 
agreement between two or more raters [184]. Predictive validity was tested 
by correlating the CMQAT ratings with the effect sizes of the studies being 




In stage one testing, inter-rater reliability was only slight, and 
predictive validity testing found no significant correlations between the 
CMQAT or EPHPP score and study effect size. Between testing stages one 
and two, a number of changes were made to the rating criteria based on 
the comments of the stage-one assessors. Stage two testing observed an 
improvement in inter-rater reliability to “fair”. Inter-rater reliability of the 
EPHPP was also tested during this stage, to allow a comparison of an 
established quality assessment tool with the CMQAT. EPHPP inter-rater 
reliability was only slight. In stage three, the updated rating criteria were 
tested for predictive validity, however, no significant correlations were 
observed between CMQAT score and study effect size. There is a potential 
explanation for our inability to ascertain predictive validity at both stages 
one and three. Namely, that our assumption that higher quality studies will 
produce larger effect sizes may have been incorrect. One study has shown, 
that in some circumstances, lower quality studies can actually 
overestimate the effectiveness of an intervention, artificially inflating 
effect sizes [189]. Although there is more work to be done before the 
CMQAT can be used in a research context, the work performed here 
provides a strong base on which this future work can build. 
6.1.3 Pilot Study 
The findings from both the meta-analysis and CMQAT were then used to 
inform the development of a pilot/feasibility study. Given that CM had 
never been tested as an intervention for tobacco smoking during opiate 
addiction treatment in the UK before, but had been tested successfully in 
this context in the US, it was decided that a pilot/feasibility study, rather 
than a larger scale trial, was the most appropriate choice of study design. 
This study was statistically powered, using the method of Viechtbauer et 
al. [196], to detect with over 90% certainty, any issues that might occur 
with a probability of over 5%. An integral part of the pilot/feasibility study 
was that CM was integrated into routine stop smoking services treatment 
in the UK, requiring the identification of an addiction treatment centre that 
also ran a stop smoking clinic. A number of potential study sites were 
considered, however, only one of these had an extant stop smoking clinic 
and was, therefore, chosen as the study site. After ethical approval for the 
study had been granted, it then transpired that due to other clinical 
pressures, the smoking cessation clinic was temporarily closed, 
necessitating the retraining of staff at the treatment centre and the 
relaunch of the smoking cessation clinic for this study. This caused 
significant delays in the implementation of the pilot. In the 
pilot/feasibility study, participants were randomised to one of two 
conditions, CM for smoking abstinence (experimental condition) and CM 
for attendance at the smoking clinic (control condition). Participants in the 
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experimental condition received vouchers for providing breath CO 
recordings of <10ppm, and those in the control condition for attending the 
smoking cessation clinic.  
Of the 40 participants recruited into the study, only 10 completed 
the five-week intervention. This 25% retention rate was much lower than 
the 60% target. Moreover, no participants attended the six-month follow-
up, with only one participant being contacted successfully. The most 
widely reported reason for study withdrawal was that the smoking clinic 
was not run at convenient times. Although the study was not statistically 
powered to detect intervention efficacy, CM also appeared to have little 
impact on tobacco smoking behaviours, with no significant differences 
apparent between conditions for point prevalence smoking or breath CO 
recordings. There was a significant decrease in the number of cigarettes 
smoked between baseline and week five for those remaining in the study. 
However, the poor retention rates and consequent small sample size mean 
that this should be interpreted with caution.  
6.2 Implications for Research 
One of the main implications for research, is the direction in which future 
research concerning the use of CM for smoking cessation during opiate 
addiction treatment should take. Although the focus of the final study of 
this thesis was concerned solely with the pilot and feasibility testing of the 
treatment of tobacco smoking in those undergoing treatment for opiate 
addiction, this narrow focus may not be the most appropriate. As was seen 
in the demographics of participants in the pilot study, all participants were 
receiving treatment for more than one drug of abuse, with many receiving 
treatment for three. This has also been observed in much larger samples 
of drug users. In one study carried out in the US, of  nearly 70,000 
admissions to drug addiction treatment between 1998 and 2004, just 
under half were for polydrug abuse [216]. Smoking prevalence is far higher 
than in the general population, not only in opiate addiction treatment, but 
across treatment for all drug addictions [32]. Additionally, CM 
interventions have been implemented in the treatment of addiction to a 
range of different drugs [91–95]. From a research perspective, it is 
desirable to focus on smoking cessation in a treatment population using 
only a single illicit substance (for example those in treatment for opiate 
addiction), as this better fits with the experimental method and 
circumvents the difficulties that arise from differing dosages, means of 
administration etc. that vary across different substances [217]. However, 
this focus on the use on participants using only a single substance does 
not represent the true make-up of drug use observed in treatment centres, 
with a growing body of evidence suggesting that patients presenting with 
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abuse of only a single substance are becoming progressively more scarce 
[218–223]. Given this, it may be better to broaden the focus of future 
research on CM for smoking in drug treatment, to individuals in treatment 
for addiction to any substances rather than focussing on smoking solely 
in those in treatment for opiate addiction.  
Another important implication of the work carried out pertains to 
the efficacy of CM interventions at follow-up, after rewards have been 
withdrawn. The meta-analysis that I conducted, analysing the efficacy of 
CM as an intervention for non-prescribed drug use during opiate addiction 
treatment, updated and enhanced the findings of a similar, but 
unsystematic, meta-analysis performed in 1999 [125]. In comparing the 
findings of these two meta-analyses, what was particularly interesting, was 
that neither our meta-analysis, nor that of Griffith et al. [125], was able to 
investigate the effects of CM in this context at follow-up. In the original 
review, of the 30 studies included only two implemented a follow-up, and 
of the 22 included in our meta-analysis, 10 studies included a follow-up, 
but data were only available for two of these. One of the main criticisms 
of CM is that its effects often deteriorate rapidly after rewards are 
removed, with one meta-analysis showing that after six months, positive 
effects of treatment were no longer apparent [95]. It would therefore 
appear that the longer-term effects of CM, particularly with regard to what 
happens when rewards are no longer available, needs to be a clear focus 
of future research.   
 This also highlights another broad issue affecting CM research, 
namely the poor reporting of data in published articles. In the systematic 
search for the meta-analysis, a total of 43 studies meeting inclusion 
criteria were identified. However, only 22 of these studies could be 
included in the quantitative synthesis. The primary reason for this was a 
lack of usable data within the published articles that would allow the meta-
analysis to be performed. Moreover, without seeking data from the authors 
of the studies identified in the search, the number of studies included in 
the quantitative synthesis would have been even smaller. In total, data 
requests were sent to the authors of 35 studies, with data for six studies 
being received. Resultantly, 15 studies were excluded from the analysis 
due to missing data. Losing over a third of studies due to poor reporting 
of data seriously compromises the findings of a meta-analysis, as the 
inclusion of data from such a large number of studies has the potential to 
dramatically change the overall results. A similar issue was encountered 
during the development of the CMQAT. During stage one, it was found that 
a majority of the published articles were missing the requisite information 
to allow for assessment of quality, particularly with regard to the 
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“frequency of incentive distribution” and “timing of the incentive” criteria. 
In total, the authors of 19 of the 22 studies used during stage one testing 
were contacted to obtain additional information regarding the 
implementation of their studies. This lack of detail regarding the way in 
which studies were conducted, severely limited the ability to rate the 
quality of studies, and compromised the assessment of the CMQAT. It 
therefore seems clear that the poor reporting of CM studies is an issue that 
requires addressing before meta-analysis can offer a truly accurate 
representation of the efficacy of CM interventions. The introduction of the 
CMQAT may act as a first step towards improving the way in which CM 
studies are reported. If studies were to report the data required for 
assessment with the CMQAT, a great deal of the difficulties with poor 
reporting of data may have been avoided. It may be that the CMQAT itself 
could be translated into a set of instructions for the reporting of CM trials. 
The CONSORT (Consolidated Standards of Reporting Trials) statement is a 
series of guidelines designed to improve the reporting of randomised trials 
[194], first introduced in 1996. However, as with the development of the 
CMQAT, there are currently no existing guidelines designed specifically to 
improve the reporting of CM studies. Development of guidelines like those 
of the CONSORT statement specifically for CM studies, would ensure that 
important methodological elements of CM interventions are all reported 
with sufficient detail. These could include design elements such as how 
soon after the display of a desired behaviour rewards are administered, 
the rationale behind the length of the intervention, or whether participants 
were consulted on the types of rewards used in the intervention. Given the 
increasingly widespread use of CM interventions both within addictions 
research and in other fields, the development of a set of guidelines for CM 
studies, similar to the CONSORT statement, should be a priority of future 
research.  
Perhaps a more important implication, is the extent to which CM can 
be implemented in routine practice as an effective treatment for tobacco 
smoking during treatment for opiate addiction. The systematic search 
performed for my meta-analysis identified four studies [70–73] reporting 
CM to be an effective intervention for tobacco smoking in this client group. 
CM has also been observed to be effective for smoking cessation in a 
number of other treatment contexts, including pregnancy [101], 
adolescence [102], schizophrenia [104], and post-traumatic stress disorder  
[105]. There is, therefore, little question that CM can be effective for 
smoking cessation in a variety of contexts. However, whether this can be 
translated to routine treatment is a question that remains unaddressed, as 
only one of these studies implemented its intervention in standard UK stop 
smoking services [101]. A potential barrier to this is highlighted in the 
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research undertaken here, relating to the cost of treatment. When 
formulating the protocol for the pilot study, one of the major 
considerations was the value of rewards that would be made available to 
participants. Initially, this was designed using the values of rewards in the 
four existing studies researching CM for tobacco smoking in opiate 
addiction treatment [70–73] in line with the assessment for the CMQAT. 
However, once the total cost was calculated, it transpired that this would 
have exceeded £20,000 for the 40 participants to be included in the pilot 
study. Not only was this far beyond the resources available for the pilot 
study, it also represented an amount that could not realistically be funded 
during the normal course of treatment. Resultantly, the reward values for 
the study were reduced, instead being based on those of a study using 
financial incentives to encourage completion of Hepatitis B vaccinations 
by opiate addiction treatment patients [195]. The results of our pilot study 
though are very different to those of the studies identified during the 
meta-analysis or in the Hepatitis B study. Rather than the significant 
reduction in tobacco smoking or increased adherence to vaccination 
protocols in the CM groups observed in other studies, only two 
participants in the CM for smoking cessation even finished treatment. With 
the design of the study, and the results obtained, it is not possible to 
assess what role, if any, reward values played in this discrepancy. What is 
clear, however, is that reward value should be a focus of any future work 
in this area. If the reward value required for CM to be effective for 
encouraging smoking cessation amongst those in treatment for opiate 
addiction is higher than that viable for implementation in the real world, 
then there would be little use in continuing its research in this capacity. 
This is not to say, however, that CM cannot play an important role 
within addictions research. If, with future research, it transpires that CM 
interventions that reward participants for abstinence are not economically 
viable, there may still be a place for CM in this treatment context. As can 
be seen from the results of the study investigating the use of CM for 
adherence to Hepatitis B vaccinations [195], even relatively low reward 
values (in this case £30) seem to be effective at engaging those in treatment 
for opiate addiction with treatment. A similar effect is also suggested by 
the results of our pilot study, where participants in the control condition 
(CM for attendance) appeared to reduce the number of cigarettes that they 
were smoking. This result should be interpreted with caution due to the 
small N and high attrition, but may point towards the ability of CM to 
engage and maintain those undergoing treatment for opiate addiction, in 
smoking cessation treatment. Further support for this comes from a study 
investigating the efficacy of CM for adherence to naltrexone treatment. 
Naltrexone is a pharmacological treatment for opiate addiction, and blocks 
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the reinforcing effects of opioids by acting as a long-acting competitive 
opioid agonist (i.e. it blocks opioid receptors in the brain, diminishing the 
ability of opiates to bind with receptors) [224]. CM incentives not only 
resulted in ingestion of a significantly greater number of naltrexone doses, 
but in a retention rate more than double that of the control condition. It 
may therefore be more prudent to shift the focus of future research of the 
efficacy of CM for smoking during opiate addiction treatment from 
abstinence, to engaging clients with, and maintaining them in, smoking 
cessation treatment.  
Based on the evidence presented here, though, it is not possible to assert 
that CM does not represent a potentially effective treatment for smoking 
cessation during opiate addiction treatment. In order for this to be 
determined, further studies like the one reported here are necessary and 
the findings of our pilot/feasibility study hold a number of important 
implications for this research. Primary amongst which, is that access to 
the treatment should be made as convenient as possible for potential 
participants. In our pilot/feasibility study, participants could only attend 
on a Monday afternoon across a two-hour period. This restrictive access to 
treatment may not only have dissuaded potential participants from taking 
part, but also contributed to the poor retention rates observed. As 
previously mentioned, the most commonly cited reason for participants 
dropping out was that the smoking clinic was not run at convenient times. 
An additional benefit of this increased access, would be in allowing for the 
use of Russell Standard [110] guidelines for testing the efficacy of the 
intervention as discussed in the discussion section of the previous 
chapter. However, the increased contact required for attending multiple 
sessions may in turn be too much of a commitment, again dissuading 
participants from taking part in the study. Related to this is another 
important implication of the pilot/feasibility findings for the demographic 
make-up of the participants. Ninety seven percent of our sample were 
unemployed, with it being unclear whether this was driven by the sample 
of individuals undergoing treatment at the clinic, or by some other factor. 
It may be, for example, that those who were unemployed were the only 
people who could attend a smoking clinic held between 2pm and 4pm on 
a Monday. It would seem logical then, in a future study, to ensure that 
recruitment is stratified based on the demographic make-up of the clinical 
population.  
Overall, the findings of this thesis hold a number of important 
implications for future research into the use of CM interventions for 
tobacco smoking, in those undergoing treatment for opiate addiction. 
Despite tobacco smoking having posed a major issue in UK drug treatment 
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for a number of years and CM having been successfully implemented in a 
number of drug treatment settings, this is the first time that CM has been 
investigated as a potential intervention for tobacco smoking during opiate 
addiction treatment in the UK. The primary implication of the research 
conducted in this thesis is that despite the efficacy of CM within an 
experimental context, its ability to be successfully implemented in a 
clinical setting alongside standard care, is both unclear and potentially far 
more complex than initially envisaged. Future research should focus on 
the role that CM may be able to play within standard care, the optimal use 
of CM within this context (whether that be encouraging abstinence, 
treatment adherence, or other relevant behavioural targets), and on 
improving our current understanding of the longer-term effects of CM 
interventions. Notably, in accordance with MRC guidelines [111] as 
highlighted in the introduction and methods chapters (Chapters 1 and 4 
and figure 11), the ultimate aim of pilot and feasibility work is to feed into 
the development of a full-scale RCT. Future research efforts should, 
therefore, reflect this goal. In order to progress to a full scale RCT of CM’s 
efficacy in this treatment context, a great deal more pilot and feasibility 
work remains to be done. The main issue that requires addressing is the 
high rate of attrition and poor follow-up rate. How best to test this remains 
unclear, with a number of potential options including increasing the 
number of sessions per week, increasing reward values, changing the CM 
procedures and many more. Perhaps, then, the first work that should be 
carried out, and that was not carried out in the current study, is some form 
of user involvement research. For example, a piece of qualitative research 
assessing the motivations of those in treatment for opiate addiction to quit 
smoking, the acceptability of different treatments, and the necessary 
requirements of treatment to maintain their participation in an 
intervention, would allow for the design of a far more effective and better 
attended intervention. 
6.3 Implications for Clinical Practice 
Although this thesis reports the conduct and findings of a pilot/feasibility 
study, there are still important implications for clinical practice arising 
from the findings observed. For example, the number of participants 
recruited by keyworkers at the clinic is lower than the numbers recruited 
by the experimenter. Given their greater number and contact with potential 
participants, this is somewhat surprising. However, it has been shown that 
addictions treatment staff often view smoking cessation as far less 
important than treating primary drug use [32,225–227], so perhaps this 
should not be unexpected. This feeling amongst treatment staff is 
mirrored in the poor provision of smoking cessation treatment for those 
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in treatment for opiate addiction. As few as 18% of clinics in the US offer 
individual or group smoking cessation counselling, with only 12% 
prescribing NRT [65].  This is in stark contrast to the demand for smoking 
cessation treatment amongst both those in treatment for opiate addiction 
[228] and the broader drug treatment population [32]. This was also 
evident in the current study, with the average rating of the importance of 
stopping smoking amongst participants reported as ten out of ten. 
Moreover, of the participants that completed the end of treatment 
questionnaire, the majority reported that their main motivation for taking 
part in the study was to quit smoking and that they would have tried to 
quit even if no rewards were available. Resultantly, one of the main 
implications of this study for clinical practice, is the need for an increased 
awareness amongst treatment centre staff of the demand amongst their 
clients for smoking cessation services. Linked to this, a concerted effort 
must be made both within opiate addiction treatment and wider drug 
treatment settings to increase provision of smoking cessation treatment. 
Without this, the demand for these services amongst those in treatment 
will continue to go unanswered.  
 Related to this is the issue of the shift in focus of addiction treatment 
in the UK from abstinence, to harm reduction. Traditionally, drug addiction 
was conceptualised as being akin to a disease, the logical implication of 
this being that it could, in some way, be cured [229]. The result of this was 
that abstinence became the primary focus of addiction treatment [229]. 
More recently, however, the literature has developed to support a different 
conceptualisation of addiction, as a chronic relapsing condition [230,231]. 
Consequently, it is now recognised that for some individuals, long-term 
abstinence may never be achievable [232]. Therefore, harm reduction 
strategies have become more widely accepted in treatment. For example, 
the National Institute for Health and Care Excellence (NICE) now have 
guidelines specifically for harm reduction in tobacco cessation, which 
support the use of NRT for as long as they both reduce the desire to smoke 
and prevent relapse to smoking [233]. E-cigarettes, which are becoming 
increasingly popular [234], may represent a further evolution of this harm 
reduction approach. Although not a licensed NRT product, e-cigarettes 
have already been shown to aid smoking cessation both in the general 
population [209–212] and in those undergoing treatment for opiate 
addiction [69]. They were also well received in the current study, with e-
cigarettes rated as helpful or very helpful in giving up smoking by more 
participants than vouchers. Given that the majority of those undergoing 
treatment for opiate addiction receive methadone maintenance treatment 
[235], a harm reduction treatment itself, it is reasonable to suggest that a 
harm reduction approach to smoking may garner more approval among 
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staff in addictions centres than an abstinence approach. Moreover, as 
those in treatment for opiate addiction are already accustomed to harm 
reduction techniques in their opiate treatment, it stands to reason that this 
may be a potentially useful technique in their smoking cessation 
treatment. Importantly, the implementation of this approach without 
improvement in the provision of smoking cessation treatment in general 
would be of little use. Therefore, a combined focus on both the 
improvement and formulation of treatment is imperative.  
 Another implication for clinical practice stems from our inability to 
use electronic participant records to ascertain potential effects of the 
intervention on illicit drug use and treatment. This was simply the result 
of poor recording of these data, with very few records providing up to date 
information. Without accurate recording of medical information, it is 
impossible to understand the potential effects of any intervention on a 
participant’s current medical treatment. Electronic patient records also 
have a number of benefits for general medical practice, including 
improving quality of care and patient safety [236–241]. It is, therefore, also 
beneficial to general medical practice to have this information maintained 
properly. The poor recording of addiction treatment observed here may be 
symptomatic of falling budgets within drug treatment [242], but 
nevertheless requires urgent attention and rectification if treatment 
standards are to be maintained.  
6.4 Implications for Policy 
The findings of this thesis also highlight one important implication for 
policy. Namely, the need for smoking cessation to have a more prominent 
role in the care of those undergoing treatment of opiate addiction. 
Smoking prevalence in those in opiate addiction treatment is nearly five 
times that of the general population [27–31], yet the provision of smoking 
cessation treatment for this group is minimal. As mentioned above, studies 
in the US have found that less than 20% of methadone clinics offered 
individual or group smoking cessation counselling or 12% prescribed NRT 
[65]. This low priority of tobacco smoking in opiate addiction treatment is 
borne out in the wider literature. In our meta-analysis, of the 22 included 
studies, only one investigated CM for smoking cessation, whereas eight 
studies investigated CM for cocaine use and a further six for combined 
opiate and cocaine use. This is despite the fact the smoking prevalence in 
opiate addiction treatment has been recorded to be as high as 98% [30], yet 
prevalence of smoking among cocaine users is under 50% [223]. This low 
priority of smoking cessation in opiate addiction treatment cannot be 
attributed to disinterest in those undergoing treatment. Of the participants 
recruited into our pilot study, 70% had previously tried to quit smoking, 
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with an average of over three previous quit attempts. This is mirrored in a 
larger-scale study, where a majority of opiate addiction patients have 
expressed interest in smoking cessation [243]. There is, therefore, a great 
deal to be done in terms of policy-making, to elevate the importance of 
smoking cessation within the context of opiate addiction treatment. A large 
body of evidence now exists showing the positive impact of smoking 
cessation during treatment for opiate addiction and the demand for this 
service from those in treatment, but that provision of this is lacking.  
6.5 Conclusion    
Overall, I believe this thesis constitutes a significant contribution to the 
CM literature and the findings have a number of important implications 
for research, clinical practice, and policy. Firstly, the findings of the meta-
analysis offer further support for the efficacy of CM as an intervention for 
non-prescribed drug use during opiate addiction treatment. As a result of 
this meta-analysis, it was discovered that no quality assessment tool for 
CM studies existed. Resultantly, the CMQAT was developed and tested in 
three stages. This can now form the foundation for future development of 
the tool and better reporting of CM trials in the literature. The findings of 
the meta-analysis and the research carried out in constructing the CMQAT 
were then used to develop a CM intervention for tobacco smoking in 
individuals undergoing treatment for opiate addiction, which was tested 
in a pilot study. This was the first time that CM had been tested in this 
context in the UK.  The pilot study led to a number of important 
observations regarding the ability of CM to be implemented in this context. 
Namely, that with the CM protocol used, retention in treatment was poor, 
with only ten of 40 recruited participants completing the five-week 
intervention.  
Taken together, these findings have a number of implications. Perhaps the 
most important of these though, is that despite the now well-documented 
efficacy of CM for encouraging abstinence from a wide range of both illicit 
and licit drugs during opiate addiction treatment, when this is transferred 
out of an experimental environment and into standard care, 
implementation seems to be severely compromised. More research is 
required to ascertain whether CM does or does not represent an effective 
means of encouraging abstinence from smoking during opiate addiction 
treatment, but it may well be that better integration with routine opiate 
treatment provision will enhance engagement with smoking cessation. 
Similarly, targeting behaviours other than abstinence, such as attendance 
at cessation treatment, may represent a more fruitful avenue for future CM 
research. Methodologically, I have introduced a new tool, the CMQAT to 
support improved reporting and implementation of CM trials. There is the 
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potential for this to be further developed alongside a statement similar to 
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Search carried out in Embase, PsychInfo and PsychArticles, from inception to March 2015: 
Search 




"contingency management".mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, tx, ct, 
tc, id, tm] 4180 
2 reward.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, tx, ct, tc, id, tm] 81032 
3 payment.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, tx, ct, tc, id, tm] 32841 
4 incentive.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, tx, ct, tc, id, tm] 25567 
5 prize.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, tx, ct, tc, id, tm] 9309 
6 substance.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, tx, ct, tc, id, tm] 294314 
7 misuse.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, tx, ct, tc, id, tm] 30461 
8 drug.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, tx, ct, tc, id, tm] 6941070 
9 narcotic*.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, tx, ct, tc, id, tm] 49362 
10 tobacco.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, tx, ct, tc, id, tm] 152660 
11 smok*.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, tx, ct, tc, id, tm] 443219 
12 stimulan*.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, tx, ct, tc, id, tm] 48239 
13 cocaine.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, tx, ct, tc, id, tm] 79734 
14 alcohol.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, tx, ct, tc, id, tm] 572022 
15 opiate.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, tx, ct, tc, id, tm] 123411 
16 opioid.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, tx, ct, tc, id, tm] 88148 
17 heroin.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, tx, ct, tc, id, tm] 28038 
18 methadone.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, tx, ct, tc, id, tm] 36461 
19 1 or 2 or 3 or 4 or 5 143581 
20 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 7790725 
21 15 or 16 or 17 or 18 194478 
22 19 and 20 and 21 4873 
23 
limit 22 to english language [Limit not valid in Journals@Ovid; records were 
retained] 4747 
24 limit 23 to human [Limit not valid in Journals@Ovid; records were retained] 2870 
25 
limit 24 to humans [Limit not valid in Journals@Ovid,PsycINFO; records were 
retained] 2870 
26 remove duplicates from 25 2447 
 
Search carried out in PubMed, from inception to March 2015: 
 (Contingency Management) OR (Reward) OR (Payment) OR (Incentive) OR (Prize) AND 
(Substance) OR (Misuse) OR (Drug) OR (Narcotic*) OR (Tobacco) OR (Smok*) OR 
(simulan*) OR (Cocaine) OR (Alcohol) AND (opiate) OR (opioid) OR (heroin) OR 
(methadone) AND Humans[Mesh] AND English[lang] 
Results: 3807 









CMQAT: Instructions for use 
 
General Instructions: 
• Each of the quality rating criteria are marked on a three-point scale that 
rates the paper as strong (3), medium (2) or weak (1) for that criterion.  
• Where the information required for a rating to be made is missing, the 
study should be rated for that criterion based on the information 
available in the published paper. Authors should then be contacted to 
clarify this information and the assessment altered accordingly.   
• All contingency management schedules should fall under that of 
“reinforcement” rather than “reward” [90]. The “reward” model entails the 
completion of a large, often long-term goal (for example two weeks of 
abstinence), whereas the “reinforcement” model breaks behaviours down 
into smaller steps (for example 2 days of abstinence) that are each 
rewarded. Any study implementing a “reward” schedule of reinforcement 
should not be rated, and should be excluded from any analyses. 
 
1. Target behaviour and contingency schedule 
•  “Measurable” refers to a behaviour that can be measured using an 
objective recording method, for example urine, blood or breath levels of 
a drug [186].  
• “Observable” refers to the behaviour being directly observable and 
validated by a member of the treatment team. For example observed or 
pH or heat tested urine samples [186]. 
• The same contingency management schedule should be maintained for 
the duration of the intervention, unless there is an a priori investigative 
motive for not doing so. Any study that alters the contingency 
management schedule without this being part of the initial study design 
should be marked as weak for this criterion.     
 
2. Target population: 
“Between participant differences” – Demographic variables/participant 
characteristics statistically tested for differences between groups (e.g. 
experimental vs control).  
3. Choice of reinforcer: 
• The choice of reinforcers used should only be considered to have been 
influenced by participants if this was done prior to the initiation of the 
study. For example, the exchange of earned vouchers for goods of 
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participants’ choice would not fall under this definition, as participants 
had no input as to whether the wanted rewards to take this form or not. 
 
4. Incentive Magnitude: 
• For monetary vouchers/cash rewards, the total available reward value for 
each study should be adjusted for inflation from the year the study was 
conducted to the current year. This value should then be divided by the 
number of weeks that the study ran for, and the studies ranked based on 
these average weekly reward values.   
• Studies using other reward types, for example clinical privileges, should 
be ranked as moderate, unless there is evidence in the literature that 
these are of greater intrinsic value than monetary vouchers/cash rewards 
ranked in the middle quartile.  
• If quality assessments are being conducted on only a small number of 
studies, or outside of the context of a systematic review/meta-analysis, 
the reward values of similar studies in the relevant field should instead 
be used a reference point for rating incentive magnitude. Incentives of a 
greater magnitude than those commonly used in the field should be rates 
as strong, those on a par with those commonly used in the field as 
moderate, and those of lower magnitude than those commonly used in 
the field as weak. 
 
5. Frequency of incentive distribution 
• If data are missing for frequency of incentive distribution, score the 
study as moderate if the frequency would capture all drug use (for 
example testing for cocaine every two days [187]). Authors should still be 
contacted for explicit verification of this and the quality assessment 
adjusted accordingly.  
 
6. Timing of the incentive 
• It should be noted that for “fishbowl” type interventions (where for each 
verified display of the desired behaviour, participants earn the right to 
draw tickets from a bowl that can represent money or prizes), it is the 
earning of draws from the “fishbowl” that constitutes the reward, not the 
later exchange of these earned rewards for physical goods.  
 
7. Duration of the intervention 
• For example, treatment for illicit drug use often takes place over 12 
weeks as it is widely accepted that this is the minimum duration of 
treatment required to derive benefit [188]. A study that did not explicitly 
state this but followed this treatment duration would be rated as 
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moderate. Authors should still be contacted for explicit verification of 
intervention duration and the quality assessment adjusted accordingly.  
 
 
CMQAT: Rating Criteria 
 
1. Target behaviour and contingency schedule 
Strong (3) – Both observable AND measurable, with biochemical 
verification or treatment staff / experimenter verification 
Moderate (2) – Measurable but not observable  
Weak (1) – Neither observable nor measurable, ill-defined target behaviour 
or not related to condition being treated OR self-report 
2. Target population: 
Strong (3) – Specific and well-defined target population / condition AND 
no significant between participant differences 
Moderate (2) – Specific and well-defined target population / condition AND 
any significant between participant differences have been controlled for 
in analysis. 
Weak (1) – Non-specific and ill-defined target population / condition 
AND/OR significant between participant differences, that have NOT been 
controlled for in analysis OR between participant differences not reported 
(contact authors to request data). 
3. Choice of reinforcer: 
Strong (3) – The choice of reinforcer has been influenced by the 
participants taking part in the study AND shown empirically to be of utility 
in the particular treatment population. 
Moderate (2) – The choice of reinforcer has been shown in previous 
research to be of some efficacy, but participants have not been consulted. 
Weak (1) – The choice of reinforcer is neither based on consultation with 
participants nor has empirical support.  
4. Incentive Magnitude: 
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Strong (3) – Studies with reward values in the top quartile of all studies 
being rated. 
Moderate (2) – Studies with reward values in the middle two quartiles of 
all studies being rated. 
Weak (1) – Studies with reward values in the bottom quartile of all studies 
being rated. 
5. Frequency of incentive distribution: 
Strong (3) – Explicit evidence of this being set to establish total compliance 
with agreed behavioural goals (e.g. drug abstinence)  
Moderate (2) – Evidence of this having the ability to establish total 
compliance with agreed behavioural goals (e.g. drug abstinence) OR no 
evidence of the frequency to establish total compliance provided but the 
frequency would catch all drug use 
Weak (1) – No evidence of this being set to establish total compliance with 
agreed behavioural goals (e.g. drug abstinence) 
6. Timing of the incentive 
Based on the meta-analysis of (Griffith et al. (2000) 
Strong (3) – Reward administered on the same calendar day as display of 
desired behaviour 
Moderate (2) – Reward administered the one calendar day after the display 
of desired behaviour 
Weak (1) – Reward administered more than one calendar day after display 
of desired behaviour OR timing of incentive administration not reported 
(contact authors to request data).  
7. Duration of the intervention 
Strong (3) – Explicit justification of the intervention duration being based 
on empirical support of efficacy  
Moderate (2) – No explicit justification of the intervention duration but it 
follows clinical precedent or aligns with other treatments being 
administered to patients (e.g. methadone treatment, drug detox etc.) 
Weak (1) – No explicit justification of the intervention duration and no 
evidence of following either a precedent in the literature or other 
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Participant ID    
    
Gender   Male, Female, Not reported 
    
Pregnant Yes, No, Not reported 
    
Breastfeeding Yes, No, Not reported 
    
Eligible for free prescriptions? Yes, No, Not reported 
    
Ethnic Group White British, White Irish, White Other, Mixed 
White & Black Caribbean, Mixed White & Black 
African, Mixed White & Asian, Mixed Other, 
Asia/Asian Brit – Indian, Asia/Asian Brit – 
Pakistani, Asia/Asian Brit – Bangladeshi, 
Asia/Asian Brit – Other, Black/Black Brit - 
Caribbean 
Black/Black Brit – African, Black/Black Brit – 
Other, Chinese, Any other ethnic group 
    
Employment Status Full time student, Never Worked/Unemployed for 
over 1 year, Retired, Sick/Disabled/Unable to return 
to work, Home carer (unpaid), 
Managerial/Professional, Intermediate occupation 
(e.g. clerical worker), Routine & Manual 
occupation (e.g. electrician) Other 
    
How did you hear about the service? GP , Practice nurse, Pharmacist, Other Professional, 
NHS National smoking helpline, Internet, 
Family/Friends, Previous user of the service, 






   
        
Quitting confidence  1 (Not at all) – 10 
(Very) 
    
        
Quitting importance 1 (Not at all) – 10 
(Very) 
    
        
Quitting Readiness 1 (Not at all) – 10 
(Very) 
    
        
Tried to stop smoking before?  Yes / No # Times:   
        
# weeks since last quit attempt       
        
Longest period of abstinence       
        
Have you tried NRT?  Yes / No Types:   
    How long 
used for  
  
        
Ever tried Zyban/Champix?  Yes / No How long 
used for 
  
        
Have you used other stop smoking 
aids? 









    
What type of tobacco do you smoke? Cigarettes, Roll-ups, Cigars, Oral 
    
How many cig. Do you smoke per day?  
(if hand rolled, how many ounces per  
week - 0.5 oz is 12.5g, or 20 cigs) 
 
    
How soon after waking do you have your  
first cig.? 
 Less than 5 mins, 5-15 mins, 15-30 mins, 30-60 
mins, 1-2 hours, More than 2 hours 
    
How many years have you smoked?   
    
Age started smoking   
    





Appendix 6: Participant Information Sheet and 






Participant Information Sheet 
V1 14/03/2016 
IRAS ID: 171709 
We invite you to take part in a research study 
• Before deciding to take part in the study, it is important for you to understand why the research is 
being done and what taking part will involve 
• Please take time to read the following information carefully and discuss it with friends and 
relatives if you wish  
• You are free to decide whether or not to take part in this study. If you choose not to take part this 
will not affect the care that you receive at Lorraine Hewitt House or anywhere else  
• If there is anything that is not clear or you would like more information, then please ask  
Important things you need to know 
• Tobacco smoking is very common amongst opiate and methadone users. This makes them likely 
to experience negative health effects. 
• Stopping smoking is one of the best things you can do for your health. It can also reduce the 
discomfort resulting from opiate use treatment. 
• Rewards are one way of helping people stop smoking. This is sometimes called contingency 
management.  
• Contingency management has been shown to work well in changing lots of different behaviours. 
We want to see whether it could help opiate use patients to stop smoking. 
• The aim of this study, is to see whether or not it would be possible to test this treatment in a larger 
trial 
• If you take part in the study, you are free to withdraw from the study at any time, without giving 
any reason. If requested, any data that we have collected from you will be destroyed.  
• We might ask you to fill out a small questionnaire if you do decide to withdraw from the study, to 
help us improve our interventions in the future. There is no obligation to complete this 
questionnaire though. 
Requirements 
In order to take part in the study you need to: 
• Be in treatment for opiate addiction 
• Smoke at least 10 cigarettes per day 
• Be between 18 and 65 years old 
• Must NOT be in treatment for any other drug addiction 
• Must NOT be participating in any other research 
Study title: Addition of contingency management to stop smoking services for in-treatment opiate 
addicts: a randomised controlled pilot study 












Centre Number:  IRAS ID: 171709 
Participant ID: 
Name of Researcher: Tom Ainscough 
1. I confirm that I have read the information sheet dated 28/04/2016 
(version 1.1) for the above study. I have had the opportunity to consider 
the information, ask questions and have had these answered 
satisfactorily. 
 
2. I am aware that I am required to attend the stop smoking clinic at 
Lorraine Hewitt House once a week for a total of     weeks (please 
complete). 
 
3. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical care 
or legal rights being affected. 
 
4. I understand that my medical notes about my drug use treatment, the 
and data collected during the study may be looked at by individuals from 
The Institute of Psychiatry, Psychology and Neuroscience, King’s College 




5. I agree to take part in the above study. 
Name of participant    Date    Signature 
Smoking Cessation study 
Study title: Addition of contingency management to stop smoking services for in-treatment opiate 
addicts: a randomised controlled pilot study 
Initial 
Name of person taking consent  Date    Signature 
V1 14/04/2016 
